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Abstract 
 
Thymocyte-expressed molecule involved in selection 2 (Themis2) is the 
second member of the Themis family. Recently, the first member of the 
Themis family, Themis, has been reported to be part of the TCR signalling 
cascade and its deletion severely affects thymocyte progression from the 
double positive to the single positive stage. All family members share 
similar domains and high sequence similarity and show tissue specific 
expression with Themis2  being expressed in B lymphocytes, 
macrophages and dendritic cells. THEMIS2 associates with BCR 
signalling molecules such as GRB2, VAV or LYN and is phosphorylated in 
response to BCR stimulation. For these reasons I hypothesised that 
Themis2 might have an important role in B cell development or activation. 
I show that Themis2  is expressed throughout the B cell lineage and 
exclude redundant expression of other Themis family members. After B 
cell activation Themis2 expression is downregulated. Analysis of a newly 
created Themis2-deficient mouse strain showed that B cell development 
proceeds normally in the absence of THEMIS2. Experiments on in vitro 
cultured Themis2-deficient primary B cells demonstrated that proliferation 
and survival, BCR internalisation and antigen presentation as well as 
expression of activation markers and cytokines were unaffected. RNA 
sequencing revealed only minor changes in transcription in follicular B 
cells, even after activation. Similarly, antibody levels to in vivo 
immunisation with T-dependent or T-independent antigens or challenge   4 
with influenza virus did not suggest that Themis2 is required for antibody 
responses either. Reactions to a model of acute allergic airway 
inflammation showed only marginally reduced cell numbers in the 
bronchoalveolar lavage fluid yet all other markers of inflammation were all 
normal. In conclusion, I found that Themis2  is not required for B cell 
development, activation or antibody responses. Further studies will be 
required to define the role of Themis2 in the immune system. 
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ITAM  Immunoreceptor tyrosine-based activation motif 
iTreg  Inducible regulatory T cell 
IκB  Inhibitor of κB 
J gene  Joining region gene segment 
JAK  Janus kinase 
JNK  C-Jun NH2-terminal kinase 
KLF2  Krüppel-like factor 2 
KO  Knock-out 
LAB  Linker for activation of B cells 
LAT  Linker for activation of T cells 
LFA1  Lymphocyte function-associated antigen 1 
LMPP  Lymphoid-primed multipotent progenitors 
LN  Lymph node 
LP  Lamina propria 
LPS  Lipopolysaccharide 
LRR  Leucine-rich repeat 
LTα  Lymphotoxin alpha 
M-CSF  Macrophage-colony-stimulating factor 
MAML1  Mastermind-like 1 
MAP3K1  Mitogen-activated protein kinase kinase kinase 1 
MAPK  Mitogen-activated protein kinases 
MEKK1  Mitogen-activated protein kinase kinase kinase 1   24 
MHC  Major histocompatibility complex 
mLN  Mesenteric lymph nodes 
MPP  Multipotent progenitors 
MTA3  Metastasis-associated 1 family, member 3 
µHC  Mu heavy chain 
MYD88  Myeloid differentiation primary response gene 88 
MZ  Marginal zone 
MZB  Marginal zone B cell 
MZP  Marginal zone precursor cell 
NBH  B  cell helper neutrophil 
Neo
R  Neomycin resistance 
NFAT  Nuclear factor of activated T-cells 
NFκB  Nuclear factor κ-light chain-enhancer of activated B cells 
NIK  NF-κB-inducing kinase 
NK cell  Natural killer cell 
NKT cell  Natural killer T cell 
NKTFH cells  Follicular helper natural killer T cell 
NLR  NOD-like receptors 
NLS  Nuclear localisation sequence 
NOD  Nucleotide-binding oligomerisation domain 
NP  4-Hydroxy-3-nitrophenylacetyl 
NTAL  Non-T cell activation linker 
nTreg  Natural regulatory T cell 
Omp  Outer membrane protein 
pA  Polyadenylation signal 
PALS  Periarteriolar lymphoid sheath 
PAMP  Pathogen-associated molecular patterns 
PAX5  Paired box gene 5 
PB  Plasmablast 
PC  Plasma cell 
PD-1  Programmed cell death 1 
PD-L2  Programmed cell death ligand 2   25 
PDK1  Phosphoinositide-dependent kinase 1 
PEC  Peritoneal exudate cells 
PETG   2-Phenylethyl β-D-thiogalactoside 
PGN  Peptidoglycan 
PI3K  Phosphoinositide-3 kinase 
PIP2  Phosphatidylinositol 4,5-bisphosphate 
PIP3  Phosphatidylinositol 3,4,5-trisphosphate 
PLCγ2  Phospholipase C gamma 2 
pLN  Peripheral lymph nodes 
PMA  Phorbol-12-myristate-13-acetate 
pMHC  Peptide-major histocompatibility complex molecules 
PNA  Peanut agglutinin 
PP  Peyer’s patches 
PRR  Pattern recognition receptor 
PRS  Proline-rich SH3-binding site 
PTC  Premature termination codon 
pTreg  Peripheral regulatory T cell 
PU.1  Purine box factor 1 
RAC  RAS-related C3 botulinum substrate 
RAF1  V-Raf-leukemia viral oncogene 1 
RAG  Recombination activating gene 
RANK  Receptor activator of nuclear factor-κB 
RAR  Retinoic acid receptor 
RAS  Resistance to audiogenic seizures 
RASGRP  Resistance to audiogenic seizures guanyl releasing protein 
RBP-Jκ  Recombination signal binding protein for immunoglobulin 
kappa J region 
RIG-I  Retinoic acid-inducible gene 
RIP1  Receptor-interacting serine/threonine-protein kinase 1 
RLR  RIG-I-like receptor 
RNA  Ribonucleic acid 
RNAi  Ribonucleic acid interference   26 
RORγt  Retinoic acid receptor-related orphan receptor gamma t 
RSS  Recombination signal sequences 
S region  Switch region 
S1PR  Sphingosine-1-phosphate receptor 
SAM  Sterile α-motif 
SAP  Signalling lymphocyte activation molecule–associated protein 
SH2  Src homology 2 
SH3  Src homology 3 
SHM  Somatic hypermutation 
SHP  SH2 domain-containing protein tyrosine phosphatase 
sIg  Surface immunoglobulin 
siRNA  Small interfering ribonucleic acid 
SLAM  Signalling lymphocyte activation molecule 
SLP-65  SH2 domain–containing leukocyte protein of 65 kD 
SLP-76  SH2 domain–containing leukocyte protein of 76 kD 
SMUG1  Single-strand selective monofunctional uracil DNA 
glycosylase 
SNP  Single nucleotide polymorphism 
SOS  Son of sevenless homologue 
SP  Single positive thymocyte 
ssRNA  Single stranded ribonucleic acid 
STAT  Signal transducer and activator of transcription 
STIM  Stromal interaction molecules 
SYK  Spleen tyrosine kinase 
T  Thymidine 
T-BET  T-box expressed in T cells 
T1/2/3  Transitional stage 1/2/3 
T2A  T2A self-cleaving oligopeptide 
TACI  Transmembrane activator and calcium modulator and 
cyclophilin ligand interactor 
TAK1  TGFβ-activated kinase 
TANK  TRAF family member-associated NFκB activator   27 
TBK1  TANK-binding kinase 1 
TCR  T cell receptor 
TdT  Terminal deoxynucleotidyl transferase 
TEMED  Tetramethylethylenediamine 
Tfh  T follicular helper 
Tfr  Follicular regulatory T cell 
TGFβ  Transforming growth factor beta 
Th  T helper 
THEMIS  Thymocyte-expressed molecule involved in selection 
TICAM2  Toll-like receptor adaptor molecule 2 
TIR domain  Toll/IL-1 receptor homology domain 
TIRAP  TIR domain-containing adaptor protein 
TLR  Toll-like receptor 
TMB    3,3’,5,5’-Tetramethylbenzidine 
TNFR  Tumour necrosis factor-receptor 
TNFα  Tumour necrosis factor alpha 
TNP  Trinitrophenyl 
TRAF  TNF-associated factor 
Treg  Regulatory T cell 
TRIF  TIR-domain-containing adaptor protein inducing IFNβ 
tTreg  Thymic regulatory T cell 
TWEAK  TNF-related weak inducer of apoptosis 
Ub  Ubiquitin 
UNG  Uracil DNA glycosylase 
UTR  Untranslated region 
V gene  Variable region gene segment 
VCAM1  Vascular cell adhesion molecule 1 
VEGF-A  Vascular endothelial growth factor A 
VLR  Variable lymphocyte receptor 
WASP  Wiscott-Aldrich syndrome protein 
WT  Wild type 
Xid  X-linked immunodeficiency   28 
XLA  X-linked agammaglobulinaemia 
Ym1  Chitinase-like 3 
ZAP70  Zeta-chain associated protein kinase 70   29 
1  Introduction 
1.1   The immune system 
The immune system of mammals can be divided into the innate and 
adaptive immune system. Both systems are primarily designed to prevent 
the host from succumbing to infection but the immune system also has 
surveillance functions in preventing cancer and detecting sterile damage 
leading to wound healing. The innate immune system consists of barriers 
such as the skin and mucosal surfaces and of innate immune cells such 
as macrophages, dendritic cells and neutrophils (Iwasaki and Medzhitov, 
2010; Medzhitov, 2007; Murray and Wynn, 2011). The adaptive immune 
system, based on the clonal selection theory proposed by Sir MacFarlane 
Burnet, is composed of lymphocytes, which develop antigen specific 
receptors (Sir Frank MacFarlane, 1959). Historically, it can be subdivided 
into humoral and cellular immunity based on B and T cell lineages 
respectively. Humoral immunity refers to the production of antibodies by B 
cells whereas cellular immunity refers to cytotoxic T lymphocytes, which 
directly attack and destroy target cells. However, cellular immunity also 
refers to cells of the innate immune system, in particular phagocytes, 
which similarly to cytotoxic T cells, eliminate infected cells. Their increased 
phagocytic capacity is increased by T helper (Th) cells, another cell type 
considered part of cellular immunity. As such, a strict division would leave 
out crucial interactions between cells of both cellular and humoral 
immunity, which is why this division is indistinct (Silverstein, 2003).   30 
Equally, the innate and the adaptive immune system are also connected in 
orchestrating the immune response as a whole (Schenten and Medzhitov, 
2011; Shanker, 2010). 
 
1.1.1  Innate immunity 
The innate immune system is considered the first barrier to invading 
pathogens. Its roots are ancient and similar mechanisms are found in the 
most primitive metazoans such as sponges (Hirano et al., 2011). Cells of 
the innate immune system use pattern recognition receptors (PRRs) to 
detect conserved molecules of pathogens or signs of cellular damage, 
which are called pathogen-associated molecular patterns (PAMPs) and 
danger-associated molecular patterns (DAMPs) respectively (Kawai and 
Akira, 2009; Petrilli et al., 2007). The most prominent class of these 
receptors are Toll-like receptors  (TLRs) which are horseshoe-shaped 
transmembrane receptors located at either the cell surface or within 
endosomes. They detect a range of PAMPs using leucine-rich repeat 
(LRR) sequences including bacterial cell wall components such as 
lipopolysaccharide (LPS) or peptidoglycan (PGN) or viral ribonucleic acids 
(RNAs) such as double-stranded RNA (dsRNA), single stranded RNA 
(ssRNA) and CpG deoxyribonucleic acid (CpG DNA). Other classes of 
PRRs are retinoic acid-inducible gene (RIG-I)-like receptors (RLRs), 
nucleotide-binding oligomerisation domain (NOD)-like receptors (NLRs) 
and  C-type lectin receptors (CLRs)  (Geijtenbeek and Gringhuis, 2009; 
Kawai and Akira, 2009). RLRs and NLRs are located in the cytoplasm and   31 
generally detect foreign RNA species whereas CLRs are membrane 
proteins mostly recognizing fungal and bacterial PAMPs (Kawai and Akira, 
2011).  Engagement  of these receptors leads to activation of signalling 
pathways, which ensure tailored immune responses by both the innate 
and the adaptive immune system in line with the theory initially proposed 
by Charles Janeway (Janeway, 1989). 
 
1.1.2  Adaptive immunity 
Vertebrates have developed an adaptive immune system in addition to the 
innate immune system. Two divergent adaptive immune systems using 
recombinatorial receptors have arisen during evolution. Jawless 
vertebrates have an immune system based on variable lymphocyte 
receptors (VLRs), which use LRR motifs for antigen binding. Jawed 
vertebrates in contrast use an immunoglobulin (Ig)-domain based system 
to produce T cell receptors (TCR) and B cell receptors (BCR). Both 
systems have in common that they are subdivided into two separate 
lymphocyte branches and that activation-induced cytidine deaminase 
(AID) is used for receptor diversification (Hirano et al., 2011). The 
recombinatorial nature of such a systems enables the adaptive immune 
system to construct diverse, anticipatory receptors, specific for possible, 
future antigens. Thus an immune response against specific antigens can 
be mounted by the adaptive immune system (Bonilla and Oettgen, 2010; 
Hirano et al., 2011).   32 
1.1.2.1  Cellular immunity 
Cellular immunity is mostly referred to immunity mediated by cluster of 
differentiation (CD) 8-positive (CD8
+) cytotoxic T lymphocytes (CTLs) and 
CD4
+ T helper (Th) cells. These T cells develop in the thymus. T-lymphoid 
progenitors from the bone marrow seed the thymic parenchyma from 
vessels in the corticomedullary junction of the thymus and travel during 
their development though the cortex towards the capsule and then back 
into the medulla to then emigrate to peripheral lymphoid organs though 
blood vessels as recent thymic emigrants (RTEs) (Takahama, 2006). CD4
- 
CD8
- double negative (DN) thymocytes are the earliest T cell progenitors 
in the thymus and are divided into 4 sequential stages, DN1 to DN4, 
depending on the expression of CD44 and CD25. Lineage commitment is 
not finished until the DN2 stage. TCRβ or TCRγδ rearrangement occurs at 
the DN3 stage and cells are tested for successful recombination at the 
following  β-selection checkpoint. Expression of a pre-TCR consisting of 
the rearranged TCRβ chain, pre-Tα and CD3 chains lets the cells progress 
into the  DN4 stage and then the  CD4
+  CD8
+  double positive cell (DP) 
stage. Cells that diverge into the TCRγδ lineage recombine both the γ and 
δ  chain and the rearrangement is checked together (Carpenter and 
Bosselut, 2010). 
DP cells rearrange their TCRα chains and are subject to positive selection 
for a functional TCRαβ  complex that recognises peptide-major 
histocompatibility complex molecules (pMHC). Negative selection ensures 
that this complex does not recognise autoantigens and in cells with such   33 
autoreactive TCRs apoptosis is induced. Lack of signalling due to non-
productive TCR rearrangements leads to death by neglect of DPs whereas 
excessive signalling through the TCR induced by autoantigens leads to 
activation-induced cell death (Carpenter and Bosselut, 2010; Fu et al., 
2014). The signalling strength through the TCR is thought to determine 
CD4 versus CD8 lineage choice. If a αβTCR interacts with MHC class II as 
opposed to MHC class I, it receives a stronger signal as the co-receptor 
for  MHC class  II is CD4. CD4 has stronger interactions with the 
downstream signalling molecule LCK than the MHC class I-restricted CD8 
co-receptor, thus CD4 lineage decision is made by stronger TCR signalling 
and the CD8 lineage is preferred for lower-strength TCR signals (He et al., 
2010). In addition, CD4
+ thymocytes with particularly strong affinity for self-
antigen and thus strong TCR signalling are diverted into the regulatory T 
cell lineage (Carpenter and Bosselut, 2010; Josefowicz et al., 2012). 
Termination of either CD4 or CD8 expression marks the transition of the 
DP thymocytes to the  single positive thymocytes (SP),  which  emigrate 
from the thymus into the periphery as RTEs (Carpenter and Bosselut, 
2010). RTEs mature in the periphery to become mature T cells which can 
exert T cell effector functions. The maturation process in RTEs is thought 
to reset downstream signalling processes so that cells respond with T cell 
activation and effector mechanisms rather than with activation-induced cell 
death (Fink, 2013).  
The principal effector function of CD8
+ CTLs is direct killing of target cells 
infected with intracellular pathogens such as viruses or intracellularly   34 
dividing bacteria. Th cells are regulators of other immune cells and enable 
effective killing of phagocytosed pathogens by for example macrophages 
as well as helping B cells recognizing a foreign antigen to get activated 
and differentiate into antibody secreting plasma cells and form germinal 
centre B cells (GCB) (Bonilla and Oettgen, 2010; Shanker, 2010). 
Th cells are classified into different subsets, which develop upon activation 
of the cell. Naïve Th cells are termed Th0 before activation and give rise to 
T helper 1 (Th1), T helper 2 (Th2), T helper 17 (Th17), regulatory T cells 
(Treg), T follicular helper cells (Tfh) or the recently described T helper 9 
(Th9) subsets depending on the antigen-presenting cell (APC) and the 
cytokine milieu. 
Th1 cells are induced by interleukin (IL)-12, characterised by having the 
lineage transcription  factor T-box expressed in T cells (T-BET) and 
producing mainly interferon (IFN)γ and IL-2. Th1 cells generally promote 
cell-mediated responses by activating mononuclear phagocytes, natural 
killer (NK) cells and CTLs for effective killing of intracellular pathogens. 
Th2 cells are induced by IL-4, have GATA binding protein 3 (GATA3) as 
their lineage transcription factor and produce IL-4, IL-5 and IL-13 and have 
functions in enhancing antibody responses, in fighting helminth infections 
and in hypersensitivity (Bonilla and Oettgen, 2010). 
Th17 cells are induced by IL-6 and transforming growth factor β (TFGβ) 
(Bettelli et al., 2006; Veldhoen et al., 2006), characterised by retinoic acid 
receptor (RAR)-related orphan receptor γ  t (RORγt) as their lineage 
transcription factor (Ivanov et al., 2006) and produce mainly IL-17A and IL-  35 
17F which are potent proinflammatory cytokines driving IL-6 and tumour 
necrosis factor α (TNFα) expression and granulocyte recruitment (Bonilla 
and Oettgen, 2010; Harrington et al., 2005; Park et al., 2005). Th17 cells 
have been implicated in several autoimmune diseases including arthritis, 
multiple sclerosis and systemic lupus erythematosus and inflammatory 
bowel disease (Bonilla and Oettgen, 2010; Langrish et al., 2005; Marwaha 
et al., 2012). 
Th9 cells have been described as IL-9 producing cells, which  are 
reprogrammed from Th2 cells using transforming growth factor β (TGFβ) 
and IL-4 (Dardalhon et al., 2008; Veldhoen et al., 2008). These cells have 
been implicated in ulcerative colitis (Gerlach et al., 2014). 
In vivo  Tregs can either be generated in the thymus by high-affinity 
autoantigen interactions, termed thymic or natural Tregs (tTregs or 
nTregs), or they can be induced in the periphery by subimmunogenic 
antigen presentation as peripheral Tregs (pTregs) (Curotto de Lafaille and 
Lafaille, 2009).  In vitro  differentiated Tregs are referred to as induced 
Tregs (iTregs) (Povoleri et al., 2013). Differentiation into Tregs is induced 
by TGFβ and IL-2 (Josefowicz et al., 2012). They are characterised by the 
expression of the transcription factor forkhead box P3 (FOXP3) and they 
suppress proinflammatory processes through a variety of secreted and 
surface molecules including IL-10, TGFβ, cytotoxic T-lymphocyte-
associated protein 4 (CTLA4), CD39 and CD73 (Chaudhry and Rudensky, 
2013; Fontenot et al., 2003; Kim and Rudensky, 2006).   36 
Tfh cells are characterised by the expression of chemokine (C-X-C motif) 
receptor 5 (CXCR5) enabling them to migrate into the B cell follicle to 
provide help to B cells in the germinal centre reaction and the CD28 family 
member programmed cell death 1 (PD-1) and inducible T cell co-stimulator 
(ICOS). They express the lineage transcription factor B cell 
leukaemia/lymphoma 6 (BCL6) and their hallmark cytokine IL-21 and 
express CD40 ligand (CD40L) which is necessary to select B cell clones 
with higher affinity antibodies after somatic hypermutation in the germinal 
centre  (Johnston et al., 2009; Nurieva et al., 2009; Rolf et al., 2010; 
Victora and Nussenzweig, 2012; Vogelzang et al., 2008).  
 
1.1.2.2  Humoral immunity 
Humoral Immunity is defined as immunity mediated by antibodies found in 
the extracellular body fluids (or humours) such as blood and lymph. 
Antibodies are produced by plasma cells, which are a terminally 
differentiated B cell subset. To reach this end stage of differentiation and 
produce antibodies, B cells not only need antigen-induced signalling by the 
BCR but also signalling through other receptors, which are often activated 
by  ligands from other cells such as dendritic cells and T cells. This is 
crucial for B cells to follow  appropriate differentiation pathways during 
development, perform class switch recombination (CSR) to produce the 
adequate antibody isotype and to perform somatic hypermutation (SHM) to 
increase antibody affinity (Bonilla and Oettgen, 2010; Clark et al., 2014; 
Oracki et al., 2010).   37 
1.2   B cell development 
In adult mammals B cells develop in the bone marrow (Kurosaki et al., 
2010; Pieper et al., 2013). After their development in the bone marrow 
they travel to peripheral organs such as the spleen and lymph nodes and 
progress into the naïve, mature B cell pool where they survey the 
environment for foreign material using the BCR. If B cells encounter 
cognate BCR ligands they become activated and differentiate further into 
germinal centre B cells, memory B cells and plasma cells. An overview of 
the standard model of B cell development in given in Figure 1. 
 
1.2.1  B cell development in the bone marrow 
1.2.1.1  Development of B lineage precursors 
B cell development is preceded by a first wave of haematopoiesis in the 
mouse foetus at day E7.5 in the yolk sac whilst blood circulation is 
established (Moore and Metcalf, 1970). A second wave gives rise to the 
first lymphoid cells among other cell types derived from haematopoietic 
progenitor cells originating from the aorta-gonad-mesonephros area of the 
developing foetus (Sánchez et al., 1996). The first B-lymphoid cells and 
myeloid cells develop in one wave from the foetal liver  on day E12.5 
(Strasser, 1989) and from E13.5 onwards, B cell development proceeds 
continuously from pluripotent haematopoietic stem cells (HSCs) in the 
bone marrow as it does later on in the adult life (Arai et al., 2009; Tsuneto 
et al., 2014).   38 
 
 
Figure 1: Canonical view of B cell development.  
CLP-derived prepro-B cells develop into pro-B cells, which start to 
rearrange their immunoglobulin heavy chain. Upon successful 
recombination and expression of a rearranged VDJ-Cµ heavy chain and 
co-expression of V-preB and λ5, the pre-BCR is formed and cells become 
large blasting pre-B cells to expand successfully rearranged clones. After 
blasting, cells start rearranging their κ  light chain locus or, upon 
unsuccessful recombination of the κ locus, initiate rearrangement of the λ 
light chain locus. Successful recombination on either of these loci 
produces immature B cells expressing the complete BCR in the form of 
IgM. These cells leave the bone marrow and migrate to the periphery 
where they start to co-express IgD on their surface through differential   39 
splicing and transit through the T1 and T2 transitional stages to become 
mature follicular B cells. In the spleen, mature marginal zone B cells can 
also develop from T2 B cells. Upon activation by cognate antigen, follicular 
B cells can either become a short lived plasma cell (PC) or go into the 
germinal centre reaction to produce other antibody isotypes by class 
switch recombination (CSR) and increase antibody affinity by somatic 
hyper  mutation (SHM). The latter, germinal centre B cells (GCB) then 
develop either into affinity–matured memory B cells (Bmem) or even more 
highly affinity-matured, long-lived antibody-producing PCs, which migrate 
into a survival niche in the bone marrow and sustain humoral immunity. 
Marginal zone B cells can also form memory but generally are fast 
responders to produce short-lived PCs. More details can be found in the 
text.   40 
When differentiating, HSCs lose self-renewing potential and become 
multipotent progenitors (MPPs), which keep on losing the capacity to 
differentiate into different haematopoietic lineages and become more and 
more committed towards one lineage (Bryder and Sigvardsson, 2010). The 
commitment towards the lymphoid lineage is induced by the transcription 
factor IKAROS in these early progenitor cells (Georgopoulos et al., 1992; 
Ng et al., 2009). The first commitment to the lymphoid lineage is marked 
by low expression of recombination activating gene 1 (RAG1) (Igarashi et 
al., 2002). MPPs then develop into lymphoid-primed multipotent 
progenitors (LMPPs), which can still produce granulocytes and 
macrophages but not erythrocytes or megakaryocytes (Adolfsson et al., 
2005). LMPPs are induced by the action of the transcription factor E2A 
(Dias et al., 2008). These then give rise to common lymphoid progenitors 
(CLPs) in which myeloid potential is strongly reduced and  which can 
almost exclusively produce lymphoid lineages (defined as NK, B and T 
cells) (Kondo et al., 1997). CLPs express the receptors FMS-like tyrosine 
kinase 3 (FLT3) and the IL-7 receptor (IL-7R) which are both vital for 
development of B cells at this stage but not earlier on in commitment 
towards the B cell lineage (Sitnicka et al., 2003; Sitnicka et al., 2002). 
Expression of IL-7R is controlled by the transcription factor purine box 
factor 1 (PU.1) (DeKoter et al., 2002), however higher levels of PU.1 inhibit 
B cell development and favour development of macrophages (DeKoter, 
2000). The IL-7R regulates B cell lineage commitment through the 
regulation of the expression of the transcription factor early B cell factor 1   41 
(EBF1) (Dias et al., 2005). It has been suggested that EBF1 is the critical 
factor for this commitment to the B lymphoid lineage in CLPs (Zandi et al., 
2008). CLPs develop into B220
+  CD19
-  pre-pro B cells, which already 
show strong commitment to the B cell lineage (Rumfelt et al., 2006) 
(Mansson et al., 2010). However, some of these cells can still seed the 
thymus and become T cells (Martin et al., 2003). In fact, CLPs can commit 
strongly to the B cell lineage before they progress into the B220
+ CD19
- 
pre-pro B cell stage indicated by a λ5-reporter mouse. However, when 
reaching the B220
+ CD19
- pre-pro B cell stage, cells lack myeloid potential 
and show little commitment to the T cell lineage (Mansson et al., 2008). 
Since RAG1 expression is already turned on, cells begin rearranging their 
IgH locus. As not all cells are committed to the B cell lineage, D to J 
rearrangements at the IgH locus can also be found even in T cells (Born et 
al., 1988). E2A, EBF1 and PU.1 together control the expression of the 
transcription factor paired box gene 5 (PAX5) (O'Riordan and Grosschedl, 
1999). PAX5 is a crucial transcription factor for commitment to the B cell 
lineage at this stage (Nutt et al., 1999) and is essential for maintaining B 
cell lineage commitment in mature B cells as well (Cobaleda et al., 2007a). 
It has thus been called the guardian of B cell identity and function 
(Cobaleda et al., 2007b). PAX5 is hardly detectable in CLPs or pre-pro B 
cells and its expression coincides with full commitment to the B cell 
lineage (Fuxa and Busslinger, 2007). The CD19
+ pro-B cell stage marks 
the stage of full commitment to the B cell lineage as opposed to earlier 
progenitors, which can still produce other lineages (Rumfelt et al., 2006).   42 
1.2.1.2  Development of the B lineage  
Early developmental B cell stages have been split up using two sets of 
surface markers to characterise the cells by flow cytometry. The two 
commonly used nomenclatures ranging from pre-pro B cells to mature B 
cells are the Philadelphia nomenclature (Hardy et al., 1991; Hardy and 
Hayakawa, 2001; Li et al., 1996) which is sometimes split into fractions A 
to F instead of naming each developmental stage and the Basel 
nomenclature (Osmond et al., 1998). Here, the Philadelphia nomenclature 
is used throughout. 
Pro B cells rearrange their variable (V), diversity (D) and joining (J) gene 
segments of the IgH locus with DH - JH rearrangements preceding VH - DJH 
rearrangements (Chowdhury and Sen, 2001). This process is dependent 
on IL-7, PAX5, the transcription factor Yin Yang 1 (YY1) and high levels of 
RAG1 and RAG2 (Liu et al., 2007; Oettinger et al., 1990; Xu et al., 2008). 
Successful rearrangement of the VDJH locus results in expression of the 
pre-BCR composed of the µ heavy chain (µHC) and the two surrogate light 
chains Vpre-B and λ5 which are expressed together on the surface (Kudo 
and Melchers, 1987; Mårtensson et al., 2010; Sakaguchi and Melchers, 
1986; Tsubata and Reth, 1990). Cells expressing the pre-BCR are termed 
pre-B cells. Signalling by the pre-BCR and the IL-7R leads to proliferation 
of large pre-B cells via phosphoinositide-3 kinase (PI3K) and extracellular 
signal-regulated kinase (ERK) signalling pathways (Fleming and Paige, 
2001). The ligand for the pre-BCR or whether a ligand is required at all is 
currently unknown and several hypotheses  on how the signalling is   43 
initiated exist (Mårtensson et al., 2010). A second function of the pre-BCR 
checkpoint is to stop recombination of second IgH allele by allelic 
exclusion and prevent expression of more than one receptor in a single B 
cell. This has been shown to be dependent on pre-BCR surface 
expression (Boekel et al., 1998) and on downstream signalling molecules 
such as spleen tyrosine kinase (SYK) and zeta-chain associated protein 
kinase 70 (ZAP70) among others (Schweighoffer et al., 2003). 
After proliferation,  pre-B cells enter  the  G1  phase  of the cell cycle, 
upregulate the Rag genes again and start recombination of the IgL chain 
to complete the production of a functional BCR (Kurosaki et al., 2010). 
There are two light chain loci, Igκ and Igλ. Interestingly, in mice κ is the 
preferred locus for the first attempt of creating a functional light chain. 
Twenty times more κ light chains are found in mice than λ light chains 
whereas in humans the ratio is roughly 1:1. The reasons for this species 
difference and the κ preference in mice is unknown but it has been shown 
to be independent of antigenic selection as the ratio of κ to λ is the same 
in immature as in mature B cells (McGuire and Vitetta, 1981). The 
activation of recombination is achieved by enhanced accessibility of the 
locus, which is exploited by the transcription factors interferon regulatory 
factor 4 (IRF4) and PU.1 (McDevit et al., 2005). Both access of IRF4 and 
reduced signalling by IL-7 mediate the activation of light chain 
recombination potentially by upregulation of CXCR4, which  mediates 
migration away from IL-7 producing stromal cells (Johnson et al., 2008). 
Allelic exclusion of other IgL  alleles is achieved through differential   44 
methylation (Mostoslavsky et al., 1998) and a regulatory region between 
VH  and D genes  termed intergenic control region 1  containing  CTCF 
looping/insulator factor-binding elements (Guo et al., 2011). 
The complete BCR consists of 2 heavy chains, 2 light chains and the 
functional subunits Igα  and Igβ  (also known as CD79A and CD79B 
respectively) and B cells expressing only the µ heavy chain but not the δ 
heavy chain are termed immature B cells (Kurosaki et al., 2010). 
BCRs are highly diverse in their paratopes, which are the antigen binding 
regions. The joining of the different VDJ genes is one of the mechanisms 
to create a diverse BCR repertoire against foreign antigens (Tonegawa, 
1983). The IgH locus in C57BL/6 mice extends over ~ 3 Mb and consists 
of 110 functional V genes and 85 V pseudogenes, 10 D genes, 4 J genes 
and 8 constant region (C) genes (Johnston et al., 2006). However, 
differences in the exact number of genes of the locus are found between 
mouse strains (Ye, 2004). Both heavy and light chain loci together allow 
more than 10
12 combinations to be made in the mouse (Mårtensson et al., 
2010). In comparison, the human IgH  locus contains 123 VH  genes of 
which 79 are pseudogenes (Matsuda et al., 1998) indicating that these loci 
are quite different between species and that the number of genes is not 
the only mechanism to diversify the receptor. Complementarity 
determining region 3 (CDR3) of the IgH (and the TCRβ chain) has been 
shown to be the most important part of the BCR (and TCR) for 
determination of its specificity (Xu and Davis, 2000). CDR3 is encoded by 
the recombined VH to DH junction, the whole DH gene segment as well as   45 
the  DH  to  JH  junction  (Davies and Chacko, 1993; Zhao and Lu, 2010). 
These  junctions  are particularly diverse as the enzyme terminal 
deoxynucleotidyl transferase (TdT) adds so-called  N nucleotides at the 
recombination break points by template-independent synthesis. Thus, TdT 
is a major contributor to antibody diversity (Gilfillan et al., 1993). Some of 
the created combinations will recognise foreign antigen, others however 
might recognise self-antigen or will be out of frame or fold wrongly. 
 
1.2.2  Selection and tolerance in B cell development 
Consequently, cells at the immature B cell stage are subject to positive 
and negative selection to test whether the newly formed BCR is functional. 
A functional BCR gives a signal for positive selection, but if reacting too 
strongly, i.e. with self-antigen, leads to activation-induced cell death, also 
termed deletion. As a rescue mechanism, the BCR can be changed by a 
process called receptor editing in which usually the light chains are again 
recombined to allow testing of a new BCR specificity (Luning Prak et al., 
2011) Alternatively, cells can go into anergy or clonal ignorance (Pillai et 
al., 2011). Anergic B cells still migrate to the periphery but do not respond 
to antigenic stimulation (Yarkoni et al., 2010) whereas ignorant B cells, 
which only have weakly self-reactive BCRs, are stopped from being 
activated by having a high activation threshold. 
Receptor editing is the most common outcome of creating a non-functional 
receptor during B cell development (Hippen et al., 2005). This means 
another round of recombination occurs leading to use of different V, D or J   46 
genes. It most commonly happens at the light chain loci as in the heavy 
chain usually only DJH leapfrogging occurs as otherwise the 12/23 rule is 
broken. The 12/23 rule states that recombination occurs preferentially 
between recombination signal sequences (RSS) with different spacer 
lengths. RSS are signal sequences for recombination and consist of a 
conserved heptamer sequence and a nonamer sequence separated by a 
spacer. In the mouse heavy chain locus VH genes and JH genes have 23 
nucleotide long RSS spacers and DH genes have 12 nucleotide long RSS 
spacers. Thus DH genes recombine with both VH and JH genes but VH 
genes do not recombine with JH genes (Sakano et al., 1981). However, 
this rule is only a preference and recombinations breaking the rule have 
been reported (Vinocur et al., 2009). 
DJH leapfrogging denotes an upstream DH gene segment recombining with 
a downstream JH gene segment thus deleting the already recombined DJH 
segment in between. This is only possible if the VH genes have not been 
recombined and is thus found mainly early in development. (Luning Prak 
et al., 2011). However, for receptor editing at the immature B cell stage VH 
to VH recombination can occur using a cryptic RSS replacing only part of 
the originally recombined VH gene, leaving the 3’ part of the original VH in 
place and thus usually leaving the CDR3 sequence untouched (Luning 
Prak et al., 2011). It also has been recently reported that receptor editing 
of Vκ genes can be found not only in the bone marrow of mice but also in 
the lamina propria (LP) from around day 18 to 28 after birth suggesting   47 
that gut microbiota can influence the mature B cell repertoire (Wesemann 
et al., 2013). 
If receptor editing fails, immature B cells with self-reactive BCRs can go 
into anergy. Anergy is based on the theory that lymphocyte activation 
requires two distinct signals (Bretscher and Cohn, 1970). Anergy is 
induced if B cells receive an activating signal by self-antigen but fail to 
receive another second signal within a given time  frame. The second 
signal could be for example a TLR signal or T cell help mediated by CD40 
ligand (CD40L) - CD40 interactions (Yarkoni et al., 2010). The functional 
consequences of anergy are reduced life-span possibly mediated by 
competition for B cell-activating factor (BAFF) (Lesley et al., 2004) and 
higher levels or the pro-apoptotic protein B cell leukaemia/lymphoma 2-like 
11 (BCL2L11), also known as BCL2-interacting mediator of cell death 
(BIM)  (Oliver et al., 2006)  or induction of apoptosis by CD95-CD95L 
interaction with CD4
+ T cells (Rathmell et al., 1995). 
If immature B cells have a weakly self-reactive BCR, the mechanism of 
clonal ignorance can maintain tolerance. Clonal ignorance of weakly 
autoreactive B cell clones is mediated by inhibitory BCR signalling 
molecules such as CD22, which increase the activation threshold of B 
cells (O'Keefe et al., 1999). If a self-antigen that is physically linked to a 
foreign antigen is recognised, endocytosed and displayed by a self-
reactive B cell to a T cell cognate for the foreign antigen, an autoimmune 
reaction could occur as the T cell would give help to the B cell. This can be 
stopped by a higher BCR signalling threshold preventing B cells from   48 
becoming activated and consequently preventing B cell migration to the 
T/B border, thus precluding T cell help (Pillai et al., 2011). 
Avoidance of self-reactivity is important but a functional BCR must not only 
be non-reactive to self-antigen but also be able to produce a positive 
selection signal. It is thought that for positive selection at the immature B 
cell stage the BCR is involved in delivering a potentially ligand-
independent, tonic survival signal to immature B cells. Indeed, loss of a 
functional BCR leads to rapid cell death of immature and mature B cells 
(Kraus et al., 2004; Lam et al., 1997) and presence of a functional BCR, 
composed of IgH, IgL, Igα  and Igβ  chains, already leads to some 
phosphorylation of downstream signalling molecules (Wienands et al., 
1996). Functional immunoreceptor tyrosine-based activation motifs 
(ITAMs) of both essential signalling components Igβ and Igα are required 
for normal development of B cells (Kraus et al., 2004; Kraus et al., 1999; 
Reichlin et al., 2001). Remarkably, a fusion protein of Igα  and Igβ 
delivered to the cell surface could also sustain B cell development in the 
absence of a complete BCR (Bannish et al., 2001). Interestingly, it was 
recently suggested that the surface BCR, in particular Igα and Igβ, might 
only serve as a signalling scaffold for delivery of the tonic survival signal. It 
was shown that BAFF binding to the BAFF receptor (BAFFR) leads to Igα 
and Igβ phosphorylation and recruitment of SYK, which then transduces 
the survival signal. In this model the tonic signal would therefore originate 
from BAFFR engagement and would be independent of a ligand for the 
BCR. However, there could also be a requirement for two distinct signals,   49 
both of which are required for B cell survival: A (tonic) BCR signal and a 
BAFF-induced signal (Schweighoffer et al., 2013). In support of the former 
hypothesis, BAFFR expression directly correlates with tonic BCR 
signalling as assessed by RAS-driven ERK activation (Rowland et al., 
2010a; Rowland et al., 2010b). 
In the next step of B lymphopoiesis, selected, immature B cells migrate to 
peripheral lymphoid organs such as the spleen and lymph nodes to 
complete their development. 
 
1.2.3  B cell development in peripheral compartments 
Further maturation of immature B cells is necessary for functional 
competence  since immature B cells respond with cell death to antigen 
encounter instead of activation and proliferation (Norvell et al., 1995). In 
the spleen, these immature B cells are  called transitional B cells and 
divided into transitional stage 1, 2 and 3 (T1, T2, T3). As opposed to 
mature B cell subsets in the spleen, transitional B cells all express CD93 
and are split up by the expression of IgM and CD23 into IgM
high CD23
- T1, 
IgM
high CD23
+ T2 and IgM
low CD23
- T3. The T2 stage can also be further 
subdivided into CD21 high marginal zone precursors (Allman et al., 2001). 
At this stage cells start to depend on BAFF (Batten et al., 2000; 
Schiemann et al., 2001) and upregulate IgD. For transition to the T3 stage 
signalling by Bruton’s tyrosine kinase (BTK), a kinase found in the BCR 
signalling pathway, seems to be partially required. Moreover, there seems   50 
to be on-going selection as cells are lost at the T1/T2 and the T2/T3 
transition (Allman et al., 2001; Allman and Pillai, 2008). 
The T3 stage has been suggested to contain a high amount of anergic B 
cells and may not constitute a developmental subset although the 
evidence so far is not clear (Merrell et al., 2006). 
Interestingly, it has also been proposed that B cells can also continue 
maturing in the bone marrow. This idea is supported by the fact that the 
mature recirculating B cell pool in the  bone marrow  is functionally 
heterogeneous and a T2-like stage has been described. As  in the 
periphery these B cells start responding to BAFF, upregulate IgD and 
CD23 and it is thus likely that B cells leave the bone marrow as immature 
or semi-mature B cells (Lindsley et al., 2007). 
 
1.2.4  Mature B cell populations 
A major peripheral site of B cell maturation is the spleen. The spleen is an 
encapsulated organ, split by trabeculae and is functionally divided into the 
red pulp and the white pulp. 
The red pulp filters blood and is also involved in the removal of  old 
erythrocytes and iron recycling. Arterial blood arrives in the cords of the 
red pulp, which do not have an endothelial lining. They are specialised 
structures consisting of fibroblasts, reticular fibres and macrophages. The 
blood then passes through a mesh of stress fibres into venous sinuses 
with endothelial lining which filters out old erythrocytes that are then 
phagocytosed by macrophages from the cords (Mebius and Kraal, 2005).   51 
In addition, the red pulp is a site where plasmablasts and plasma cells are 
retained (Sze et al., 2000). 
The white pulp is the lymphoid part of the spleen and resembles lymph 
nodes. It forms a lymphoid sheath around the branching arterioles. Closest 
to and surrounding the vessels is the T cell zone or periarteriolar lymphoid 
sheath (PALS). Follicular B cells (FOB) are found in the adjacent follicles 
in which germinal centres (GCs) are formed (Mebius and Kraal, 2005). 
GCs are the sites of SHM and CSR and the selection of the highest-affinity 
B cell clones (Victora and Nussenzweig, 2012). Surrounding the follicles 
and PALS is the marginal zone, which separates the white pulp from the 
red pulp. In it, marginal zone B cells (MZB), marginal zone macrophages 
and marginal zone metallophilic macrophages can be found. The marginal 
zone contains marginal zone sinuses through which part of the arterial 
blood flows in the direction of the red pulp. Towards the red pulp reticular 
fibroblasts, which are continuous with fibroblast in the red pulp, form the 
basis of the marginal zone together with sinus lining cells. MZB, DCs and 
marginal zone macrophages are found interspersed in this region. 
Towards the white pulp a layer of sinus-lining cells separates the marginal 
zone from the white pulp. Underneath these sinus-lining cells a layer of 
marginal zone metallophilic macrophages is located which then borders 
the PALS or follicles of the white pulp. Lymphocytes enter the white pulp 
through the marginal zone. In contrast, lymph nodes which otherwise have 
a very similar structure to the white pulp of the spleen do not contain a 
marginal zone. Here, lymphocytes enter mostly via high endothelial   52 
venules located in the T cell zone or through afferent lymphatic vessels. 
Whereas in lymph nodes cells leave through efferent lymphatic vessels 
this process is currently not clearly defined in the spleen but evidence 
suggests that B cells leave via the marginal zone into the red pulp and 
then into the circulation whereas T cells probably avoid the marginal zone 
and pass into the red pulp via marginal zone bridging channels that 
directly connect PALS with the red pulp (Cyster and Schwab, 2012; 
Mebius and Kraal, 2005; Mueller and Germain, 2009). 
In the spleen transitional B cells either mature to FOBs or MZBs. FOBs 
constitute the majority of mature B cells and can be even further 
subdivided into surface IgM
low CD21
low FOB I and surface IgM
high CD21
mid 
FOB II which have been suggested to be functionally distinct. FOB I 
represent two thirds of FOBs whereas FOB II constitute the remaining one 
third. In contrast to FOB I, FOB II develop independently of antigen, BTK 
and NOTCH signals. FOB II are thought to potentially be a reservoir for 
repopulating the MZB compartment during infections (Cariappa et al., 
2007). 
MZBs are located in the marginal sinuses of the spleen at the border of 
the white pulp and are retained there by the action of sphingosine-1-
phosphate (S1P) binding to S1P receptor 1 (S1PR1) (Cinamon et al., 
2004; Pillai and Cariappa, 2009). They interact with immature dendritic 
cells (DCs), which provide them with antigens (Balázs et al., 2002; 
Ferguson et al., 2004). They are particularly responsive to T-independent 
antigens respond rapidly to blood-borne pathogens and are highly mobile   53 
(Pillai and Cariappa, 2009). Additionally, since the marginal zone is a site 
of blood flow with easy access for sampling antigens in circulation, MZBs 
help shuttle antigen to the follicle. This process is dependent on CXCR5 
for movement towards the follicle and S1PR1 and S1PR3 (Arnon et al., 
2013; Cinamon et al., 2008). MZBs express high levels of CD1d, which is 
a molecule for presentation of lipid antigens by APCs. MZB have been 
shown to instruct invariant natural killer cells (iNKT) via CD1d which in turn 
provide help to the MZB in the form of CD80, CD86, IFNγ and CD40L but 
not IL-4 (Leadbetter et al., 2008). 
It has been noted that development of transitional B cells into either FOBs 
or MZBs depends on different signalling molecules. Mutations that 
influence lineage choice of MZB versus FOB development are generally 
categorised into mutations affecting BCR signalling strength, BAFFR 
signalling, nuclear factor κ-light chain-enhancer of activated B cells (NFκB) 
signalling, NOTCH-pathway signalling and chemokine and integrin 
signalling  (Pillai and Cariappa, 2009).  For example,  Btk-deficient mice 
have strongly reduced numbers of FOB I (Hardy et al., 1983) as do mice 
with mutations in phospholipase C γ 2 (PLCγ2) which is signalling 
downstream of BTK (Hikida et al., 2003; Pillai and Cariappa, 2009; Wen et 
al., 2003). Loss of the positive BCR signalling regulator CD45 also leads to 
loss of FOB I but was restored if the negative BCR signalling regulator 
SH2 domain-containing protein tyrosine phosphatase 1 (SHP1) was also 
deleted  (Pani et al., 1997). In general, data indicates that lower BCR 
signalling favours development of MZB  whereas stronger BCR signals   54 
favour development into FOBs. In support of this, marginal zone precursor 
cells (MZP) were reduced in Aiolos-deficient mice, which have increased 
BCR signalling (Cariappa et al., 2001). Upon loss of the BCR signalling 
inhibitory molecule CD22 similar results were obtained (Samardzic et al., 
2002). Several other B cell signalling component-deficient mice and 
transgenic BCR mouse models support this hypothesis (Pillai et al., 2005). 
BAFFR signalling and NFκB signalling are also critical for the MZB versus 
FOB B cell lineage decision. NFκB activation can be achieved by two 
different pathways using different NFκB subunits. These pathways are 
referred to as the canonical and the non-canonical NFκB pathway. 
Canonical NFκB signalling is required for development of MZBs but not 
FOBs (Cariappa et al., 2000). It was noted that although BAFFR signalling 
can elicit both canonical and non-canonical NFκB signalling it mainly 
activates non-canonical signalling and this was thought to be important for 
B cell survival (Claudio et al., 2002). Interestingly, BAFFR-deficiency, and 
thus development of both MZBs and FOBs, can be rescued by a 
constitutively active form of inhibitor of κ B kinase β (IKKβ), which elicits 
canonical NFκB signalling (Sasaki et al., 2006). These results suggest that 
BAFF-induced canonical NFκB signalling can substitute normal BAFF-
induced non-canonical signalling and that non-canonical signalling is 
dispensable for MZB development. Besides, it was thought that tonic BCR 
signalling provides the non-canonical NFκB component p100 as a 
substrate for the processing by BAFF-induced signalling (Stadanlick et al., 
2008). However, these results have to be evaluated in the light of BAFFR-  55 
signalling through SYK (Schweighoffer et al., 2013)  as in the previous 
study conclusions were based on the use of SYK inhibitors (Stadanlick et 
al., 2008). This suggests that BAFFR signals could suffice to provide p100 
for processing via the non-canonical pathway. 
Signalling by NOTCH2 has also been shown to be required for 
development of MZBs although the exact signalling mechanism is 
currently not clear. Mice lacking NOTCH signalling components like 
NOTCH2  (Saito et al., 2003), recombination signal binding protein for 
immunoglobulin kappa J region (RBP-Jκ)  (Tanigaki et al., 2002), 
Mastermind-like 1 (MAML1) (Oyama et al., 2007; Wu et al., 2007) and the 
notch ligand Delta-like 1 (DL1) (Hozumi et al., 2004)  all show reduced 
MZB compartments. Conversely, if NOTCH signalling is increased, mice 
have more MZBs such as in mice lacking the NOTCH signalling 
suppressor SPEN (also known as MINT) (Kuroda et al., 2003). 
Several chemotactic, cell adhesion and motility genes also contribute to 
the formation of MZB in the marginal zone. As mentioned above S1P is 
the chemotactic ligand for S1PR1 that retains MZB in the marginal zone 
thus resisting the CXCL13 gradient for recruitment into the follicles 
mediated by CXCR5 (Cinamon et al., 2004; Cinamon et al., 2008). 
Furthermore, MZBs are held in the marginal zone by the integrin 
lymphocyte function-associated antigen 1 (LFA1) and α4β1 integrins on 
MZBs binding to intercellular adhesion molecule 1 (ICAM1) and vascular 
cell adhesion molecule 1 (VCAM1) expressed in the marginal zone. 
Integrins  are downregulated by MZBs upon activation with LPS and   56 
contribute to the relocalisation of the cells (Lu and Cyster, 2002). Wiscott-
Aldrich syndrome protein (WASP), critical for regulation of cellular 
movement, is also important for MZB development. Cells deficient for 
WASP do not respond to S1P (Westerberg et al., 2008). RAC1 and RAC2, 
which promote actin polymerisation, have also been reported to be critical 
for normal numbers of MZB (Croker et al., 2002; Walmsley et al., 2003). 
Additionally, mutations of proteins related to integrin and BCR function or 
signalling are also linked to changes in the MZB compartment such as 
CD19, its downstream phosphoinositol signalling cascade including the 
PI3K isoform p110δ or the phosphatase and tensin homologue (PTEN) 
(Pillai and Cariappa, 2009). 
In summary, the current model for the development of murine MZBs 
probably starts with weak BCR signalling in immature B cells, followed by 
DL1 and BAFF signals upon arrival in the spleen through the red pulp. 
Assuming that marginal zone precursors reside in the follicle, chemotactic 
signals then lead the transitional B cell to migrate towards the marginal 
zone, where they are retained by integrin signals. If the MZB compartment 
is full but cells do not have strong enough BTK signalling to commit to 
FOB I lineage they may develop into FOB II to serve as a reservoir in case 
MZB are rapidly depleted such as in malaria infection (Achtman et al., 
2003; Pillai and Cariappa, 2009). 
   57 
1.2.5  B1 B cells 
In addition to the cells discussed above, which are generally referred to as 
B2 B cells, another B cell lineage exists in rodents termed B1 B cells with 
different developmental requirements and functions. In mice,  the B1 B 
cells are firmly established and are characterised by lacking expression of 
CD23 and are separated into CD5
+  B1a B cells which constitute the 
majority of B1 B cells and CD5
-  B1b B cells (Baumgarth, 2010).  In 
contrast, the existence of B1 B cells in human is currently under debate 
(Tangye, 2013). A human CD5
+ B cell subset does not seem to be the 
equivalent of mouse B1a B cells (Pillai and Cariappa, 2009). Human B1 B 
cells were characterised as CD20
+  CD27
+  CD45
+  (Griffin et al., 2011), 
however, studies showed that this population constitutes pre-plasmablasts 
leaving the possibility that it is either a mixed population with B1 B cells or 
just cells starting to commit to plasma cell differentiation (Covens et al., 
2013; Tangye, 2013). Functionally, B1 B cells are more considered 
mediators of innate immunity as their antibodies often recognise repetitive 
epitopes such as carbohydrates and they are generally more self-reactive. 
In contrast, B2 B cells are generally thought to mediate adaptive immunity 
and form germinal centres and humoral immunity (Montecino-Rodriguez 
and Dorshkind, 2012). 
With regards to the development of B1 B cells,  two opposing theories 
exist. The “selection model” states that B1 B cells are selected by reacting 
with  specific  antigens  (Haughton et al., 1993)  whereas the “layered 
immune system” model proposed distinct progenitor cells for B1 B cells as   58 
opposed to B2 B cells (Herzenberg and Herzenberg, 1989)  which is 
currently supported by more evidence  (Montecino-Rodriguez and 
Dorshkind, 2012). 
B1 B cells were first identified in 1983 (Hayakawa et al., 1983) after a 
search for CD5
+ B cells was prompted by CD5
+ B cell lymphomas (Lanier 
et al., 1981). In support of the “layered immune system” theory a distinct 
lineage
- CD19
+ B220
low-negative B1 B cell progenitor cell has been identified 
(Montecino-Rodriguez et al., 2006). 
B1 B cells create the first wave of B lymphocytes. They are thought to 
even precede HSCs as B1 B cells can be derived from unidentified 
progenitors in the yolk sac and para-aortic splanchnopleura at embryonic 
day 8.5 - 9.0 before HSCs appear on day 10.5 in the aorta-gonad 
mesonephros region. These unidentified progenitor cells give rise to the 
lineage
-  CD19
+  B220
low-negative  B1 progenitor cells that differentiate 
exclusively to B1 B cells and MZP (Yoshimoto et al., 2011). 
B1 B cells can be produced by the adult bone marrow as well (Duber et 
al., 2009; Kikuchi and Kondo, 2006) however neonatal tissues are more 
effective at reconstituting B1 B cells. It was shown that there are distinct 
CLPs for B1 and B2 B cells and that the number of B1-producing CLPs 
decreases towards adulthood explaining why neonatal tissues perform 
better at the reconstitution (Barber et al., 2011). 
It has been proposed that B1 B cell development also progresses though 
a transitional B cell stage (Casola, 2007), which is supported by the first 
wave of transitional B cells giving rise to mostly B1 B cells (Montecino-  59 
Rodriguez and Dorshkind, 2011). However, there are differences to 
transitional B2 cells. B1 cells are BAFF-independent  (Montecino-
Rodriguez and Dorshkind, 2011; Sasaki et al., 2004; Schiemann et al., 
2001) and their development occurs as long as either the canonical or the 
non-canonical NFκB pathway are functional whereas B2 B cells depend 
critically on the non-canonical pathway. B1 B cells can develop thought 
the transitional stage without canonical NFκB signalling but later seem to 
critically depend on canonical NFκB signalling for their maintenance 
(Montecino-Rodriguez and Dorshkind, 2011; Montecino-Rodriguez and 
Dorshkind, 2012). This dependence on canonical NFκB signalling is 
further supported by findings in other canonical NFκB signalling molecule-
deficient mice (Thome, 2004). Other signalling molecules that have been 
reported to be critical for B2 B cell development have also been shown to 
be dispensable for B1 B cells including IL-7 (Carvalho et al., 2001) and 
PU.1 (Rosenbauer et al., 2006; Ye et al., 2005). 
The current model suggests that B1 B cells are generated in several 
waves (Montecino-Rodriguez and Dorshkind, 2012). However, there might 
still be remaining plasticity between B1 and B2 B cells as B2 cells have 
been reported to acquire B1 cell phenotypes under certain conditions 
(Hastings et al., 2006). Moreover, B1 B cells turn over much more slowly 
than B2 B cells and are maintained mostly by self-renewal instead of 
constant influx from the bone marrow (Hao and Rajewsky, 2001). The self-
renewal seems to be in part regulated by IgM levels as lower IgM levels 
induce more B1 B cells (Lalor et al., 1989).   60 
Mature B1 B cells are predominantly located in the peritoneal and pleural 
cavities (Hayakawa et al., 1985). They have a different VDJH gene usage 
compared to B2 cells and fewer N nucleotides (Kantor et al., 1997; 
Tornberg and Holmberg, 1995). Their BCRs show increased specificities 
for self-antigens and pathogen-expressed molecules (Baumgarth, 2010). 
This repertoire is created in the absence of exogenous antigens (Haury et 
al., 1997). It is thought that the mild self-reactivity of the BCRs actually 
helps the cells in positive selection (Hayakawa et al., 1999) and it has 
been proposed that potentially all autoreactive BCRs cross-react with a 
foreign antigen and that thus only “useful” clones are selected (Baumgarth, 
2010; Baumgarth et al., 2005). Interestingly, splenic and bone marrow B1 
B cells are the major producers of the natural IgM antibodies whereas B1 
B cells from coelomic cavities produce little (McIntyre et al., 1991). 
However, about 80 % of all serum IgM is estimated to come from B1 B 
cells  (Baumgarth et al., 1999). There is ample evidence that natural 
antibodies contribute to defence against infection, acting directly at the 
barrier even before innate immunity. Protection mechanisms by natural 
antibodies include neutralisation, complement activation, inhibition of 
pathogen activation and potentially increasing adaptive responses by 
helping deposit antigen on follicular dendritic  cells (FDCs) for antigen-
presentation to B2 cells in a germinal centre reaction (Baumgarth, 2010). 
In addition, B1 B cells can class switch, particularly to IgA and thus 
participate in responses at mucosal surfaces as well (Kaminski and 
Stavnezer, 2006). Secretion  of natural IgA by B1 B cells seems to be   61 
dependent on early exposure during ontogeny to the commensal bacteria 
as challenge with individual commensal microbes in adult gnotobiotic mice 
resulted in B2 B cell-derived IgA responses (Thurnheer et al., 2003). 
Moreover B1 B cells can contribute to immune homeostasis by 
phagocytosis and promotion of phagocytosis of apoptotic debris via 
autoreactive IgM (Chen et al., 2009; Rodriguez-Manzanet et al., 2010). 
Overall, B1 B cells seem to be more responsive to secondary signals such 
as PRR engagement and less responsive to BCR activation compared to 
B2 B cells (Baumgarth, 2010; Martin et al., 2001). 
In general B1a B cells are thought to mediate more  innate immune 
responses by secretion of natural antibodies whereas B1b B cells mediate 
adaptive responses to particular antigens. For example CD19-deficient 
mice lack B1a B cells and are susceptible to infection with Streptococcus 
pneumonia  because they lack natural antibodies functioning as first 
barrier. CD19-transgenic mice in contrast produce ample amounts of 
natural antibody and are protected. However, if mice were first immunised 
with pneumococcal polysaccharide,  CD19-transgenic  mice were not 
protected against lethal Streptococcus pneumonia challenge whereas 
CD19-deficient mice were protected due to higher numbers of B1b B cells 
(Haas et al., 2005). Other functions of B1b cells include protection against 
Salmonella typhimurium  though antibodies against outer membrane 
proteins (Omps), in particular OmpF (Gil-Cruz et al., 2009) and against 
Borrelia hermsii  by generating a T-independent IgM response that also   62 
generated T-independent memory again emphasising the adaptive nature 
of B1b B cells (Alugupalli et al., 2004). 
 
1.3   B Cell activation 
B cells become activated following encounter of cognate antigen. Cross-
linking of the BCR by the antigen  induces  downstream  BCR signalling 
(Tolar and Spillane, 2014). B cells can be activated by soluble antigen; 
however, in vivo the size of the antigen is limited to about 70 kDa because 
bigger antigens are filtered out before reaching the follicle due to anatomic 
constraints (Gretz et al., 2000; Pape et al., 2007; Sixt et al., 2005). Bigger 
antigens are readily presented by APCs such as DCs (Bergtold et al., 
2005; Heesters et al., 2013). 
 
1.3.1  Early events in B cell activation 
Upon B cell activation the BCR must change from a resting state into an 
activated state that induces downstream signalling. The natural 
conformation of the BCR on the surface of a resting B cell is currently 
controversial. Conflicting data point either to single molecules being 
present on the surface (Tolar et al., 2005) or the aggregation of BCRs into 
oligomers (Schamel and Reth, 2000; Yang and Reth, 2010). The overall 
organisation of BCRs on the cell surface seems to be of importance as 
BCRs on resting B cells are restricted in their diffusion. Disruption of this 
segregating network by  interfering with the actin cytoskeleton leads to   63 
BCR signalling and increased BCR mobility  in the plasma membrane 
(Treanor et al., 2010). 
If antigen is bound, BCRs form microclusters, which then initiate signalling 
by downstream kinases (Depoil et al., 2008). Two competing but not 
necessarily mutually exclusive theories explain how initial BCR signalling 
might be regulated (Harwood and Batista, 2010). The “conformational 
change model” predicts a change in the structure of  a single BCR 
molecule upon antigen binding. The structural change is the signal 
transferred into the cell to activate the downstream signalling cascade. 
However, direct evidence for this model is still missing although it has 
been shown that BCRs have mechanosensory properties since they 
respond to the stiffness of the presented antigen and initial oligomerisation 
depends on the Cµ4 domain of the BCR (Tolar et al., 2009; Wan et al., 
2013). The second model is called the “kinetic segregation model” in which 
bulky BCR signalling-inhibiting phosphatases such as CD45 and CD148 
are excluded from the immunological synapse and thus allow signalling 
upon clustering of the BCR and formation of the central supramolecular 
activation cluster (cSMAC) (Harwood and Batista, 2010). Evidence for this 
model comes from the involvement of the cytoskeleton in the movement 
and segregation of BCR signalling molecules including IgD, IgM, CD19 
and CD81 (Depoil et al., 2008; Mattila et al., 2013; Treanor et al., 2011). 
After initial signalling, the BCR is internalised together with the antigen, 
which is then processed for presentation to T cells via MHC molecules 
(Lanzavecchia, 1985).  The internalisation  process again involves the   64 
cytoskeleton and mechanically tests the affinity of the BCR for the antigen 
if the antigen is presented on the surface of an APC (Natkanski et al., 
2013). 
Apart from activation through the BCR, B cells can be activated by other 
signals such as CD40L, IL-4, TLR ligands or BAFF (Hua and Hou, 2013; 
Rush and Hodgkin, 2001; Schneider et al., 1999; Wykes, 2003). In 
response to activation by different stimuli, activation markers such as 
CD23, CD69, CD86 or MHC class  II are differentially regulated often 
serving as a read-out to measure activation (Barr et al., 2007; Erlanson et 
al., 1998). 
B cell activation results in differentiation of naïve B cells into antigen-
experienced B cell subsets with effector functions such as plasma cells or 
memory B cells (Harwood and Batista, 2010). The main effector function of 
B cells is considered to be antibody production as fully differentiated 
plasma cells. In addition to antibody production, B cells have other effector 
functions often mediated though production of cytokines. These include 
enlargement of lymph nodes, hence facilitating other cell-cell interactions, 
support of Tfh cells in the germinal centre and  regulation of immune 
homeostasis particularly in several autoimmune disorders (Angeli et al., 
2006; Leon et al., 2012; Mauri and Bosma, 2012).  
Cytokines produced by B cells include IL-1, IL-2, IL-4, IL-6, IL-10, IL-12, IL-
13, IL-16, IFNγ, Lymphotoxin α and β (LTα and LTβ), TGFβ and TNFα and 
vascular endothelial growth factor A (VEGF-A) which mediate several of   65 
these effector functions (Angeli et al., 2006; Lund, 2008; Lund et al., 
2005). 
BCR ligands that lead to B cell activation can be classified into a number 
of different categories. Classically, BCR ligands have been divided into 
thymus (or T)-independent or T-dependent antigens depending on 
whether athymic mice can generate antibodies in response to the antigen 
(Vinuesa and Chang, 2013). T-independent antigens have been further 
subdivided into T-independent type 1 and T-independent type 2 antigens 
depending on whether CBA/N mice, which have an X-linked deficiency in 
the kinase BTK,  which is  important for BCR signal transduction, can 
respond to the antigen (Mond et al., 1995; Mosier et al.,  1977). T-
independent type 1 antigens are microbial ligands that activate PRRs such 
as TLRs and thus,  in addition to the BCR signal,  deliver a second 
activation signal via these receptors (Bekeredjian-Ding and Jego, 2009). 
T-independent type 2 antigens  are typically multivalent antigens that 
extensively crosslink the BCR and provide a long, sustained signal 
transmitted via BTK leading to B cell activation (Mond et al., 1995). 
More recently, antibody responses have been further divided, adding T-
independent type 3 responses and splitting T-dependent responses into 
type 1 and type 2. T-independent type 3 responses are characterised by 
help to B cells by bone marrow-derived innate immune cells in response to 
mucosal or blood born bacteria instead of thymus-derived cells (Vinuesa 
and Chang, 2013). In this regard, it has been shown that a subset of 
neutrophils termed B cell helper neutrophils (NBH) locate at the periphery   66 
of the marginal zone and help MZB to perform SHM, CSR to IgG and IgA 
and secrete Ig dependent on NBH  secretion of BAFF, a proliferation 
inducing ligand (APRIL) and IL-21 (Puga et al., 2012). Other data indicate 
a similar mechanism for DCs and macrophages in providing help to B cells 
via BAFF or APRIL (Balázs et al., 2002; García de Vinuesa et al., 1999; 
Tezuka et al., 2007). Some data also suggests that mast cells, basophils 
and eosinophils can also provide help to B cells to elicit antibody 
responses (Gauchat et al., 1993; Merluzzi et al., 2010; Wang and Weller, 
2008). 
T-dependent antibody responses are subdivided by the type of antigen 
and the type of cell providing the help. T-dependent type 1 responses are 
the classical responses to protein antigen in which B cells interact with Tfh 
cells generating germinal centres and giving rise to long-lived plasma cells 
and memory B cells as well as short-lived extrafollicular plasma cells 
(Vinuesa and Chang, 2013). T-dependent type 2 responses are against 
microbial, synthetic or self-non-protein glycolipid antigens that can be 
presented by CD1d on B cells such as α-galactosylceramide 
(Venkataswamy and Porcelli, 2010; Vinuesa and Chang, 2013). Instead of 
interaction with Tfh cells, B cells are helped by natural killer T (NKT) cells 
to induce antibody responses (Barral et al., 2008; Chang et al., 2012; 
Detre et al., 2012; Leadbetter et  al., 2008). NKT cells develop in the 
thymus and the response is consequently T-dependent  (Godfrey and 
Berzins, 2007; Vinuesa and Chang, 2013). Antigen is taken up by DCs 
and presumably presented to NKT cells, which activates NKT cells in an   67 
IL-12 and CD40 dependent manner (Kitamura et al., 1999). Similarly to 
Tfh, activated NKT T cells develop into follicular helper NKT (NKTFH) cells 
together with B cells presenting the glycolipid antigen via CD1d. This 
process is dependent on BCL6 (Chang et al., 2012)  and signalling 
lymphocyte activation molecule (SLAM)–associated protein (SAP) (Detre 
et al., 2012). NKT cell help to B cells is provided in the form of CD40-
CD40L and CD28-CD80/CD86 interactions and leads to a rapid 
extrafollicular plasma cell response (Chang et al., 2012; Leadbetter et al., 
2008). Although T-dependent type II responses generate germinal centres 
in which affinity maturation and CSR occur, they do not result in formation 
of long-lived plasma cells or humoral memory. Interestingly, both the 
extrafollicular plasma cell response and the germinal centre formation 
depend on NKT-derived IL-21 (Chang et al., 2012; King et al., 2012). 
 
1.3.2  The germinal centre reaction 
Germinal centres are the sites of SHM and affinity-based selection of B 
cells (Berek et al., 1991; Jacob et al., 1991). They are separated into a 
light zone and a dark zone (Nieuwenhuis and Opstelten, 1984). The light 
zone was originally shown to be the site of antigen retention on follicular 
dendritic cells located there and the dark zone was shown to contain 
proliferating cells (Mandel et al., 1980; Mandel et al., 1981). It is now clear 
that cells shuttle between these two zones, proliferate in the dark zone and 
then migrate to the light zone and back (MacLennan, 1994; Victora et al., 
2010). Germinal centres are open structures where B cells can enter and   68 
leave and interact with FDCs and T cells. Germinal centre B cells in the 
dark zone are called centroblasts and are bigger and proliferating while 
germinal centre B cells in the light zone are called centrocytes, which are 
smaller and interact with T cells to compete for selection (Allen et al., 
2007a; Allen et al., 2007b; Hauser et al., 2007; Schwickert et al., 2007). 
However, cells also proliferate in the light zone to a certain degree and the 
cell proliferation programme is already initiated in the light zone (Allen et 
al., 2007a; Bannard et al., 2013; Victora et al., 2010). As dark zone cells 
are proliferating they display a higher nucleus to cytoplasm ration and thus 
appear darker in light microscopy (Nieuwenhuis and Opstelten, 1984). 
Phenotypically GCB are IgD
-, high in surface n-glycolylneuraminic acid 
which is bound by the antibody clone GL7, high for CD95 expression, high 
in binding peanut agglutinin (PNA) and CD38 expression is reduced on 
GCB in mice but elevated in humans (Victora and Nussenzweig, 2012). 
GCB  can further be subdivided  into CXCR4
high  CD83
low  CD86
low 
centroblasts and CXCR4
low CD83
high CD86
high centrocytes (Victora et al., 
2010). 
Apart from germinal centre B cells, these structures contain several other 
cell types. A small number of IgD
+ naïve B cells transiting through the GCs 
have been reported. Newly-activated B cells either seed germinal centres 
or reuse old ones potentially from an unrelated immune response. Rarely, 
they can also be entered by exceptional, naïve high-affinity clones which 
directly enter affinity maturation (Schwickert et al., 2009; Schwickert et al., 
2007).   69 
The light zone contains a network of FDCs and T cells (Lindquist et al., 
2004). Conventional DCs are found as well which might serve to stimulate 
T cells (Grouard et al., 1996), however, their function is currently elusive 
(Lindquist et al., 2004). FDCs serve to display antigen to GCB undergoing 
affinity maturation and display antigen as iccosomes or immune 
complexes on their surface (Szakal et al., 1985; Szakal et al., 1988). 
Furthermore, tingible body macrophages are found in the light zone. 
These cells are thought to take up apoptotic bodies of B cells that failed 
selection. Tingible body macrophages mainly serve in the downregulation 
of the germinal centre reaction as defective signalling in this population 
leads to enhanced GC responses (Rahman et al., 2010; Victora and 
Nussenzweig, 2012). 
Another population of major importance in the GC are T cells, in particular 
Tfh. Tfh are the major cell type providing help to GCB (Ramiscal and 
Vinuesa, 2013). Their development begins at the T:B border after 
encounter of B cells displaying cognate antigen. After a prolonged 
encounter with the B cell, antigen-specific T cells start to upregulate BCL6, 
CXCR5 and PD-1. They precede B cells in the migration to the follicle to 
establish the GC. (Kerfoot et al., 2011). Generation of Tfh also depends on 
BCL6, IL-21, and inducible co-stimulator (ICOS) and SAP (Linterman et 
al., 2010; Nurieva et al., 2008; Nurieva et al., 2009; Qi et al., 2008; 
Vogelzang et al., 2008). Interestingly, GCB and Tfh mutually depend on 
each other for survival and keep the GC reaction going by expression of 
IL-21 by T cells and ICOS ligand (ICOSL) by B cells (Nurieva et al., 2008;   70 
Vogelzang et al., 2008). The main stimuli used by Tfh to regulate GCB 
affinity maturation and survival are CD40L and IL-21 (Han et al., 1995; 
Linterman et al., 2010). As mentioned above, in addition to Tfh, also NKT 
cells can serve as B cell helpers when differentiating into NKTFH cells in 
the case T-dependent type 2 antigens (Ramiscal and Vinuesa, 2013; 
Vinuesa and Chang, 2013). 
Moreover, follicular regulatory T cells (Tfr) have been identified in the 
germinal centre. These cells are CD4
+ CD25
+/- CXCR5
high PD-1
high Foxp3
+ 
BCL6
+ BLIMP1
+ and depend on SAP and BCL6 much like Tfh and seem to 
arise from nTregs although generation from pTregs has not been formally 
excluded. They regulate Tfh and GCB numbers and lack of Tfr leads to 
increased non-antigen-specific GCB and bigger GCs (Chung et al., 2011; 
Linterman et al., 2011; Wollenberg et al., 2011). Furthermore, a distinct 
CD8
+ Treg lineage has been described that is critical for maintenance of 
self tolerance via targeting Tfh expressing the MHC class I molecule Qa-1. 
Disruption of the interaction of these CD8
+ Tregs with Qa-1
+ Tfh leads to a 
systemic lupus erythematosus-like autoimmune disorder in mice (Kim et 
al., 2010). 
The current model of selection in the germinal centre is that GCB cycle 
between light zone and dark zone (Victora and Mesin, 2014). In the dark 
zone cells proliferate and upregulate AID to perform SHM and CSR 
(Victora and Mesin, 2014; Victora and Nussenzweig, 2012). After around 
an average of two divisions cells return to the light zone to test their 
mutated BCRs for affinity (Gitlin et al., 2014). Mutated GCB clones then   71 
collect antigen from FDCs; the higher the affinity the more antigen can be 
endocytosed and subsequently displayed as pMHC by a given clone. GCB 
then compete for help by Tfh (Gitlin et al., 2014; Schwickert et al., 2011; 
Victora et al., 2010). Tfh interact with GCB in transient large contacts and 
interact with both selected and non-selected cells (Shulman et al., 2014). 
The more antigen a B cell presents via pMHC to a cognate Tfh, the more 
likely it is that the B cell will receive T cell help for survival. Successful 
clones initiate S phase in the light zone and return to the dark zone to 
proliferate and start another round of selection. The variable number of 
GCB cell divisions initiated in a round of selection seems to be controlled 
by Tfh (Gitlin et al., 2014; Schwickert et al., 2011; Victora et al., 2010). 
As the process of selection in the germinal centre is becoming more and 
more well-defined, several other questions about germinal centres remain 
unanswered. The regulation of how an activated B cell becomes either an 
extrafollicular plasma cell or a GCB is currently obscure. Reports on the 
involvement of  BCR signalling strength through antigen affinity are not 
clear cut but some data suggests that low affinity clones preferentially 
become GCB whereas high-affinity ones differentiate into extrafollicular 
plasma cells (Paus et al., 2006; Shih et al., 2002; Zotos and Tarlinton, 
2012). Signals that lead to exit from the germinal centre and differentiation 
into memory B cells or plasma cells are currently elusive too. However, 
there is evidence for a temporal divide between those to cell fates with 
memory B cells generally arising earlier and having fewer  mutations 
whereas long-lived plasma cells are produced later in the response,   72 
showing more mutations and higher affinity (Shlomchik and Weisel, 2012; 
Smith et al., 1997; Takemori et al., 2014). Furthermore, it is a conundrum 
how negative selection of autoreactive GCB clones that also cross-react 
with foreign antigen is achieved. These cells could potentially be positively 
selected by Tfh cells and thus lead to autoimmunity. Tfr have arisen as a 
possible candidate population to be responsible for this phenomenon 
(Ramiscal and Vinuesa, 2013). 
 
1.3.2.1  Somatic hypermutation 
Germinal centres are the sites of SHM. SHM is the second mechanism 
after VDJ recombination by which antibody variable genes are diversified. 
SHM is the mechanism that introduces mutations into the V(D)J regions of 
the IgH and IgL loci (Matthews et al., 2014). Mutations occur at a rate of 1 
in 100 – 1000 base pairs per generation (McKean et al., 1984) and occur 
along the entire variable region but preferentially at RGYW / WRCY 
(R = A / G, Y = C / T, W = A / T) motifs which is due to the enzyme AID 
(Rogozin and Diaz, 2004). AID is specifically expressed in germinal centre 
B cells (Muramatsu et al., 1999) and is required for SHM as well as for 
CSR and gene conversion (Harris et al., 2002; Muramatsu et al., 2000). 
The region that is subject to mutation  stretches from 100 – 200 bp 
downstream of the promoter region of the V genes to 1.5 – 2 kB further 
downstream  (Lebecque and Gearhart, 1990; Rada et al., 1994)  and 
requires transcription of these regions (Peters and Storb, 1996). SHM is 
generally divided into two phases. The first phase starts with AID   73 
deaminating deoxycytidine (dC) to deoxyuridine (dU) at 
dC:deoxyguanosine (dG) base pairs (Petersen-Mahrt et al., 2002; Rada et 
al., 1998). This can lead to transition mutations via replication over the 
dU:dG pair, termed phase 1A. Alternatively, dU can be removed by base 
excision repair enzymes, mainly uracil DNA glycosylase (UNG) but also by 
single-strand selective monofunctional uracil DNA glycosylase (SMUG1), 
thus creating an abasic site (Di Noia and Neuberger, 2007; Dingler et al., 
2014; Rada et al., 2002). This site can give rise to all four bases if 
replicated and preference of the inserted base would depend on the 
polymerase. This process is called phase 1B. Otherwise, normal repair 
would involve removal of the whole nucleotide by apyrimidic endonuclease 
and normal template-based correction back to dC by a DNA polymerase. 
Phase 2 is the main pathway for creation of mutations at adenosine 
(A) : thymidine (T) pairs. Here a dU:dG mismatch can also be recognised 
by the mismatch repair machinery which nicks the DNA around the 
mismatch site and excises it, usually a stretch of around 30 – 100 bp in 
length. The error prone DNA polymerase η  then could create more 
mutations at this site at A:T pairs (Di Noia and Neuberger, 2007; Petersen-
Mahrt et al., 2002). 
 
1.3.2.2  Class switch recombination 
CSR is the mechanism for exchanging the constant region of the Ig-heavy 
chain i.e. Cµ for a Cγ, Cα or Cε region. Thereby expression is switched 
from IgM to IgG, IgA or IgE respectively. Eight CH genes comprise the   74 
C57BL/6 mouse IgH locus: Cµ, Cδ, Cγ3, Cγ1, Cγ2b, Cγ2c, Cε  and Cα 
(Matthews et al., 2014; Zhang et al., 2012). In the recombination process, 
upstream CH genes of the constant region to be exchanged are deleted. 
All mouse CH  genes are preceded by a switch (S) region with the 
exception of Cδ, which is usually simultaneously expressed through 
differential splicing with Cµ and creates double-positive IgM
+ IgD
+ B cells 
(Matthews et al., 2014; Moore et al., 1981). Switch regions are required for 
CSR (Shinkura et al., 2003) and need to be germline transcribed. Each 
constant region with the exception of Cδ  is comprised  of a cytokine 
inducible promoter, an intervening (I)-exon, the S region and the 
respective coding exons for the CH  region. I, S and CH  exons are 
transcribed, and the S region is spliced out creating a non-translated, 
sterile, germline transcript (Lennon and Perry, 1985; Matthews et al., 
2014).  Cµ  germline transcription is constitutive and transcription of a 
particular downstream CH gene leads to switching to this isotype. Which 
isotype is switched to depends on the stimulus. In  mice,  LPS leads to 
IgG2b and IgG3 switching, IL-4 to IgG1 and IgE switching, BAFF signalling 
to IgG and IgA switching, and TFGβ to IgA switching (Litinskiy et al., 2002; 
Lutzker et al., 1988; Rothman et al., 1988; Stavnezer et al., 1988). 
Transcription of the germline transcripts leads to formation of RNA that 
stays bound to the template strand due to high GC content of the region. 
The single-stranded non-template strand forms an R-loop, which serves 
as a template for AID (Chaudhuri et al., 2003; Matthews et al., 2014; 
Shinkura et al., 2003). Similar to SHM, AID deaminates dCs on single   75 
stranded DNA (Chaudhuri et al., 2003; Pham et al., 2003)  and two 
pathways can lead to the required double strand break (DSB) for the 
recombination to occur. The main pathway seems to be via UNG, which 
generates an abasic site followed by generation of a nick by 
apurinic/apyrimidinic endonuclease 1 (APE1). Two similar nicks, close but 
on opposite strands, generate a staggered DSB. Alternatively, mismatch 
repair can recognise the dU:dG mismatch, generate a nick and digest a 
stretch to create single-stranded DNA. Again two such events on opposite 
strands can create a DSB (Matthews et al., 2014; Rada et al., 2004). 
DSBs are then repaired by the classical non-homologous end joining 
pathway or the alternative end joining pathway, bringing together the 
variable region with a new CH region and excising the intervening DNA 
between participating S regions into a circle called the switch circle 
(Iwasato et al., 1990; Matsuoka et al., 1990; Matthews et al., 2014). 
 
1.3.3  Plasma cells 
Plasma cells are the terminally differentiated B cell subset that produces 
antibodies. There are two ways in which a plasma cell can be generated. 
The first possibility is that plasma cells arise in an extrafollicular response, 
which is generally faster. The second way is that plasma cells arise in the 
follicle from germinal centres, which generally creates long-lived plasma 
cells (Oracki et al., 2010). Plasma cells can be phenotypically identified by 
high expression of CD138 (syndecan-1)  (Sanderson et al., 1989). B 
lymphocyte-induced maturation protein 1 (BLIMP1), encoded by the   76 
Prdm1 gene, is the signature transcription factor of plasma cells (Shaffer 
et al., 2002; Turner et al., 1994). Developing plasma cells are termed 
plasmablasts. Expression levels of BLIMP1 identify different stages of 
plasma cell development. Low BLIMP1 levels are found in plasmablasts, 
intermediate levels in short-lived plasma cells and high levels in plasma 
cells (Kallies et al., 2004). BLIMP1 regulates the plasma cell fate together 
with the transcription factors IRF4 and XBP1 counteracting the 
transcription factors for naïve or GCB fate decisions including PAX5, BCL6 
and metastasis-associated 1 family, member 3 (MTA3) and BTB and CNC 
homology 1, basic leucine-zipper transcription factor 2 (BACH2) (Dent et 
al., 1997; Fujita et al., 2004; Hwangbo et al., 2004; Lin et al., 2004; Nutt et 
al., 2011; Shapiro-Shelef and Calame, 2005). Interestingly, similar to 
PAX5 for B lineage commitment, BLIMP1 is not the initiator of plasma cell 
development, as upregulation of several other plasma cell-related genes 
precede Blimp1 transcription. Moreover, chimeras of Rag1-deficient mice 
reconstituted with foetal liver Prdm1-deficient bone marrow also have 
serum antibodies (Kallies et al., 2007). 
Extrafollicular antibody responses are the main pathway in response to T-
independent antigen and are  often,  but not exclusively,  initiated by 
marginal zone or B1 B cells (Lane et al., 1986; MacLennan et al., 2003; 
Martin et al., 2001; Oliver et al., 1997; Vinuesa et al., 2003). Although T-
independent antigens mostly lead to an extrafollicular antibody response, 
abortive germinal centres have been reported as well (de Vinuesa et al., 
2000; Shih et al., 2002). In the case of T-dependent responses, which can   77 
generate such extrafollicular foci as well, it has been shown that OX40-
OX40L interactions and IL-21 by T cells are important for the development 
of extrafollicular foci (Odegard et al., 2008; Stüber and Strober, 1996). 
Extrafollicular responses only generate short-lived plasma cells as these 
cells rapidly disappear after the response (Smith et al., 1996). 
T-dependent responses generally lead to the generation of germinal 
centres. Plasma cells arising from this pathway are generally high-affinity 
and long-lived and reside in the bone marrow (Oracki et al., 2010). As 
discussed earlier the signals leading to the differentiation of plasma cells 
from GCB are not clear but might involve an affinity threshold and 
instructions by T cells (Paus et al., 2006; Phan et al., 2006; Smith et al., 
1997). These cells home from the follicle to either the splenic red pulp or 
the bone marrow, dependent on several chemokines. Lack of S1PR1 has 
been shown to reduce numbers of antibody secreting cells (AFCs) in the 
blood and bone marrow (Kabashima et al., 2006). Similar results were 
obtained upon deficiency of the S1PR1 regulator, Krüppel-like factor 2 
(KLF2) (Winkelmann et al., 2011). Expression of CXCL12 is found in the 
bone marrow and splenic red pulp. Plasma cells upregulate CXCR4 to 
respond better to CXCL12 whereas they downregulate CXCR5 and CCR7 
to stop responding to CXCL13 in the follicle and to CCL19 and CCL21 in 
the T cell zones leading to their movement into the bone marrow or red 
pulp  (Hargreaves et al., 2001). A niche in the bone marrow seems to 
support the survival of a limited number of long-lived plasma cells helping 
to keep antibody serum levels constant (Radbruch et al., 2006). The   78 
survival niche in the bone marrow is not completely defined yet but is 
comprised of VCAM1 and CXCL12-expressing stromal cells (Tokoyoda et 
al., 2004)  and recently identified APRIL and IL-6-producing eosinophils 
(Chu and Berek, 2013; Chu et al., 2011). The maintenance of plasma cells 
is independent of cognate antigen (Manz et al., 1998). 
 
1.3.4  Memory B cells 
Together with long-lived plasma cells, which maintain serum levels of 
antibodies against previously encountered antigens, memory B cells form 
the basis of humoral, immunological memory (Takemori et al., 2014). 
Upon restimulation these cells can quickly differentiate into AFCs or 
generate new germinal centres to produce even higher affinity clones 
(Dogan et al., 2009). Several reasons have been put forward to explain the 
faster kinetics of secondary responses compared to a primary responses. 
Firstly, there is a higher precursor frequency of antigen-specific cells in a 
secondary response making early activation of antigen-specific cells more 
likely. Secondly, memory B cells are strategically located at sites of 
antigen drainage such as the marginal zone and memory B cells seem to 
be generally maintained in the spleen (Mamani-Matsuda et al., 2008; 
Tangye and Tarlinton, 2009). Thirdly, they, at least partially, have higher 
affinity BCRs due to SHM. Fourthly,  again at least partially, memory B 
cells have switched BCR isotypes, which might confer better signalling 
properties compared to an IgM or IgD BCR. Fifthly, they constantly 
express higher levels of the co-stimulatory molecules CD80 and CD86   79 
(Surova and Jumaa, 2014; Tangye and Tarlinton, 2009) and lastly, they 
have an altered transcriptional profile suggesting that memory B cells are 
poised for activation (Bhattacharya et al., 2007; Tomayko et al., 2008). 
Studies on memory B cells have been hampered by a lack of consensus 
on the definition of B cell memory. Moreover, it has recently become clear 
that memory B cells are heterogeneous and they have been divided up by 
several systems including expression of antibody isotypes (Dogan et al., 
2009; Pape et al., 2011; Taylor et al., 2012a; Taylor et al., 2012b; Weill et 
al., 2013), dependence or independence on the germinal centre reaction 
(Good-Jacobson and Tarlinton, 2012; Kaji et al., 2012; Shlomchik and 
Weisel, 2012; Takemori et al., 2014; Taylor et al., 2012b; Weill et al., 
2013) or the expression of surface markers rather unspecific for murine 
memory B cells including CD80, programmed cell death ligand 2 (PD-L2), 
CD73 and CD35 (Anderson et al., 2007; Shlomchik and Weisel, 2012; 
Tomayko et al., 2010; Zuccarino-Catania et al., 2014). 
It was shown that memory B cells can form in response to T-dependent 
immunisation without the need for germinal centres. As expected these 
germinal centre-independent memory B cells have fewer mutations than 
germinal centre derived ones (Kaji et al., 2012; Toyama et al., 2002). In 
addition, memory B cells have a unique transcriptional profile. As these 
cells seem to self-renew, they share transcriptional similarities with HSCs 
(Bhattacharya et al., 2007; Ehrhardt et al., 2008; Klein et al., 2003; Luckey 
et al., 2006; Tomayko et al., 2008).   80 
Functional differences have been ascribed to the different subsets using 
cell surface markers and antibody isotypes. For example, it was initially 
reported that IgM
+ memory B cells differentiate into new germinal centres 
whereas IgG
+  memory B cells become AFCs (Dogan et al., 2009). 
Similarly, it was proposed that IgM
+ memory B cells constitute a long-lived 
reservoir that sustains the memory pool whereas switched Ig memory B 
cells respond rapidly and initially keep antibody serum levels high (Pape et 
al., 2011). More recently it was shown that CD80
+ PD-L2
+ memory B cells 
produce AFCs but not germinal centres and CD80
- PD-L2
- memory B cells 
produce germinal centres but not AFCs independent of the antibody 
isotype. In relation to the previous studies it should be noted though that 
switched memory B cells (defined as IgM
- in this study) were 73 % CD80
+ 
PD-L2
+ and unswitched (i.e. IgG1
-) memory B cells were 45 % CD80
- PD-
L2
- but also contained 15 % CD80
- PD-L2
+ and 27 % CD80
+ PD-L2
+ cells 
(Zuccarino-Catania et al., 2014). 
In summary, several types of memory B cells exist and their different 
contributions to various aspects of humoral immunity still need to be 
evaluated in more detail. Reliable surface markers to define distinct 
memory B cell subsets would substantially facilitate research and make 
results easier to compare. Nevertheless, the contribution of B cell memory 
to a protective immune response against  repeated pathogen challenge 
and in vaccination is indispensable (Good-Jacobson and Tarlinton, 2012; 
Takemori et al., 2014). 
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1.3.5  Regulatory B cells 
B cells not only participate in proinflammatory reactions but also have 
roles in immune homeostasis and the downregulation of immune 
responses (Vaughan et al., 2011). It was initially suggested that there is a 
type of suppressive B cell derived from delayed-type hypersensitivity 
studies (Katz et al., 1974; Neta and Salvin, 1974). Later it was shown that 
B cell-deficient mice have reduced recovery from  experimental 
autoimmune encephalomyelitis (EAE) (Wolf et al., 1996) and that B cells 
can prevent colitis in the context of TCRα-deficient mice (Mizoguchi et al., 
1997). It was later shown that B cell-derived, immunosuppressive IL-10 
was necessary for protection against EAE (Fillatreau et al., 2002; Mauri et 
al., 2003; Saraiva and O'Garra, 2010).  
In addition to IL-10,  several  other immunosuppressive mechanisms of 
regulatory B cells (Bregs) have been identified. Thus, the gold standard for 
their identification is suppressive function upon transfer although 
production of IL-10 is very often used for identification as well (Mauri and 
Bosma, 2012; Rosser et al., 2014). Bregs can be subdivided into a 
number of subsets although their origins and relations to each other are 
not completely clear. In the mouse T2-MZP cells could be adoptively 
transferred and had immunosuppressive functions (Blair et al., 2009; 
Carter et al., 2012; Evans et al., 2007). Marginal zone B cells have also 
been reported to suppress immune responses to Leishmania donovani 
and have been implicated in tolerance to apoptotic cells (Bankoti et al., 
2012; Gray et al., 2007; Miles et al., 2012). Moreover, IL-10-producing   82 
CD138
+ plasmablasts have been identified in a Salmonella typhimurium 
infection model (Neves et al., 2010). Another subset of IL-10 producing, 
CD1d
hi  CD5
+  B cells, termed B10 cells, was found to ameliorate T-
dependent inflammation (Yanaba et al., 2008). B10 cells have been 
proposed to have dedicated progenitors called B10pro, which depend on a 
particular BCR specificities as they are strongly reduced in BCR 
transgenic mouse models (Kalampokis et al., 2013; Yanaba et al., 2009). 
These cells have so far only been identified by the production of IL-10 
upon appropriate stimulation as all other markers overlap with normal B 
cell populations (Kalampokis et al., 2013).  
Several cellular targets by which Bregs mediate their homeostatic function 
have been identified. For example, Bregs can increase Treg numbers 
(Carter et al., 2012; Sun et al., 2008). Cognate interactions with CD4
+ T 
cells have also been shown to be essential for suppression and depend on 
CD40 - CD40L interactions and IL-21  (Yoshizaki et al., 2012). Breg-
derived  IL-10 can also regulate CD8
+  T cells (Bankoti et al., 2012; 
Schioppa et al., 2011). IL-10 secretion by Bregs can reduce IL-12 
production by DCs and thus reduce Th1 development (Sun et al., 2005; 
Zhang et al., 2007). Enhanced potential to phagocytose was also shown 
for macrophages in the absence of Bregs (Horikawa et al., 2013). 
Neutrophils too can also be regulated  by Bregs, as they are found in 
higher numbers in mice with reduced numbers of Bregs (Neves et al., 
2010). Furthermore, Bregs can also regulate B cell responses themselves 
either in a direct or indirect fashion. Many models find reduced   83 
autoantibody levels following  Breg-mediated suppression (Evans et al., 
2007; Gray et al., 2007; Mauri et al., 2003; Miles et al., 2012). 
Due to the increasing amount of data on Breg-mediated suppression, their 
functional mechanisms have also been categorised. Bregs can either 
mediate suppression through direct cognate antigen-mediated 
interactions, direct cell-contact without cognate interactions, bystander 
suppression via cytokines, or indirect suppression via APCs or Tregs 
(Rosser et al., 2014). 
 
1.4   Signalling pathways in B cells 
Several B cell signalling pathways have been mentioned throughout the 
text. I will briefly discuss the most salient features of their downstream 
signalling cascades. 
 
1.4.1  B cell receptor signalling 
As discussed earlier, cross-linking of BCR leads to B cell activation via 
BCR signalling. The main signalling pathways subsequent to BCR ligation 
are  summarised in Figure 2. The  signalling subunits of the BCR are 
CD79A (Igα) and CD79B (Igβ). Both contain a single ITAM motif, which 
initiates  signal transduction after activation (Dal Porto et al., 2004; 
Flaswinkel and Reth, 1994). ITAMs contain a consensus sequence 
surrounding two tyrosines which can be phosphorylated and then bind src-
homology 2 (SH2) domains (Cambier, 1995; Reth, 1989). The exact   84 
mechanism is not clear but it is thought that increased recruitment of src-
family protein tyrosine kinases such as LYN, FYN, BLK and LCK following 
BCR microclustering leads to the phosphorylation of the ITAM tyrosines 
(Clark et al., 1992; Dal Porto et al., 2004; Pleiman et al., 1994). 
Phosphorylation of both tyrosines in an ITAM site creates a binding site for 
SYK. SYK then autophosphorylates itself and becomes active (Rowley et 
al., 1995). SYK then functions as  a major hub in the activation of 
downstream signalling pathways (Mócsai et al., 2010). It has been shown 
to be an essential kinase (Turner et al., 1995) (Cheng et al., 1995) and is 
of major importance for B cell development (Turner et al., 1997). One of its 
targets that is phosphorylated and activated is B cell linker (BLNK), also 
known as SH2 domain–containing leukocyte protein of 65 kDa (SLP-65) or 
B cell adaptor containing SH2 domain (BASH). BLNK acts as a signalling 
scaffold and connects the BCR to various other signalling molecules 
including growth factor receptor bound protein 2 (GRB2), PLCγ and VAV 
proteins (Fu et al., 1998; Goitsuka et al., 1998; Wienands et al., 1998). 
LYN also phosphorylates motifs on CD19 to recruit PI3K (Fujimoto et al., 
2000; Tuveson et al., 1993). PI3K then phosphorylates the membrane lipid 
phosphatidylinositol 4,5-bisphosphate (PIP2) to phosphatidylinositol 3,4,5-
trisphosphate (PIP3). BTK binds PIP3 via its pleckstrin homology domain 
and becomes activated (Saito et al., 2001). BTK is  a kinase of major 
importance and mutations in BTK lead to X-linked immunodeficiency (Xid) 
in mice (Rawlings et al., 1993) and X-linked agammaglobulinaemia (XLA) 
in humans (Tsukada et al., 1993).   85 
Apart from SYK and the src-family kinases, in particular LYN, BTK is the 
third critical upstream kinase in BCR signalling from which more diverse 
and distal signalling event emanate (Dal Porto et al., 2004). 
Activation of BLNK by SYK leads recruitment of its signallosome to the 
plasma membrane including PLCγ2 that  connects BCR cross-linking  to 
Ca
2+  influx  (Fu et al., 1998; Goitsuka et al., 1998; Ishiai et al., 1999; 
Wienands et al., 1998). In addition, BLNK also interacts with BTK 
(Hashimoto et al., 1999) and phosphorylation by both SYK and BTK are 
required for optimal PLCγ2 activation (Chiu et al., 2002). In TCR signalling 
in T cells, recruitment of the BLNK homologue SH2 domain–containing 
leukocyte protein of 76 kDa (SLP-76) is mediated through the protein 
linker for activation of T cells (LAT) and the adaptor protein GRB2-related 
adaptor downstream of SHC (GADS) (Boerth et al., 2000; Ishiai et al., 
2000; Zhang et al., 1998). Interestingly, expression of SLP-76 alone 
cannot rescue BLNK deficiency in B cells, only if LAT and GADS are co-
expressed, BCR signalling is restored suggesting that BLNK and SLP-76 
are recruited to the membrane by different mechanisms. Indeed, it was 
shown that BLNK is directly recruited to CD79A via a non-ITAM tyrosine 
residue (Engels et al., 2001; Kabak et al., 2002). Since LAT is critical in 
TCR signalling (Zhang et al., 1999), due to the essential recruitment 
mechanism of SLP-76 to the membrane, this might also explain the lack of 
requirement for the LAT homologue linker for activation of T cells 2 (LAT2) 
in B cells (also known as non-T cell activation linker (NTAL) or linker for 
activation of B cells (LAB) (Wang et al., 2005; Zhu et al., 2004). Given that   86 
LAT2 can even substitute LAT in T cell development (Brdicka et al., 2002) 
its dispensability in B cell development might be due to BLNK being 
effectively recruited to the membrane by a different mechanism than SLP-
76 in T cells, i.e. not relying on an adaptor for its localisation upon BCR 
stimulation. However, LAT2 might serve other functions in B cells. 
Activated PLCγ2 catalyses the hydrolysis of PIP2 to diacylglycerol (DAG) 
and inositol-3,4,5-phosphate (IP3). IP3 leads to the release of Ca
2+ into the 
cytosol, mostly from the ER by binding to IP3-receptors on the ER 
membrane  (Sugawara et al., 1997). The Ca
2+  decrease in the ER is 
sensed by stromal interaction molecules 1 (STIM1) and 2 (STIM2), which 
translocate to ER-plasma membrane junctions to open Ca
2+  release-
activated Ca
2+  channels  (CRAC)  formed by ORAI proteins which pump 
Ca
2+ from the extracellular space into the cytoplasm leading to a sustained 
Ca
2+ release (Kurosaki et al., 2010; Shaw et al., 2013). Ca
2+ in turn leads 
to the activation of calmodulin, which activates calcineurin phosphatase 
(CN) (Crabtree and Olson, 2002; Klee et al., 1998; Winslow et al., 2006). 
CN then initiates the translocation of transcription factor nuclear factor of 
activated T-cells (NFAT) into the nucleus by dephosphorylating N-terminal 
serines on NFAT (Crabtree and Olson, 2002). Calcium and DAG also 
activate protein kinase C (PKC) leading to NFκB signalling (Dal Porto et 
al., 2004; Dolmetsch et al., 1997; Saijo et al., 2002; Trushin et al., 1999). 
In  addition to these transcription factors, signalling by the mitogen-
activated protein kinases (MAPK) p38 MAPK, ERK and c-Jun NH2-
terminal kinase (JNK) can lead to activation of several transcription   87 
factors. ERK activates ETS domain-containing protein 1 (ELK1) and 
myelocytomatosis oncogene (c-MYC), JNK activates jun proto-oncogene 
(c-JUN) and activating transcription factor 2 (ATF-2) and p38 MAPK 
activates ATF-2 and MAX (Dal Porto et al., 2004; Dong et al., 2002). 
To activate MAPK signalling, several, partially redundant signalling 
pathways are found in B cells. DAG has been shown to activate the small 
GTPase resistance to audiogenic seizures (RAS) via its exchange factor 
RAS guanyl releasing protein (RASGRP). Activation of RAS results in 
signalling via the v-raf-leukemia viral oncogene 1 (RAF1) followed by 
activation of mitogen-activated protein kinase kinase kinase 1 (MEKK1 or 
MAP3K1) and leading to ERK activation (Dal Porto et al., 2004; Ehrhardt 
et al., 2004; Nagaoka et al., 2000; Oh-hora et al., 2003; Teixeira et al., 
2003). Another minor mechanism for RAS activation is through BLNK-
GRB2-Son of sevenless homologue 1 (SOS1). SOS1 is also an exchange 
factor for RAS (D'Ambrosio et al., 1996; Kurosaki et al., 2010; Nagai et al., 
1995). 
Activation of p38 MAPK and JNK can be achieved by a pathway involving 
VAV and RAS-related C3 botulinum substrate (RAC) proteins (Hashimoto 
et al., 1998; Ishiai et al., 1999). Both VAV family proteins 
(VAV1/VAV2/VAV3) and RAC proteins (RAC1/RAC2) display intrafamily 
redundancies but are essential for the generation of functional B cells as 
mice deficient in these proteins display defects in B cell development 
(Henderson et al., 2010; Tarakhovsky et al., 1995; Walmsley et al., 2003). 
VAV proteins are connected to the BCR via BLNK and GRB2 (Fu et al.,   88 
1998; Johmura et al., 2003). In addition to activation of p38 and JNK, both 
RAC and VAV proteins are recruited to LAT2 for internalisation of the BCR 
(Malhotra et al., 2009). Moreover, VAV3 also activates PI3K via RAC1 and 
is indispensable for PI3K signalling and thus production of PIP3  and 
calcium flux (Inabe et al., 2002). 
 
1.4.2  CD40 receptor signalling 
Co-stimulatory receptors can be divided into two families, the CD28/CD80 
family and the TNF receptor (TNFR) family. CD40 is a member of the latter 
together  with the other co-stimulatory receptors OX40, BAFFR, 
transmembrane activator and calcium modulator and cyclophilin ligand 
interactor (TACI), B cell maturation antigen (BCMA) and receptor activator 
of nuclear factor κ B (RANK). The ligand for CD40 is CD40L also known 
as CD154, a TNF family ligand. Signals through CD40 are crucial second 
signals for B cells (Elgueta et al., 2009). Most of the CD40 signalling 
activity is mediated through the activation of the TNF-associated factors 
(TRAFs), a family of E3-ubiquitin ligases, and leads to the activation of 
NFκB, MAPKs, PLCγ and PI3K signalling pathways (Elgueta et al., 2009). 
Engagement of CD40 leads to its trimerisation but higher order structures 
can also be formed (Haswell et al., 2001; Pullen et al., 1999a). These 
complexes directly or indirectly recruit TRAF1, TRAF2, TRAF3, TRAF5 
and TRAF6 to their cytoplasmic tails (Pullen et al., 1999b; Pullen et al., 
1998).   89 
 
Figure 2: Simplified BCR signalling scheme.  
Upon cognate antigen binding and cross-linking of surface immunoglobulin 
(sIg), the BCR recruits src-family kinases to the ITAMS of its Igα and Igβ 
subunits. Most prominently, kinase activity by LYN leads to 
phosphorylation of ITAMs and recruitment of SYK, which upon 
autophosphorylation gets activated to phosphorylate downstream 
signalling molecules such as BTK and BLNK. These in turn activate 
signalling via phospholipids and calcium or GTPases to activate MAP-  90 
kinase signalling via p38, JNK and ERK. These pathways then lead to the 
translocation of transcription factors such as ATF-2, JUN, c-MYC, NFκB, 
or NFAT into the nucleus and initiation of transcription of target genes. 
Details in the text. Kinases are shown in orange, GTPases in red, guanine 
nucleotide exchange factors in light green, phosphatases in dark green, 
adaptors in pink and transcription factors at the bottom in light blue.   91 
Recruitment of TRAF2 to CD40 in B cells leads to activation of JNK, p38 
and thymoma viral proto-oncogene 1 (AKT) pathways (Lee et al., 1997). 
The activation of JNK and p38 and c-JUN is dependent on MAP3K1 
(Gallagher et al., 2007). 
The mechanism of activation of the NFκB pathway by TRAFs upon CD40 
ligation has been elucidated recently (Gardam et al., 2008; 
Vallabhapurapu et al., 2008). A heterodimer of TRAF2 and TRAF3 in 
complex with cellular inhibitor of apoptosis 1 (cIAP1) and 2 (cIAP2) 
constantly degrades the NF-κB-inducing kinase (NIK), which would 
activate the non-canonical NFκB pathway. Upon CD40 engagement 
TRAF2 and TRAF3 are recruited to the receptor and degraded by 
autoubiquitinylation or cIAP1 and cIAP2-mediated degradation, thus 
preventing the degradation of NIK. NIK then accumulates though new 
protein synthesis and activates NFκB signalling (Brown et al., 2002; 
Elgueta et al., 2009; Hostager and Bishop, 2013; Vallabhapurapu et al., 
2008; Zarnegar et al., 2008). 
In B cells, casitas-B-lineage lymphoma protein-B (CBLB) has been shown 
to have a negative role in the regulation of CD40 signalling by reducing the 
recruitment of TRAF2 to CD40 leading to reduced NFκB and JNK 
activation (Qiao et al., 2007). Conversely, CBLB has the opposite role in 
DCs (Arron et al., 2001). Similarly, Janus kinase (JAK) signalling by JAK3 
directly binding to CD40 and being critical for B cell gene expression 
(Hanissian and Geha, 1997) could not be verified in human B cells as 
JAK3 was not phosphorylated here. However, monocytes could   92 
phosphorylate JAK3 upon CD40 ligation again showing differences in 
CD40 signalling between B cells and other cell types (Revy et al., 1999). 
 
1.4.3  Interleukin-4 receptor signalling 
IL-4 binds the IL-4 receptor (IL-4R) to initiate signalling. There are two 
types of IL-4 receptors: type 1 receptor is composed of IL-4Rα chain and 
the IL-2 receptor common γ chain (γc) whereas the type 2 receptor consists 
of the IL-4Rα chain and the IL-13α1 receptor chain, to both of which IL-4 
can bind via the IL-4Rα  chain and then recruit the second chain for 
signalling (Luzina et al., 2012). The related cytokine IL-13 can bind to type 
2 receptors through binding to the IL-13Rα1 chain and initiate similar 
signalling mechanisms but with distinct outcomes depending on the 
expression to the types of receptor on different cell types and slightly 
different activation of downstream signalling pathways (Wills-Karp and 
Finkelman, 2008). In addition, IL-13 can bind to another chain, termed IL-
13Rα2, mostly acting as a decoy receptor (Kawakami et al., 2001; Luzina 
et al., 2012). Signalling through IL-4 has been implicated with several 
different phenotypes in particular switching to IgE in B cells and 
polarisation of Th0 cells towards the Th2 lineage. IL-13 on the other hand 
is more associated with mediating airway hyperresponsiveness and 
mucus secretion in allergic reactions (Wills-Karp and Finkelman, 2008). 
The IL-4R chains lack intrinsic kinase activity but are associated with 
JAKs. IL-4 signalling is initiated by receptor dimerisation allowing trans- 
and autophosphorylation of JAKs and tyrosines on the receptor chains   93 
(Luzina et al., 2012). Whereas type 1 receptors activate JAK1 and JAK3 
via JAK3-mediated binding to γc, the type 2 receptor activates JAK1, JAK2 
and Tyk2 via IL-13Rα1 binding of JAK2 and Tyk2 (Wills-Karp and 
Finkelman, 2008). Moreover, SYK has been found to constitutively bind to 
IL4Rα1 in human neutrophils (Ennaciri and Girard, 2009). The 
phosphorylated tyrosines on the receptor chains serve as binding site for 
proteins with SH2-domains. Subsequent to JAK binding and 
phosphorylation of sites on the receptor chains, signal transducer and 
activator of transcription 6 (STAT6) can be recruited and phosphorylated 
by JAKs. This leads to dimerisation and translocation of STAT6 into the 
nucleus to act as a transcriptional activator (Luzina et al., 2012; Nelms et 
al., 1999; Wills-Karp and Finkelman, 2008; Witthuhn et al., 1994). 
Moreover, these residues allow binding of insulin receptor substrate (IRS) 
proteins, either IRS1 or IRS2, the type of which depending on the cell type 
with IRS2 expressed in haematopoietic cells and IRS1 in non-
haematopoietic cells (Keegan et al., 1994; Luzina et al., 2012; Nelms et 
al., 1999; Wills-Karp and Finkelman, 2008). IRS proteins become 
phosphorylated and act as signalling scaffold leading to PI3K followed by 
AKT activation as well as signalling via GRB2 and SOS resulting in MAPK 
activation.  (Nelms et al., 1999; Wills-Karp and Finkelman, 2008). 
Interestingly, another mechanism that seems to differentiate IL-13 from IL-
4 signalling in macrophages is that activation of IRS-2 is only found by 
activation of type 1 receptors. Lack of type 1 receptors on IL-4 stimulated 
bone-marrow derived macrophages led to reduced mRNA expression of   94 
alternatively activated macrophage marker genes such as Arginase 1 
(Arg1), found in inflammatory zone (Fizz1) and chitinase-like 3 (Ym1) 
(Heller et al., 2008). 
 
1.4.4  BAFF and APRIL signalling 
Like CD40L, BAFF (also known as TNFSF13B, BLyS or TALL-1) and 
APRIL (also known as TNFSF13 or TALL-2) belong to the TNF ligand 
family. Both BAFF and APRIL are homotrimeric type II transmembrane 
proteins (Mackay and Schneider, 2009). APRIL can also be trans-spliced 
with the neighbouring gene TNF-related weak inducer of apoptosis 
(TWEAK) which is gives rise to another ligand called TWE-PRIL about 
which little is known (Pradet‐Balade et al., 2002). Both BAFF and APRIL 
are proteolytically processed to form soluble ligands but BAFF is also 
found in a membrane bound form (Mackay and Schneider, 2009). BAFF 
usually forms trimers but can also form a 60-mer (Liu et al., 2003). BAFF 
and APRIL both bind to BCMA and TACI. Additionally, BAFF also binds 
and signals through BAFFR and was found to bind to the Nogo-66 
receptor on neurons (Mackay and Schneider, 2009; Vincent et al., 2013; 
Zhang et al., 2009). APRIL can bind to heparin sulphate proteoglycans 
such as syndecans found on pre-B cells and plasma cells but does not 
signal through them. However, it is still biologically active when bound in 
this form (Huard et al., 2008; Kimberley et al., 2009). The binding affinities 
of the two ligands differ between the three receptors and allow distinct 
roles of each cytokine and receptor combination (Mackay and Schneider,   95 
2009). Binding of a homotrimeric ligand induces signalling by trimerising 
the receptor although further multimerisation of the ligands might be 
required as in the case of BAFF or APRIL binding to TACI (Bossen et al., 
2008; Kimberley et al., 2009). 
Receptor oligomerisation leads to recruitment of TRAFs and downstream 
non-canonical NFκB signalling, again similar to CD40 signalling. BAFFR 
recruits TRAF3 whereas TACI recruits TRAF2 and TRAF6 (Baud et al., 
1999; Gardam et al., 2008; Mackay and Schneider, 2009; Xie et al., 2007; 
Xu and Shu, 2002).  
The signalling mechanism used by BAFFR to activate non-canonical NFκB 
is so far identical to the one used by CD40. NIK kinase activates non-
canonical NFκB signalling but is normally degraded by a complex of 
TRAF2  and TRAF3  in complex with cIAP1 and cIAP2. Upon BAFFR 
ligation, TRAF3 is recruited to the receptor at the plasma membrane and 
the complex is unable to degrade NIK, leading to NIK accumulation and 
activation of the non-canonical NFκB signalling cascade (Vallabhapurapu 
et al., 2008). Other signalling pathways are also engaged by BAFFR but 
the exact signalling mechanisms of their activation and interaction partners 
are so far obscure. These include weak activation of canonical NFκB and 
activation of PI3K (Enzler et al., 2006; Patke et al., 2006). BAFFR ligation 
leads to Igα  and Syk phosphorylation, which activates PI3K and ERK 
signalling (Schweighoffer et al., 2013). PI3K leads to AKT1 activation via 
phosphoinositide-dependent kinase 1 (PDK1). Additionally, PKCβ is also 
involved in the AKT1 activation (Patke et al., 2006). Together with signals   96 
from the kinase PIM2, which is activated by BAFF via the non-canonical 
NFκB pathway, BAFF-induced AKT1 activation results in increased 
metabolic fitness and production of anti-apoptotic proteins, in particular 
MCL1, supporting B cell survival (Enzler et al., 2006; Mackay and 
Schneider, 2009; Patke et al., 2006; Woodland et al., 2008). 
 
1.4.5  Toll-like receptor signalling 
Signalling pathways for TLRs have mostly been elucidated in myeloid cells 
such as DCs and macrophages (Peng, 2005). The major TLR signalling 
pathways in these cells have been reviewed extensively  and are 
summarised in Figure 3 (Broz and Monack, 2013; Kawai and Akira, 2009; 
Kawai and Akira, 2011; Kondo et al., 2012). The extent to which they are 
conserved in B cells and between mouse and human are not completely 
clear at the moment. Moreover, TLR expression is B cell subset specific 
and differs between mouse and human. In particular, TLR4 seems to be 
present at very low levels on human B cells whereas it is readily 
detectable on mouse B cells (Bekeredjian-Ding and Jego, 2009; 
Bekeredjian-Ding et al., 2005; Hornung et al., 2002). It should be noted 
that for example the roles of TRAF proteins seem to be different in B cells 
and myeloid cells. For example, whereas TRAF3 leads to enhanced 
responses in macrophages it seems to be a negative regulator in TLR 
responses by B cells (Hacker et al., 2006; Xie et al., 2011). 
Models for TLR signalling pathways in B cells have been proposed, 
however these are mainly based on correlations with myeloid cells and   97 
have mostly not been directly tested (Peng, 2005). TLR7 and TLR9 are 
generally strongly expressed in B cells and have been proposed to lead to 
activation of the IL-1 receptor-associated kinases (IRAKs). IRAKs in turn 
activate TRAF6 leading to activation of TGFβ-activated kinase (TAK1). 
This pathway then leads to MAPK and IKK activation resulting in activator 
protein-1 (AP-1)-family and NFκB-mediated transcription of target genes 
(Peng, 2005). The proposed model for TLR4 activation through myeloid 
differentiation primary response gene 88 (MyD88) leads to the activation of 
the same signalling pathways as proposed for TLR7 and TLR9. In 
addition, the TLR4 pathway through TIR-domain-containing adaptor 
protein inducing IFNβ (TRIF) leads to activation of TRAF family member-
associated NFκB activator (TANK)-binding kinase 1 (TBK1) and IRF3 
mediated transcription, atypical IKK activation and NFκB-mediated 
transcription and activation of protein kinase R (Peng, 2005). 
Some roles for TLR signalling in B cells have been mentioned throughout 
the text but several others have been described (Bekeredjian-Ding and 
Jego, 2009; Browne, 2012; Hua and Hou, 2013; Rawlings et al., 2012). 
Generally, TLRs in B cells are involved in the development of B cells, B 
cell cytokine secretion, CSR and antibody responses (Barr et al., 2007; 
Hayashi et al., 2005; Hou et al., 2008; Hou et al., 2011; Lutzker et al., 
1988). In particular, autoantibody production is regulated by TLRs as TLR 
ligands such as DNA, contained in immune complexes, can be a BCR 
ligand at the same time as a TLR ligand and lead to B cell activation by   98 
delivering the first and second signal simultaneously, similar to type I T-
independent antigens (Leadbetter et al., 2002; Vinuesa and Chang, 2013).   99 
 
Figure  3: Simplified TLR signalling scheme derived from myeloid 
cells. 
Cell surface TLRs signal via the adaptor protein MYD88 to IRAKs. TLR3 
signals from the endosome using the adaptor TRIF. TLR4 signals first from 
the cell surface via MYD88 and after endocytosis via TRIF using the 
adaptors TIRAP and TICAM2 respectively. IRAKs phosphorylate and   100 
activate TRAFs, a family of ubiquitin ligases, which can activate signalling 
by NFκB, IRFs and MAP kinases. IRFs generally lead to the transcription 
of type 1 interferon genes although they can also drive proinflammatory 
cytokine expression depending on the cellular context. TRAF6 though 
autoubiquitinylation recruits TAK1 via TAB adaptor proteins. TAK1 
activates the IKK complex through phosphorylation which leads to 
lysosomal degradation of IκB and thus release and translocation of p50 
and p65 NFκB subunits into the nucleus driving expression of both 
proinflammatory and type 1 interferon genes. In addition, TAK1 activates 
the MAP kinase cascade leading to phosphorylation and activation of p38, 
JNK and ERK resulting in translocation of transcription factor AP-1 into the 
nucleus and consequently transcription of proinflammatory genes. Most of 
these signalling pathways were elucidated in macrophages or dendritic 
cells and may differ in B cells. TIRAP, TIR domain-containing adaptor 
protein; TICAM2, toll-like receptor adaptor molecule 2; IkB, Inhibitor of kB; 
RIP1, Receptor-interacting serine/threonine-protein kinase 1; TIR domain, 
Toll/IL-1 receptor homology domain; Ub, Ubiquitin; other abbreviations are 
found in the main text or the list of abbreviations.   101 
 
1.5   The Themis family 
The thymocyte-expressed molecule involved in selection (Themis) family 
is a recently identified group of genes with two to three paralogues among 
mammals. The family is characterised by the presence of a cysteine-
containing, all-β  in Themis (CABIT) domain, which is predicted to be 
globular,  consisting of  extended  β-sheets that contain a conserved 
cysteine residue. This domain is often found together with a highly 
conserved proline-rich region and in the case of several higher evolved 
species it has duplicated within the same protein, giving rise to two 
consecutive CABIT domains. During evolution, the motif has been 
conserved, being found in several metazoan genomes down to cnidarians 
(Johnson et al., 2009). 
The function of the CABIT domain is still elusive and whether it purely 
serves a structural function or has an enzymatic activity is currently 
unknown although recent results suggest that the conserved cysteine in 
THEMIS, termed THEMIS1 from here on for clarity, is dispensable for T 
cell development (Zvezdova et al., 2014). The conserved cysteine residue 
is predicted to be on the surface of THEMIS1 and such residues without 
adjacent acidic or histidine residues have been observed in E2 ubiquitin 
ligases, thiol redox and sulphur carrier proteins. It is therefore possible that 
the CABIT domain has a biochemical function (Johnson et al., 2009). 
In mice there are five CABIT domain-containing proteins: Grb2 associated, 
regulator of ERK/MAPK1 (GAREM also known as Fam59A) and GAREM-
like (GAREML also known as GAREM2 or Fam59b) as well as the three   102 
Themis family members: THEMIS1, (also known as GASP, C6orf190 in 
humans), THEMIS2 (also known as ICB-1, ICB1, BC013712 in mouse or 
C1orf38 in humans) and THEMIS3 (9130404H23Rik,  in mouse). In 
contrast to mice, humans lack THEMIS3. Whereas GAREM and GAREML 
only contain one N-terminal CABIT domain, a proline-rich domain and a C-
terminal sterile α-motif (SAM) domain (Johnson et al., 2009; Taniguchi et 
al., 2013; Tashiro et al., 2009), the Themis family bears two consecutive 
CABIT domains followed by a proline-rich region (Johnson et al., 2009). 
The structure of murine Themis2 is outlined in Figure 4. 
Among the Themis family proteins only THEMIS1 and THEMIS2 have 
been studied at the  protein level so far. Evidence for THEMIS3 stems 
either from sequence predictions, large-scale transcriptomic or proteomic 
approaches (Lattin et al., 2008; Su et al., 2004; Villén et al., 2007; Wu et 
al., 2009). 
 
1.5.1  Themis1 
A function for the first family member, Themis1, has been discovered in T 
cells  (Fu et al., 2009; Johnson et al., 2009; Kakugawa et al., 2009; 
Lesourne et al., 2009; Patrick et al., 2009). Themis1-deficient mice show a 
block during positive selection of T cells, which results in decreased 
numbers of single-positive thymocytes. Two groups also reported a defect 
in negative selection using either a mouse mammary tumour virus-based 
superantigen model (Fu et al., 2009)  or a H-Y transgenic TCR model   103 
 
 
Figure 4: Gene and protein structure of murine Themis2. 
Themis2 is encoded by six exons located on mouse chromosome 4. All six 
exons are spliced into one mRNA which is translated into a protein 
consisting of two N-terminal, consecutive CABIT  domains containing 
conserved cysteine residues and a nuclear localisation sequence (NLS) as 
well as a glutamate-rich stretch. The C-terminus contains a proline-rich 
region comprising an SH3-binding site and further downstream a tyrosine 
residue (Y660), which upon phosphorylation, has been shown to be an 
SH2-binding site. Exon 4 is the biggest exon of Themis2 and encodes the 
C-terminal part of the CABIT1 domain, the whole CABIT2 domain and the 
SH3-binding site. It is also the only exon in Themis2 encoding a phase 
shift. Thus, following deletion of exon 4, exon 5 is out of frame with respect 
to exon 3.   104 
 
(Lesourne et al., 2009). However, the results were not completely 
consistent since another study using the same two models saw no effect 
on negative selection (Johnson et al., 2009). This might be due to the way 
THEMIS1 is thought to affect the selection process. It was recently 
reported that THEMIS1 functions as a rheostat that sets the threshold for 
positive and negative selection. In the absence of THEMIS1, which lowers 
the selection threshold, signals that would usually be interpreted  as 
positive selection signals cross the threshold and cells are negatively 
selected instead of positively selected resulting in diminished single-
positive thymocyte numbers. Hence, positive selecting TCR interactions in 
wild type cells are interpreted as strong self-reactive interactions in 
Themis1-deficient cells and are consequently deleted from the repertoire 
(Fu et al., 2013). In addition, the differences observed in the initial studies 
could be due to the experimental approach or due to the mice used since 
the first two studies used Themis1-deficient mice targeted at exon 1 (Fu et 
al., 2009; Lesourne et al., 2009) and the latter study used only a point 
mutated mouse strain leading to a mutant THEMIS1 truncated at the end 
of the second CABIT domain which might have sustained this function in 
negative selection (Johnson et al., 2009). 
The role of THEMIS1 in positive selection also coincides with its highest 
expression in late DN and in DP thymocytes. However, it is still detectable 
in more mature T cells and its expression is not dependent on TCR 
signalling (Fu et al., 2009; Johnson et al., 2009; Lesourne et al., 2009; 
Patrick et al., 2009). The activation and proliferation of Themis1-deficient   105 
peripheral T cells seems  to be reduced although this still awaits 
confirmation using conditional ablation of Themis1 since this might be a 
defect carried through from development (Brockmeyer et al., 2011; Patrick 
et al., 2009). Moreover, this defect was not found in all studies (Lesourne 
et al., 2009). 
The three initial studies came to different conclusions concerning the 
involvement of THEMIS1 in proximal TCR signalling (Fu et al., 2009; 
Johnson et al., 2009; Lesourne et al., 2009). However, it has become clear 
that THEMIS1 is part of the LAT signallosome and that recruitment of 
THEMIS1 to the LAT signallosome is required for its function (Fu et al., 
2013; Lesourne et al., 2012; Paster et al., 2013). It was shown that 
THEMIS1 is tyrosine phosphorylated after TCR cross-linking with similar 
kinetics to the TCR signalling scaffold proteins LAT and SLP-76 
(Brockmeyer et al., 2011; Fu et al., 2009; Lesourne et al., 2009; Paster et 
al., 2013). Overexpression studies of the kinases LCK and ZAP70 indicate 
that they are responsible for THEMIS1 phosphorylation (Paster et al., 
2013). In vitro, phosphorylation of THEMIS1 was dependent on SLP-76, 
LCK and LAT (Brockmeyer et al., 2011). Some studies failed to detect 
more distal TCR signalling defects (Johnson et al., 2009; Lesourne et al., 
2009; Patrick et al., 2009) whereas others have reported small defects in 
ERK and NFAT/AP-1 signalling and Ca
2+ influx which seem to depend on 
the strength and nature of the stimulus (Brockmeyer et al., 2011; Fu et al., 
2013; Fu et al., 2009). 
Reported interactors also fit into the role of THEMIS1 as a signalling   106 
scaffold in TCR signalling cascade including the adaptor GRB2 
(Brockmeyer et al., 2011; Johnson et al., 2009; Lesourne et al., 2009; 
Patrick et al., 2009), the IL-2 inducible T cell kinase (ITK) (Fu et al., 2009), 
PLCγ1 (Brockmeyer et al., 2011; Fu et al., 2009; Zvezdova et al., 2014) 
and VAV1 (Lesourne et al., 2012). GRB2 interacts via its N-terminal src-
homology 3 (SH3) domain with THEMIS1 (Patrick et al., 2009). This 
interaction was dependent on  the proline-rich region of THEMIS1 
(Lesourne et al., 2012; Okada et al., 2014; Zvezdova et al., 2014) however 
one study concluded that it was independent of it (Patrick et al., 2009). 
Interestingly, SOS does not seem to interact with THEMIS1 (Lesourne et 
al., 2012) which might be due to it using the same SH3 domain on GRB2 
and their binding to GRB2 therefore being mutually exclusive (Cussac et 
al., 1994; Patrick et al., 2009). GRB2 also links THEMIS1 to LAT 
(Brockmeyer et al., 2011; Paster et al., 2013). The interaction of THEMIS1 
with GRB2 seems to be constitutive and slightly increased upon TCR 
stimulation (Brockmeyer et al., 2011; Lesourne et al., 2009) but again this 
has not been found in all studies (Patrick et al., 2009). GRB2 has also 
recently been shown to have an important role in positive selection via 
conditional deletion (Jang et al., 2010). The similar results found in these 
papers indicate that the interaction of THEMIS1 with GRB2 together might 
be crucial for thymic selection and cell fate decision (Gascoigne and 
Palmer, 2011). Since there is an array of proteins in T cells containing SH2 
domains, it has been speculated that phosphorylated THEMIS1 might 
interact with SH2 domains of other proteins (Allen, 2009).   107 
In terms of protein localisation,  THEMIS1 has been detected in the 
cytoplasm and in the nucleus. In two studies transfection of tagged 
THEMIS1 into T cell lines showed exclusion form the nucleus (Johnson et 
al., 2009; Patrick et al., 2009). However, other studies located it to the 
cytoplasm and the nucleus, for example via subcellular fractionation and 
immunoblot. This is achieved via a putative nuclear localisation signal 
found in its sequence between residue 330 and 346 which was required 
for nuclear localisation (Fu et al., 2009; Lesourne et al., 2009; Lesourne et 
al., 2012; Okada et al., 2014; Zvezdova et al., 2014). The nuclear 
localisation of THEMIS1 has furthermore been confirmed by a study 
identifying it as a part of the human T-cell nucleolus proteome (Jarboui et 
al., 2011). 
Recently, the functional domains of THEMIS1 were also tested for their 
contributions to THEMIS1 functions. Deletion of the NLS, the proline-rich 
SH3 binding site (PRS) or the core motifs of the two CABIT domains 
resulted in impaired phosphorylation as well as impaired GRB2-binding 
and the mutants could not restore T cell development in a Themis1-
deficient background. Nuclear localisation was mediated by the core of 
CABIT1 and the NLS and both core mutants showed dominant-negative 
effects on T cell development (Okada et al., 2014). In another study the 
same requirements were found for the NLS and the proline-rich region, 
however, the CABIT domains were not required for THEMIS1 function in 
this study (Zvezdova et al., 2014). These results might be explained by the 
different mutations introduced into the CABIT domains. The former study   108 
deleted CABIT core sequences of 24 to 25 amino acids length whereas 
the latter only introduced alanine point mutations of the conserved 
cysteines of CABIT1 and CABIT2, which could potentially be insufficient to 
abolish THEMIS1 CABIT domain functions. 
Mutations in Themis1 have also been associated with other phenotypes. 
The description of its phenotype led to a reinterpretation of the T-helper 
immunodeficiency of the LEC rat whose defect had hitherto been ascribed 
to the neighbouring gene Ptprk. However, upon re-examination it was 
found to be attributed to the rat orthologue of Themis1 (Iwata et al., 2010). 
A more recent study identified another mutation of Themis1 in a Brown-
Norway rat colony. Reduced CD4
+ T cell levels were observed in these 
rats and the remaining T cells were skewed towards Th2 and Th17 
phenotypes. The T cell lymphopenia originated in the thymus and was T 
cell intrinsic and lead to a high incidence of inflammatory bowel disease 
(IBD). The increase in IBD was partly due to defective suppressive activity 
of regulatory T cells (Chabod et al., 2012). Furthermore, it was reported 
that histone deacetylase 1 and 2 regulate the expression of THEMIS1 
(Dovey et al., 2013). THEMIS1 has also been found to be associated with 
celiac disease, another intestinal immune-mediated disease, in a genome-
wide association study  (Dubois et al., 2010)  which was subsequently 
verified by two other studies (Bondar et al., 2013; Senapati et al., 2014). 
Another study found Themis1  upregulated in thymocytes of prediabetic 
mice linking it to type 1 diabetes (Fornari et al., 2011). Interestingly, an 
intronic single nucleotide polymorphism (SNP) in THEMIS1  has been   109 
linked to several personality traits (Wang et al., 2012) and the possibility 
has been discussed that THEMIS1 is associated with breast cancer (Bhatti 
et al., 2010). 
 
1.5.2  Themis2 
Less is known about the second member of the Themis family. THEMIS2 
was initially identified as “induced by contact to basement membrane-1” 
(ICB-1) in cultured, human cancer cells. Its transcript is upregulated upon 
binding of endothelial adenocarcinoma cells to Matrigel (Treeck et al., 
1998). Later, THEMIS2 was shown to be regulated under several different 
conditions. 
Firstly, it became associated with the monocytic differentiation of acute 
myeloid leukaemia cell line HL-60 following stimulation with retinoic acid, 
vitamin D3 and dimethyl sulfoxide (DMSO), a model for myeloid 
differentiation, in which it was upregulated (Treeck et al., 2002). As 
predicted by the HL-60 model, in another study THEMIS2  was 
undetectable in undifferentiated bone marrow but was induced in both 
lymphocyte-enriched and macrophage-enriched fractions of in vitro 
differentiated bone marrow cells cultured with macrophage-colony-
stimulating factor (M-CSF) (Peirce et al., 2010). The previous study also 
reported four possible human splice variants termed ICB-1-α, -β, γ, and -δ 
(Treeck et al., 2002). Furthermore, THEMIS2 was upregulated following 
IFNγ treatment of various cancer cell lines and its knockdown resulted in a 
stronger inhibition of proliferation by IFNγ (Treeck et al., 2005). In RAW   110 
macrophages stimulation with the proinflammatory stimulus IFNγ also led 
to an increase in THEMIS2 levels whereas anti-inflammatory stimuli such 
as TGFβ and dexamethasone reduced THEMIS2 expression (Peirce et al., 
2010). In vivo inflammatory conditions such as collagen-induced arthritis 
and influenza infection lead to THEMIS2 downregulation in splenocytes 
(Peirce et al., 2010). Conversely, it was found to be upregulated in human 
bronchial epithelial cells upon infection with rhinovirus or stimulation with 
platelet-activating factor (Katz et al., 2006). 
The discovery of a putative, imperfect oestrogen response element (ERE) 
in the promoter region of Themis2, prompted the stimulation of an array of 
cancer cells with various oestrogen receptor-α (ERα) stimuli which were 
found to induce Themis2 expression. However, the increase is slow and 
requires protein synthesis and is thus not a direct effect of ERα binding to 
the ERE (Bollmann et al., 2008). Conversely, RNA interference (RNAi) of 
THEMIS2 enhances proliferation of various cancer cell lines in response to 
oestrogen. Higher levels of ERα-dependent genes like c-FOS are 
observed and more ERα  is produced upon THEMIS2  knockdown 
(Konwisorz et al., 2010). Additionally, silencing of THEMIS2 reduces the 
vitamin D3 or all-trans retinoic acid-induced upregulation of E-cadherin, 
lactoferrin and ERβ  in a breast cancer cell line and THEMIS2  levels 
correlate with E-Cadherin levels in breast cancer samples (Haselberger et 
al., 2011). Knockdown of THEMIS2 in a human breast cancer cell line and 
analysis of global gene expression suggest a network of oncogenic and 
TNF-related genes to be differentially regulated by THEMIS2. Silencing of   111 
THEMIS2  in the human breast cancer cell line also leads to reduced 
responses to apoptosis inducing drugs (Treeck et al., 2012). Similar 
results were obtained with ovarian cancer cell lines. Knockdown of 
THEMIS2  in these cells revealed oestrogen-responsive and again TNF 
related genes to be regulated by THEMIS2.  Moreover,  THEMIS2 
knockdown results in better cell proliferation of the analysed ovarian 
cancer cell lines (Treeck et al., 2013). Other links to both breast and 
ovarian cancer were found in genetic association studies. The G allele of 
an intronic single nucleotide polymorphism (SNP) in THEMIS2 (A to G, 
rs1467465) is associated with lower breast cancer incidence in healthy 
individuals suggesting a protective role of this variation (Springwald et al., 
2009).  The  same  SNP is also  associated with susceptibility to ovarian 
cancer  with higher incidence of the A allele in ovarian cancer patients 
(Schüler et al., 2014). 
Several other studies reported regulation of Themis2  under different 
conditions. Themis2 regulation was found in extrathymic Aire-expressing 
cells (eTACs) and its expression is repressed in these cells by 
autoimmune regulator (Aire) (Gardner et al., 2008).  Themis2  is also 
upregulated in pancreatic islet cells after IFNα treatment (Hultcrantz et al., 
2007). In endometrial cancers, Ki-67 as well as THEMIS2 expression is 
elevated compared to normal endometrium and THEMIS2  positively 
correlates with v-erb-b2 erythroblastic leukemia viral oncogene homolog 2 
(HER2) expression (Springwald et al., 2010). 
Interestingly, HER2 also signals using GRB2 (Olayioye, 2001). As in the   112 
case of THEMIS1, THEMIS2 has also been found to interact with GRB2 in 
macrophages. As for THEMIS1, this interaction seems to depend on the 
presence of the conserved proline-rich region (Peirce et al., 2010). The 
proline-rich region is a potential SH3-binding domain with an atypical 
sequence, which has been shown in other proteins to bind SH3 domains 
(Lock et al., 2000).  Furthermore, THEMIS2 is  tyrosine phosphorylated 
upon LPS stimulation and associates with LYN. This phosphorylation was 
identified to be on residue Y660, making its sequence a potential SH2-
binding site at the C-terminal end of the protein. This residue was also 
required for association with LYN. Moreover, THEMIS2 was found to 
interact with VAV1, however neither the SH3- nor the SH2-binding site are 
required for this association. Overexpression of THEMIS2 in RAW 
macrophages leads to a slight increase in p38 and ERK phosphorylation 
but JNK signalling, NF-kB p65 and IRF3 translocation to the nucleus are 
unaffected. Furthermore, the overexpression leads to a twofold increase in 
TNFα production upon LPS stimulation but not upon stimulation with other 
TLR ligands such as PAM3 or poly-IC. IL-6 production and 
cyclooxygenase 2 (COX2) production are unaffected in this experimental 
system. This increase of TNFα production is dependent on both the SH3- 
and the SH2-binding sites and a 20 – 50 % knockdown of THEMIS2 in 
human macrophages results in a 50 % reduction in TNFα release. The 
effect of THEMIS2 on TNFα production is at least partially attributable to 
the transcriptional control of TNFα production (Peirce et al., 2010). Lastly, 
it was shown that THEMIS2 is phosphorylated shortly after BCR cross-  113 
linking  in primary mouse B cells,  possibly by src-family kinases, 
suggesting that it might have a function in B cells (Lesourne et al., 2012). 
 
1.5.3  Garem and Gareml 
More recently studies on these two CABIT-domain containing proteins 
have been undertaken. GAREM was found to transduce signals from the 
epidermal growth factor (EGF) receptor and influence transformation 
activity of cells. Much like the Themis proteins it is tyrosine phosphorylated 
after receptor activation and binds to GRB2 in a phosphorylation and 
proline-rich region dependent manner. SH2 domain-containing 
phosphatase 2 (SHP2) binds to GAREM and regulates ERK signalling 
independent of SOS or GRB2-associated binder (GAB1) (Tashiro et al., 
2009). 
GAREML also mediates EGF signals but whereas GAREM is expressed 
ubiquitiously, GAREML is specifically expressed in the mouse,  rat and 
human brain. Like GAREM, GAREML also is phosphorylated after 
receptor activation, binds to GRB2 and regulates ERK signalling via SHP2. 
Moreover GAREML responds to stimulation by insulin-like growth factor 1 
inducing neuronal differentiation in a neuroblastoma cell line. Whereas 
GAREM is recruited to the nucleus GAREML is cytosolic. This might be 
due to an N-terminal NLS resembling a 14-3-3ε binding site in GAREM 
(Taniguchi et al., 2013). 
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1.5.4  Differences and similarities between Themis1  and 
Themis2 
In terms of overall structure, Themis1  and  Themis2  are highly similar. 
Features of murine THEMIS2 are highlighted in Figure 4. Both feature two 
consecutive CABIT domains at the N-terminus followed by a PRS and a 
possible phosphorylation site at the C-terminal end. THEMIS2 is slightly 
longer with 663 amino acid in the mouse compared to 636 residues in 
THEMIS1. However, THEMIS1 and THEMIS2 amino acid sequences are 
highly similar (EMBOSS Needle: 31 % identical, 50 % similar in mouse) 
and are well conserved between mouse and human (65 % identical, 77 % 
similar for THEMIS2). Both also have a nuclear localisation sequence 
(NLS) found in the second CABIT domain and for both THEMIS1  and 
THEMIS2 it has been shown that they are found in the cytoplasm as well 
as in the nucleus (Fu et al., 2009; Jarboui et al., 2011; Lesourne et al., 
2009; Lesourne et al., 2012; Okada et al., 2014; Zvezdova et al., 2014).  
The proteins are so similar that THEMIS2 can substitute THEMIS1 and 
restore T cell development to wild type levels in Themis1-deficient mice if 
THEMIS2 is ectopically expressed in the T cell lineage. A construct with 
Themis2  under the control of the human CD2 promoter was used to 
express THEMIS2 in T lineage cells. The construct was introduced 
retrovirally into the bone marrow of Themis1-deficient mice and showed 
complete rescue of T cell development (Lesourne et al., 2012). 
In general, the currently known interactome of both proteins consists of 
proteins associated with T cell receptor (TCR) or B cell receptor (BCR)   115 
signalling and both share GRB2 as a binding partner through the proline-
rich domain (Patrick et al., 2009; Peirce et al., 2010).  
The biggest difference observed so far is the tissue expression pattern. 
Themis1 expression is restricted to T cells (Fu et al., 2009; Johnson et al., 
2009; Lesourne et al., 2009)  whereas according to microarray data, 
Themis2  is expressed in B cells, macrophages and dendritic cells. 
Themis3 has been detected in the intestine according to publicly available 
data (www.biogps.org and www.immgen.org) (Lattin et al., 2008; Su et al., 
2004; Wu et al., 2009). Recently, public data from the phenotyping pipeline 
at the Wellcome Trust Sanger Institute reported a mouse containing a 
reporter construct in the Themis2 locus and showed that Themis2 is only 
expressed in tissues containing B cells, macrophages and dendritic cells 
(www.sanger.ac.uk/mouseportal) (Dyke and Hubbard, 2011). Furthermore 
chromatin-immunoprecipitation experiments from the ENCODE project 
(genome.ucsc.edu/encode) indicate  that transcription factors typically 
associated with B cell development such as PAX5, EBF1 and PU.1 bind to 
the promoter region of human THEMIS2 (Rosenbloom et al., 2013). Taken 
together, these results suggest tissue specific functions for each member 
of the Themis family.   116 
 
1.6   Aims and hypothesis 
It has been noted for a long time that there are strong similarities between 
BCR and TCR signalling pathways (Weiss and Littman, 1994). Often one 
protein will exert a certain function in T cells while its paralogue performs a 
similar function in B cells. Examples are the roles of SYK-family kinases 
ZAP70 and SYK (Mócsai et al., 2010), isoforms of PI3Ks (Okkenhaug, 
2013), the adaptor proteins SLP-76 and BLNK (Koretzky et al., 2006) or 
the different requirements for the Rho-family guanine-nucleotide exchange 
factors VAV1/2/3 in T and B cells (Swat and Fujikawa, 2005). Given the 
important role for THEMIS1 in T cell development and the high degree of 
similarity between THEMIS1 and THEMIS2, I tested the hypothesis that 
THEMIS2 might have a function in B cell development or activation similar 
to that of THEMIS1 in T cells. 
Therefore I measured the expression of the Themis-family in B lineage 
cells and show that Themis2 is expressed throughout the B cell lineage in 
a non-redundant manner. After B cell activation Themis2 is downregulated 
but is also not substituted by other CABIT domain-containing proteins. The 
creation of a Themis2-deficient mouse strain allowed the me to analyse 
the effects of loss of THEMIS2 in B cells but surprisingly I found that B cell 
development, activation and antibody responses are unaffected by a 
deficiency of THEMIS2.   117 
2  Materials and methods 
2.1  Mice 
All mice were kept under specific pathogen-free conditions at the animal 
facility of the Medical Research Council National Institute for Medical 
Research (NIMR), and all animal experiments were treated according to 
institutional guidelines (NIMR Ethical Review Panel) and UK Home Office 
regulations. The C57BL/6N embryonic stem cell line JM8.F6 with the 
targeted allele Themis2
tm1a(KOMP)Wtsi were provided by the Welcome Trust 
Sanger Institute and used to generate mice on a C57BL/6 background at 
the Hammersmith Hospital. Those mice were kindly provided by Matthew 
Peirce. In order to obtain the Themis2
tm1d(KOMP)Wtsi  allele, here further 
called Themis2
KO, Themis2
tm1a(KOMP)Wtsi  mice were crossed first to 
C57BL/6J-Tg(Prm-cre)70Og mice carrying the Cre recombinase under the 
control of the Protamine promoter (also known as PC3::Cre) (O'Gorman et 
al., 1997)  and then to C57BL/6J-Tg(ACTFLPe)9205Dym mice with 
recombinase FLPe under the control of the human ACTB promoter (also 
known as ACTB::FLPe) (Rodríguez et al., 2000). All experiments used age 
and sex-matched littermate control animals. 
B6.SJL-Ptprc
a (CD45.1
+) (Shen et al., 1985), Rag1
tm1Mom (Rag1-deficient) 
(Mombaerts et al., 1992) and Tg(TcraTcrb)425Cbn (OT-II) (Barnden et al., 
1998) Il10
tm1Flv (IL-10 GFP reporter tiger mice) (Kamanaka et al., 2006), all 
on a C57BL/6 background, were obtained from the breeding facility at 
NIMR.   118 
2.2  Mixed bone marrow chimeras 
Bone marrow from femora and tibiae of B6.SJL-Ptprc
a and Themis2
KO/KO 
and wild type littermate control donor mice was harvested separately. Red 
blood cells were lysed by resuspension in ACK lysis buffer for 2 min at 
room temperature. Cell concentrations were determined and B6.SJL-
Ptprc
a  bone marrow was mixed at the  indicated ratios with either 
Themis2
KO/KO or wild type control bone marrow and then intravenously 
injected into recipient Rag1-deficient mice (at least 2 × 10
6 cells/recipient). 
Injection was done by Edina Schweighoffer and ratios were confirmed by 
flow cytometry. Recipient Rag1-deficient animals were irradiated with 5 Gy 
using a 
137Cs-source, prior to injection. Chimeric animals received Baytril 
in their drinking water (0.02 %, Bayer Healthcare) for at least 4 weeks and 
were analysed by flow cytometry from 6 weeks on after transplantation. 
 
2.3  |mmunisations and anaesthesia 
Mice were injected i.p. with PBS containing 10
9  SRBC (Innovative 
Research), or 50 μg 4-hydroxy-3-nitrophenylacetyl (NP)(0.6)-LPS in PBS, or 
50  μg NP(40)-AECM-Ficoll in PBS, or 50 μg NP(21)-CGG (all BioSearch 
Technologies) in Alum (Thermo Scientific) with PBS for primary 
immunisations, or 50 μg NP(21)-CGG in PBS for rechallenge and were bled 
or sacrificed at various time points for analysis or cell sorting. For cholera 
toxin immunisation, food was withdrawn from mice 3 h before being orally 
gavaged first with 1.5 % NaHCO3 and then with 125 µg/kg cholera toxin 
from  Vibrio cholerae  Inaba 569B (List Biological Laboratories) in PBS.   119 
Blood was withdrawn at the indicated time points. Mice were sacrificed 
14 d after immunisation to obtain faecal samples from the small intestine. 
The acute house dust mite (HDM) model  was performed together with 
Mark Wilson and mice were immunised i.p. with 10 µg crude HDM (Greer) 
in PBS with 25 % Alum (Thermo Scientific) on day 0  and day 14. For 
intratracheal challenges on day 28 and 31 mice were anaesthetised with a 
mix of 1 mg/mL ketamine with 0.1 mg/mL mededomidine in water and 
injected 0.1 mL / 10 g body weight i.p. (10 mg/kg ketamine and 1 mg/kg 
mededomidine). For intratracheal challenge each mouse received 100 µg 
HDM in 20 µL PBS by intratracheal gavage under anaesthesia. 
Anaesthesia was reversed using i.p. injection of atipamezole at 500 µg/mL 
and 0.1 mL / 10 g (5 mg/kg). For terminal anaesthesia mice received 
pentobarbitone 25 mg/mL at 0.1 mL / 10 g body weight (250 mg/kg). Mice 
were terminally bled under terminal anaesthesia.  
 
2.4  Preparation of single cell suspensions 
Single cell suspensions of bone marrow were prepared by flushing the 
bone marrow out of the bone using a syringe. Single cell suspension of 
spleen, Peyer’s patches, peripheral lymph nodes and mesenteric lymph 
nodes were prepared by pushing the organs through a 70 µm strainer and 
rinsed using medium. Blood was collected using heparinised capillaries 
and peritoneal washes were obtained by flushing the peritoneum with 
5 mL of PBS CMF containing 5 mM EDTA. Cells were generally handled 
on ice and centrifuged at 326 g (1300 rpm) for 5 min at 4 °C and kept in   120 
air-buffered Iscove’s modified Dulbecco’s medium (AB IMDM) with 2 % 
foetal calf serum (FCS) (Lonza). Lungs were pushed through a 70 µm 
strainer then live cells were purified using 40 % isotonic percoll (GE 
Healtcare) in AB IMDM, layering the cells on top and then spinning for 
20 min at 873 g (2000 rpm) with low deceleration. The pellet was used for 
further processing. Where required, cell suspensions were treated with 
ACK lysis buffer for 2 min at room temperature to remove red blood cells. 
 
2.5  Splenic B cell isolation 
Single cell suspensions were prepared as in section 2.4 and splenic B 
cells were isolated by magnetic negative depletion using biotinylated 
antibodies against CD43, CD11c, CD11b, Gr-1, and 1.2 to 1.4 × 10
8 
streptavidin-Dynabeads (Life Technologies) in MACS-buffer unless stated 
otherwise. Purities of the isolations were verified by flow cytometry and 
were generally around 95 %. 
 
2.6  Flow cytometry, cell sorting and cell enrichment 
Single cell suspensions were stained for 20 min in ice cold PBS containing 
LIVE/DEAD fixable near-IR or aqua dead cell stain (Life Technologies) and 
the appropriate, pre-titred antibodies. Cell numbers in the bone marrow 
are quoted per leg (1 femur and 1 tibia). Regulatory B cells were purified 
using the Miltenyi Biotec Regulatory B cell isolation kit with 24 h in vitro 
LPS stimulation and phorbol-12-myristate-13-acetate  (PMA)  and   121 
ionomycin for the last 5 h of stimulation followed by flow cytometric sorting 
for B220
+ CD19
+ IL-10
+ cells (Supplementary Figure 1). To isolate plasma 
cells and plasmablasts, organ suspensions from mice immunised 5 days 
earlier with SRBC were enriched for CD138
+ cells by staining with anti-
CD138-PE and then using anti-PE beads according to the manufacturer’s 
instructions (Miltenyi Biotec) followed by sorting for B220
- CD138
+ cells for 
plasma cells and B220
+ CD138
+ cells for plasmablasts. Regulatory B cells, 
plasmablasts and plasma cells were enriched in AutoMACS buffer using 
the AutoMACS Pro (Miltenyi Biotec). To isolate germinal centre B cells, 
splenocytes from mice immunised 10 days earlier with SRBC were 
depleted using anti-CD43-biotin and anti-IgD-biotin followed by 
streptavidin-Dynabeads and then sorted for B220
+  PNA
+  GL7
+  Fas
+ 
CD38
low-int. Cell identities of antigen-experienced cell types was verified by 
qRT-PCR for upregulation of lineage transcription factors or cytokines 
(Supplementary Figure 2). Data were collected on a BD FACSCanto II or 
sorted on BD FACSAria II, BD Influx or Beckman Coulter MoFlo XDP cell 
sorters. Data were analysed using FlowJo 9.6 (TreeStar). 
 
 
Table 1: Antibodies and staining reagents for flow cytometry and cell 
enrichment 
Target 
Conju-
gation 
Supplier  Cat. No.  Clone  Isotype 
Dilu-
tion 
[µ µg/ 
mL] 
CD1d 
AlexaFlu
or 488 
eBioscience  53-0011-82  1B1  Rat IgG2b, κ  1:100  5.0 
CD2  PE  BD Pharmingen  553112  RM2-5  Rat IgG2b, λ  1:800  0.25 
CD3  AF488  BioLegend  100210  17A2  Rat IgG2b, κ  1:200  2.5 
CD4 
PerCPC
y5.5 
BioLegend  100434  GK1.5  Rat IgG2b, κ  1:200  1.0 
CD4  PerCP  BioLegend  100538  RM4-5  Rat IgG2a, κ  1:200  1.0 
CD4  eF450  eBioscience  48-0042-82  RM4-5  Rat IgG2a, κ  1:400  0.5   122 
CD5  PE  eBioscience  12-0051-83  53-7.3  Rat IgG2a, κ  1:100  2.0 
CD8α  BV570  BioLegend  100739  53-6.7  Rat IgG2a, κ  1:100  2.0 
CD8α  PE  eBioscience  12-0081-83  53-6.7  Rat IgG2a, κ  1:200  1.0 
CD8α  PerCP  BioLegend  100732  53-6.7  Rat IgG2a, κ  1:200  1.0 
CD8α  PECy7  eBioscience  25-0081-82  53-6.7  Rat IgG2a, κ  1:400  0.5 
CD8α  APC  eBioscience  17-0081-82  53-6.7  Rat IgG2a, κ  1:200  1.0 
CD11b  PECy7  BioLegend  101216  M1/70  Rat IgG2b, κ  1:200  1.0 
CD11b  PE  eBioscience  12-0112-82  M1/70  Rat IgG2b, κ  1:200  1.0 
CD11b  Biotin  eBioscience  13-0112-85  M1/70  Rat IgG2b, κ  1:200  2.5 
CD11c 
Pacific 
Blue 
BioLegend  117322  N418  Ar Ham IgG  1:200  2.5 
CD11c  PE  eBioscience  12-0114-83  N418 
Ar Ham 
IgG1, λ2 
1:200  2.5 
CD11c  Biotin  eBioscience  13-0114-85  N418 
Ar Ham 
IgG1, λ2 
1:200  2.5 
CD19 
PerCPC
y5.5 
BD Pharmingen  551001  1D3  Rat IgG2a, κ  1:200  1.0 
CD19   APC  Life Technologies  RM7705  6D5  Rat IgG2a  1:100  2.0 
CD19  eF450  eBioscience  48-0193-82  eBio1D3  Rat IgG2a, κ  1:200  1.0 
CD23  PE  eBioscience  12-0232-83  B3B4  Rat IgG2a, κ  1:400  0.5 
CD23  APC  Life Technologies  MCD2305  B3B4  Rat IgG2a, κ  1:200  1.0 
CD38  FITC  eBioscience  11-0381-85  90  Rat IgG2a, κ  1:200  2.5 
CD38  PECy5  eBioscience  15-0381-82  90  Rat IgG2a, κ  1:200  2.5 
CD43  PE  BD Pharmingen  553271  S7  Rat IgG2a, κ  1:200  1.0 
CD43  Biotin  eBioscience  13-0431-85 
eBioR2/6
0 
Rat IgM  1:200  2.5 
CD45  APCCy7  BioLegend  103116  30-F11  Rat IgG2b, κ  1:200  1.0 
CD45.1  FITC  eBioscience  11-0453-85  A20  Rat IgG2a, κ  1:200  2.5 
CD45.2  PECy7  BioLegend  109830  104 
Mouse (SJL) 
IgG2a, κ 
1:200  1.0 
CD69  FITC  BD Pharmingen  553236  H1.3F2 
Ar Ham 
IgG1, λ3 
1:200  2.5 
CD86  PE  BD Pharmingen  553692  GL1  Rat IgG2a, κ  1:400  0.5 
CD93 
(AA4.1) 
APC  eBioscience  17-5892-83  AA4.1  Rat IgG2b, κ  1:100  2.0 
CD138  PE  BD Pharmingen  553714  281-2  Rat IgG2a, κ  1:200  1.0 
B220  PE  eBioscience  12-0452-85  RA3-6B2  Rat IgG2a, κ  1:200  1.0 
B220  PerCP  BD Pharmingen  553093  RA3-6B2  Rat IgG2a, κ  1:200  1.0 
B220 
PerCPC
y5.5 
BioLegend  103236  RA3-6B2  Rat IgG2a, κ  1:200  1.0 
B220  PETR  Life Technologies  RM2617  RA3-6B2  Rat IgG2a, κ  1:200  1.0 
B220  eF450  eBioscience  48-0452-82  RA3-6B2  Rat IgG2a, κ  1:200  1.0 
B220  BV570  BioLegend  103237  RA3-6B2  Rat IgG2a, κ  1:200  0.5 
CXCR5  Biotin  BD Pharmingen  551960  2G8  Rat IgG2a, κ  1:100  5.0 
F4/80  APC  eBioscience  17-4801-82  BM8  Rat IgG2a, κ  1:100  2.0 
Fas 
(CD95) 
PE  BD Pharmingen  554258  Jo2 
Ar Ham 
IgG2a, λ2 
1:200  1.0 
GL7 
(Ly77) 
AlexaFlu
or 647 
BD Pharmingen  553666  GL7  Rat IgM, κ  1:100  2.0 
Gr-1  Biotin  eBioscience  13-5931-85  RB6-8C5  Rat IgG2b, κ  1:200  2.5 
IgD  PE  eBioscience  12-5993-83  11-26c  Rat IgG2a, κ  1:200  1.0 
IgD  eF450  eBioscience  48-5993-82  11-26c  Rat IgG2a, κ  1:200  1.0 
IgD  Biotin  eBioscience  13-5993-85  11-26c  Rat IgG2a, κ  1:200  2.5 
IgM 
Fab 
FITC 
Jackson 
ImmunoResearch 
115-097-
020 
polyclon
al 
goat Fab  1:300  0.5 
IgM  PerCP  Santa Cruz  Sc-45094 
Polyclon
al 
Goat  1:200  2.0 
IgM  PECy5  eBioscience  21-5790-82  II/41  Rat IgG2a, κ  1:200  1.0 
IgM  PECy7  eBioscience  25-5790-82  II/41  Rat IgG2a  1:200  1.0 
IgM 
F(ab)2 
Biotin 
Jackson 
ImmunoResearch 
115-066-
075 
polyclon
al 
Goat F(ab)2  1:220  5.0 
IgG1  APC  BD Pharmingen  550874  X56  Rat IgG1, κ  1:200  1.0 
Ly6C 
PerCPC
y5.5 
BioLegend  128012  HK1.4  Rat IgG2c, κ  1:200  1.0 
Ly6G 
Pacific 
Blue 
BioLegend  127612  1A8  Rat IgG2a, κ  1:200  2.5 
MHC 
class II 
eF450  eBioscience  48-5321-82 
M5/114.
15.2 
Rat IgG2b, κ  1:400  0.5   123 
NK1.1  APC  eBioscience  17-5941-82  PK136  Rat IgG2a, κ  1:200  1.0 
PD-1 
(CD279) 
BV421  BioLegend  135217 
29F.1A1
2  Rat IgG2a, κ  1:200  1.0 
PNA  FITC  Vector Laboratories  FL-1071  -  -  1:1000  5.0 
Siglec-F  PE  BD Pharmingen  552126 
E50-
2440 
Rat IgG2a, κ  1:200  1.0 
Strept-
avidin 
PE  BD Pharmingen  554061  -  -  1:200  2.5 
TCRβ  FITC  eBioscience  11-5961-85  H57-597 
Ar Ham 
IgG1, λ1 
1:200  2.5 
TCRβ  PE  eBioscience  12-5961-83  H57-597 
Ar Ham 
IgG1, λ1 
1:200  1.0 
TCRβ  APC  eBioscience  17-5961-83  H57-597 
Ar Ham 
IgG1, λ1 
1:100  2.0 
TCRγδ  PE  eBioscience  12-5711-82  eBioGL3 
Ar Ham 
IgG2, κ 
1:200  1.0 
 
2.7  FACS-Gal 
Spleen, peritoneal exudate and bone marrow cells were obtained as 
above and FACS-Gal assay was performed as described previously (Guo 
and Wu, 2008) using the substrate fluorescein di-(β-D-galactopyranoside) 
(FDG) (Sigma-Aldrich) and the inhibitor 2-Phenylethyl β-D-thiogalactoside 
(PETG) (Sigma-Aldrich). Briefly, ACK-lysed single cell suspensions were 
resuspended in 100 µL at 2 × 10
7 cells/mL in Hank’s balanced salt solution 
(HBSS), pre-warmed for 10 min at 37 °C in a water bath and then mixed 
with 100 µL of equally pre-warmed 20 mM FDG in dH2O. FDG loading (at 
10 mM FDG final concentration) was stopped after 1 min by addition of 
2 mL ice-cold HBSS. For catalysis of FDG into fluorescein and galactose 
by  β-galactosidase, cells were left on ice for 45 min unless indicated 
otherwise. The reaction was then stopped by adding 44 µL of 50 mM 
PETG (1 mM final concentration). Cells were then stained for flow 
cytometry as described above. 
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2.8  BCR internalisation assay 
Single cell suspensions of splenocytes were stained on ice with anti-IgM 
F(ab)2-biotin at 10 mg/mL then aliquots were kept in a 37 °C water bath for 
the indicated times and BCR internalisation was quenched with ice-cold 
PBS. Remaining surface BCRs were stained with streptavidin-PE and 
revealed by flow cytometry. 
 
2.9  Antigen presentation assay 
Splenic B cells from Themis2
KO/KO or wild type littermate control mice were 
isolated using magnetic negative depletion with anti-CD43-PE, anti-
CD11b-PE, anti-CD11c-PE and anti-TCRβ-PE antibodies and anti-PE 
beads (Miltenyi Biotec) according to the manufacturer’s instructions. 
Splenic and lymph node CD4
+ T cells from OT-II Rag1-deficient mice were 
isolated similarly but using anti-CD11b-PE, anti-CD11c-PE, anti-CD8-PE, 
anti-B220-PE. To activate the B cells and deliver the antigen to the BCR, B 
cells were stained with 2.5 or 0.25 or 0.025 or nil mg/mL anti-IgM F(ab)2-
biotin and then with OVA antigen delivery reagent (Miltenyi Biotec) 
according to the manufacturer’s instructions. T cells were labelled with 
5 mM CellTrace Violet (CTV) (Life Technologies) in Dulbecco’s PBS 
(Gibco) for 20 min at 37 °C. Purities of cell isolations and loading of CTV 
and antigen were  checked by flow cytometry. 2 × 10
5  B cells were co-
cultured with 10
5  OT-II CD4
+  T cells in 96-well plates for 72 h  unless 
indicated otherwise. T cell proliferation was assessed by CTV dilution via 
flow cytometry and IL-2 was measured in the supernatants by ELISA.   125 
2.10   RNA  preparation and quantitative  real-time  poly-
merase chain reaction (qRT-PCR) 
Total RNA from single cell suspensions was extracted with the RNEasy 
Mini or Micro Plus kits (Qiagen) according to the manufacturer’s 
instructions. Gut and spinal cord tissue were pre-processed using the total 
RNA setting on a GentleMACS Dissociator (Miltenyi Biotec). Lung RNA 
was obtained by mashing the tissue using metal beads in Qiazol (Qiagen) 
using a Precellys 24 tissue homogenizer with Cryolys cooling (Bertin). 
Lung RNA was extracted from the homogenate first by chloroform 
extraction, followed by addition of ethanol to the chloroform phase 
(chloroform 2:7 ethanol), RNA binding of this mixture to an RNEasy Mini 
spin column (Qiagen) and subsequent purification according to the 
manufacturer’s instructions. cDNA was synthesised using the Superscript 
III First Strand Synthesis SuperMix for qRT-PCR kit (Life Technologies) 
according to the manufacturer’s instructions. Samples were analysed on 
an ABI Fast 7900HT under standard conditions using the TaqMan Gene 
Expression Mastermix and Gene Expression Assays Themis2  exon 2-3 
Mm01180768_m1, Themis2 exon 3-4 Mm01180769_m1, Themis2 exon 4-
5 Mm01180770_m1, Themis1  Mm00724485_m1,  Themis3 
Mm01239731_m1,  Hprt1  Mm03024075_m1,  Garem  Mm01158214_m1, 
Gareml  Mm01210799_m1 or the custom designed assays Themis2 
exon 3-5 AJ1RUPJ, Themis2 exon 5-6 AJGJPQS (all Life Technologies) 
according to the manufacturer’s instructions. qRT-PCRs from lung tissue 
were performed using the QuantiTect SYBR Green PCR kit (Qiagen) with   126 
primers in the table below at 1 µM concentration on an ABI Fast 7900HT 
under the following conditions 95 °C 15 min, 40 cycles of 94 °C 15 s, 
55 °C 30 s, 72 °C 30 s followed by 1 cycle of 95 °C 15 s, 60 °C 15 s, 95 °C 
15 s for a 95 °C to 60 °C dissociation curve. All data were normalised to 
Hprt1 and analysed using the comparative CT method. 
 
Table 2: List of qRT-PCR primers 
Primer   Sequence  Tm [°C] 
Arginase 1 For  GGAAAGCCAATGAAGAGCTG  57.3 
Arginase 1 Rev  GCTTCCAACTGCCAGACTGT  59.4 
Eotaxin-1 (CCL11) For  AGAGCTCCACAGCGCTTCT  58.8 
Eotaxin-1 (CCL11) Rev  GCAGGAAGTTGGGATGGAG  58.8 
Fizz1 For  CCCTCCACTGTAACGAAGACTC  62.1 
Fizz1 Rev   CACACCCAGTAGCAGTCATCC  61.8 
Gob-5(ClCA3) For  CATCGCCATAGACCACGACG  61.4 
Gob-5(ClCA3) rev  TTCCAGCTCTCGGGAATCAAA  57.9 
HPRT1 For  GCCCTTGACTATAATGAGTACTTCAGG  63.4 
HPRT1 Rev  TTCAACTTGCGCTCATCTTAGG  58.4 
IFN-gamma For  ACAGCCAGATTATCTCTTTCTACCTCAG  57.5 
IFN-gamma Rev  CCTTTTTCGCCTTGCTGTTG  57.3 
IL-13 For  CCTCTGACCCTTAAGGAGCTTAT  60.6 
IL-13 Rev  CGTTGCACAGGGGAGTCTT  58.8 
IL-17A p2 F  ACCCTGGACTCTCCACCGCAA  63.1 
IL-17A p2 R  GGCTGCCTGGCGGACAATCG  64.0 
IL-4 For  ACGAGGTCACAGGAGAAGGGA  61.8 
IL-4 Rev  AGCCCTACAGACGAGCTCACTC  64.0 
IL-5 For  TGACAAGCAATGAGACGATGAGG  60.6 
IL-5 Rev  ACCCCCACGGACAGTTTGATTC  62.1 
MUC5AC For  CAGGACTCTCTGAAATCGTACCA  60.6 
MUC5AC Rev  AAGGCTCGTACCACAGGGA  58.8 
Ym1 For  CATGAGCAAGACTTGCGTGAC  59.8 
Ym1 Rev  GGTCCAAACTTCCATCCTCCA  59.8 
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2.11   RNA sequencing and data analysis 
Follicular B cells were sorted by flow cytometry from the spleens of 
Themis2
KO/KO or wild type littermate control mice. Unstimulated samples 
were lysed directly, stimulated samples were cultured as described under 
cell culture at 3 × 10
6 cells/mL for 6 h with either 10 mg/mL anti-IgM, or 
10 mg/mL LPS or 1 mg/mL CD40L with 100 ng/mL IL-4. RNA was isolated 
using Trizol reagent (Life Technologies) according to the manufacturer’s 
instructions and cleaned up using RNEasy mini kit (Qiagen). Single end, 
unstranded, poly-A
+-enriched libraries were made using the TruSeq RNA 
sample preparation kit (Illumina). Samples were first checked for RNA 
quality, then library quality using the Agilent Bioanalyzer and subsequently 
sequenced with an Illumina HiSeq 2000, collecting 13.2 –  76.1 million 
reads of 75 bases per sample (Supplementary Figure 3A). Quality control 
and sequencing was performed by the NIMR high throughput facility. 
Avadis NGS (V1.4.7) was used for VDJ analysis and reads were mapped 
to NCBI37/mm10 genome and transcriptome including an update 
containing additional VDJ annotation derived from GenBank entries 
provided by Avadis NGS. Aligned reads were mapped to the RefSeq 
transcripts database and were normalised by DESeq (Anders and Huber, 
2010). Computational analysis of differential gene expression was done by 
Nikolay Nikolov and reads were aligned to mm10 (Ensembl version 72) 
using Tophat (version 2.0.9). Raw counts were determined using the union 
method in htseq-count (version 0.5.4p3) and mappings were filtered for a 
phred score of > 10. edgeR (Version 3.2.4) was used for filtration of lowly   128 
expressed features, normalisation and statistical analysis. Statistical 
significance of differences in gene expression was determined using the 
exact binomial test, reporting differences with a false discovery rate 
(FDR) < 0.05 (Robinson and Smyth, 2008). Gene expression is presented 
as read density defined as normalised counts per kilobase of exon. 
Pathway analysis was performed using Ingenuity IPA. All RNAseq data is 
deposited under the accession number E-MTAB-2499 in ArrayExpress 
(https://www.ebi.ac.uk/arrayexpress).  
 
2.12   Immunoblot 
Splenocyte suspensions were treated with ACK lysis buffer for 2 min at 
room temperature, incubated with biotinylated anti-CD43 and negative-
depleted  using magnetic streptavidin-Dynabeads. Purities of the B cell 
isolations were verified by flow cytometry and were generally around 95 %. 
Cell lysates were prepared using RIPA buffer. Cell debris were removed 
by centrifugation and SDS sample buffer was added to the cleared lysates 
followed by denaturation at 95 °C. for 5 min. Proteins were separated at 
100 V on 7 % SDS-PAGE mini gels in SDS-PAGE running buffer and then 
wet-blotted using CAPS buffer onto Immobilon-FL PVDF membrane 
(Millipore) at 350 mA for 1 h by standard techniques. Membranes were 
blocked for 1 h in Odyssey Blocking Buffer (Li-Cor #927-40000), and then 
probed with the following antibodies over night at 4 °C in Odyssey 
Blocking Buffer: anti-THEMIS2, ICB1 (P-14), goat polyclonal, Santa Cruz 
#sc-160439; anti-  THEMIS2, ICB1 (G-15), goat polyclonal, Santa Cruz   129 
#sc-160437; anti-  THEMIS2, ICB1 (D-14), goat polyclonal, Santa Cruz 
#sc-160436; anti-  THEMIS2, ICB1 (C-term), rabbit polyclonal, Abgent 
#AP9910b.  Then,  membranes were incubated with the appropriate 
secondary antibodies: Alexa-Fluor680 goat anti-rabbit IgG (H+L), 
Invitrogen #A21109 or IRDye700DX-conjugated donkey anti-goat IgG 
(H+L), Rockland #605-730-125 and signals were detected using the 
Odyssey Infrared Imager (Li-Cor Biotechnology). To check for loading 
membranes were then incubated over night at 4 °C in Odyssey Blocking 
Buffer with anti-α-TUBULIN mouse monoclonal (clone TAT-1), prepared 
in-house and subsequently with the secondary antibody goat anti-mouse 
IRDye800CW, Licor Biosciences #926-32210. Membranes were washed 
three times with PBS containing 0.05 % Tween20 for at least 5 min on a 
shaker at room temperature in between antibody incubation steps and 
measurements. Signals were again detected with an Odyssey Infrared 
Imager (Li-Cor Biotechnology) and analysed with the manufacturer’s 
software. 
 
2.13   ELISAs 
All plates were developed using 3,3′,5,5′-tetramethylbenzidine (TMB) 
(eBioscience) and stopped with 1 M H2SO4. Signals were quantified using 
absorption at 450 nm measurement wavelength and 570 nm reference 
wavelength on a Tecan Sapphire
2. Data was analysed in Microsoft Excel 
and Graphpad Prism 6. Only values of serial dilutions in the linear portion 
of the response curve were used to calculate analyte levels.   130 
2.13.1  Sample taking 
Blood samples were taken and left to clot for at least 10 min, then 
centrifuged twice at 17000 g to pellet cells. Serum supernatants were 
transferred into a new tube and then stored at -20 °C for short-term or 
-70 °C for long-term storage. Cell culture supernatants were obtained by 
prior centrifugation at 300 g to spin down cells. Supernatants were frozen 
at -70 °C until analysis by ELISA. Faecal samples from the small intestine 
were weighed, diluted with PBS 1 mL / 0.1 g faeces centrifuged for 5 min 
at 400 g at 4 °C to remove large debris and then for 10 min at 9000 g at 
4 °C to pellet bacteria. Supernatants were frozen at -70 °C until analysis. 
 
2.13.2  Total, NP-specific and cholera-toxin-specific 
  immunoglobulin ELISAs 
Total serum immunoglobulin levels were quantified by ELISA with the SBA 
Clonotyping System-B6/C57J-HRP (SouthernBiotech) on 96-well Maxisorp 
Immunoplates (Nunc) according to the manufacturer’s instructions. Briefly, 
plates were coated over night with 10 µg/mL AffiniPure Goat Anti-Mouse 
IgG + IgM (H + L) (Jackson Labs) and  blocked  with  3 % bovine serum 
albumin (Sigma-Alrdich) in PBS for 2 h at room temperature. Afterwards 
serial dilutions of sera and standards in PBS were incubated for 2 h at 
room temperature and HRP-conjugated antibodies were diluted 1:4000 in 
PBS with 0.05 % Tween20 (PBST) and incubated for 1 h at room 
temperature. Plates were washed three times in PBST by immersion in 
between steps. Both  NP-specific ELISAs and cholera-toxin specific   131 
ELISAs were performed analogously but plates were coated with 5 µg/mL 
NP18-BSA (BioSearch Technologies) or 1 µg/mL cholera toxin from Vibrio 
cholerae Inaba 569B (List Biological Laboratories) respectively.  
 
2.13.3  Total IgE ELISAs 
96-well Maxisorp Immunoplates (Nunc) or 96-well  ELISA half area 
Microplate, flat bottomed, high binding (Greiner Bio-One) were coated with 
2 µg/mL  purified RAT Anti-Mouse IgE  antibody (BD Bioscience,  Clone 
R35-72) in 60 mM carbonate buffer pH 9.6 over night at 4 °C. Plates were 
washed with PBST and then blocked with 5 % skimmed milk in PBS for 
2 h at 37°C an then washed again. Sera and standards were serially 
diluted in PBS and applied to the plate for 1 h at 37 °C. Plates were 
washed with PBS and 1 µg/mL biotinylated rat anti-mouse IgE (BD 
Bioscience, Clone R35-118) diluted in 5 % skimmed milk in PBST was 
added for 1 h at room temperature. After washing, 0.5 µg/mL streptavidin-
conjugated HRP (KPL) diluted in 5 % milk in PBST was added and 
incubated for 30 min at room temperature. Plates were washed seven 
times with PBST and then twice with purified water before addition of the 
substrate  TMB. Plates were incubated in the dark until developed 
sufficiently. 
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2.13.4  Anti-X31 haemagglutinin IgG-ELISA 
For determination of anti-X31 haemagglutinin (HA)-IgG, 96-well flat 
bottomed plates were coated with 2.5 mg/ml of purified X31 HA (a kind gift 
from Dr. John Skehel, NIMR) in PBS and incubated overnight at 4 °C. 
Plates were blocked with 2 % BSA in PBS for 2 h at room temperature 
then serial dilutions of heat inactivated sera samples were incubated for 
3 h at 37 °C. Then X31 HA-specific IgG was detected with HRP-
conjugated goat anti-mouse IgG antibody (BioRad) diluted 1:3000. Plates 
were washed with PBST in between steps. 
 
2.13.5  IL-2 ELISA 
The DuoSet mouse IL-2 ELISA (R&D systems) was used according to the 
manufacturer’s instructions with the following modifications: Plates used 
were  96-well  ELISA half area Microplate, flat bottomed, high binding 
(Greiner Bio-One), Streptavidin-HRP was from BD Biosciences and used 
1:1000 and plates  were washed 10 times before the addition of the 
substrate. 
 
2.14   Cell culture 
Single cell suspensions of purified B cells were prepared as described in 
section  2.5,  cultured in DMEM-plus medium (DMEM with 100 μM non-
essential amino acids, 20 mM HEPES buffer (all Gibco) 10 % FCS, 
100 U/ml Penicillin, 100 μg/ml Streptomycin and 2 mM L-Glutamine, and   133 
100 μM 2-mercaptoethanol (all Sigma-Aldrich)). Where not indicated 
otherwise, cells were stimulated with the reagents at the given 
concentration in the table below. 
 
Table 3: List of stimulatory reagents 
Reagent  Provider  Cat-No  Concentration 
Anti-IgM F(ab)2 
Jackson 
ImmunoResearch 
115-006-075  10 µg/mL 
LPS  Alexis  Alx-581-008-L002  10 µg/mL 
CD40L  R&D Systems  1163-CL  1 µg/mL 
IL-4  PeproTech  214-14  100 ng/mL 
BAFF  PeproTech  310-13  100 ng/mL 
Phorbol-12-
myristate-13-
acetate (PMA) 
Sigma-Aldrich  P1585-10MG  50 ng/mL 
Ionomycin  Sigma-Aldrich  I06354  500 ng/mL 
 
2.14.1  Cell surface activation marker measurement 
Cells were cultured as  described in section  2.14 in flat bottom 96-well 
plates at 4 × 10
5  cells/well  and stimulated with the indicated stimuli for 
24 h. Then cells were stained and analysed by flow cytometry for surface 
levels of CD23, CD69, CD86 and MHC class II as described in section 2.6  
 
2.14.2  Proliferation and survival assays 
B cells were isolated and cultured as described in section 2.14 but labelled 
with 5 µM CFSE (Life Technologies) in Dulbecco’s PBS (Gibco) for 10 min 
at 37 °C before culturing 10
6  cells/well in flat bottom 48-well plates for   134 
72 h. Proliferation was assessed by CFSE dilution and number of live cells 
was measured by a LIVE/DEAD fixable near-IR dead cell stain and 
counted using PerCP-beads (BD Calibrite) on a BD FACS Canto II flow 
cytometer. Data were analysed using the cell proliferation platform in 
FlowJo 9.6. 
 
2.14.3  Luminex cytokine assay 
B cells were isolated and cultured as described in section  2.14 in  flat 
bottom 96-well plates at 4 × 10
5/well for 72 h. Then supernatants were 
harvested and frozen at -70 °C until measurement of 16 cytokines (CCL2, 
GM-CSF, IFNγ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12 p70, IL-13, IL-17A, 
KC, MIP-2, TNFα, VEGF) using the Luminex-based 16-plex Fluorokine 
MAP assay (R&D Systems) according to the manufacturer’s instructions 
on a Luminex 100 machine (Luminex). 
 
2.15   Influenza infection 
Mice were infected intranasaly with 30 µL PBS containing X31 influenza 
TCID50 = 8 × 10
3 or 8 × 10
4 by Sophia Davidson and monitored daily for 
weight loss and clinical symptoms for 15 days. Mice were bled on day 10 
for measurement of anti-X31 HA IgG antibody levels. Mice that reached 
75 % of their starting weight were euthanised complying with UK home 
office regulations. 
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2.16   Cytospins 
Cytospins were performed by Mark Wilson on cells retrieved from 
bronchoalveolar lavages performed using 1.5 mL ice-cold PBS. Cytospins 
were prepared using a Cytospin 4 (Thermo Scientific) at 1200 rpm for 
5 min. Cells were fixed in methanol and then stained with modified 
Accustain Wright-Giemsa stain (Sigma-Aldrich) to identify cells 
morphologically. Cells were counted manually using a Leica DM1000 LED 
microscope. 
 
2.17   Histology 
For histopathological analysis the left lung lobe was removed and fixed in 
4 % paraformaldehyde in PBS for 1 day then transferred to 70 % ethanol 
for 1 day. The NIMR Histology facility embedded the samples in paraffin, 
cut into 5 µm sections and stained with hematoxylin and eosin (H&E), or 
alcian blue-periodic acid schiff, as indicated. Samples were and analysed 
on an Olympus VS120 slide scanner by Mark Wilson. 
 
2.18   Isoform PCRs and genotyping 
For genotyping, genomic DNA was extracted from mouse tail or ear 
clippings by lysis in a proteinase K (Roche)-containing tail lysis buffer 
followed by isopropanol precipitation of the gDNA. Genotyping PCRs for 
Themis2  alleles were developed using Primer3 (Rozen and Skaletsky, 
2000)  and Primer-BLAST  (Sayers et al., 2011)  and were optimised for   136 
annealing temperature by gradient PCR and titrated for optimal MgCl2 
concentration. All PCRs were performed using Thermoprimer Plus DNA 
Polymerase (Thermo Scientific) in Reaction Buffer IV (Thermo Scientifc) 
on a DNA Engine Dyad Peltier Thermal Cycler (Biorad). Reactions were 
separated in 1 – 3 % agarose in TAE buffer gels.  
PCRs for the detection of isoforms of Themis2 were performed on sorted, 
follicular B cell cDNA. Four different primer pairs annealing in exon 1 and 
exon 6 of the full-length Themis2 transcript were used to identify shorter 
transcripts. Detailed protocols and primer sequences for all reactions can 
be found in the appendix. An example of each genotyping reaction can be 
found in Supplementary Figure 4. 
 
2.19   Statistical analysis 
Statistical significance of differences between groups was assessed using 
the Mann-Whitney test or chi-square test where applicable in GraphPad 
Prism 6  or the Fisher’s exact test in Ingenuity IPA. Differences with 
p < 0.05 were considered significant.   137 
 
2.20   Solutions, buffers, media and gels 
 
Table 4: Composition of solutions, buffers, media and gels 
Solution  Composition 
AB IMDM  2.1 g NaCl, 0.06 g Penicillin, 0.1 g Streptomycin, IMDM 
powder for 1 L, 1 L dH2O, adjust to pH 7.2, sterilise by 
membrane filtration 
ACK lysis buffer  155 mM NH4Cl, 10 mM KHCO3, 0.1 mM Na2EDTA, 1 L 
dH2O 
AutoMACS 
buffer 
AB IMDM, 2 mM EDTA, 2 % FCS, sterile filtered  
CAPS buffer  4.4 g/L CAPS (3-[cyclohexylamino]-1-propanesulphonic 
acid) in dH2O, pH 11.0 
DNA Loading 
buffer 
20 % Ficoll 40, 0.1 M Na2EDTA pH 8, 1 % SDS, 
0.25 % Bromophenol blue 
RIPA lysis 
buffer 
150 mM NaCl, 1 % NP40, 0.25 % 
Sodiumdeoxychelate, 2 mM EDTA, 50 mM Tris pH 7.4, 
1 mM DTT, 1 mM NaVO3, 1 % Protease Inhibitor p8340 
(Sigma-Aldrich) 
FACS buffer  PBS, 0.1 % NaN3, 0.5 % BSA 
MACS buffer  PBS, 2 mM EDTA, 0.5 % BSA 
PBS  8 g NaCl, 0.2 g KCl, 1.15 g Na2HPO4, 0.2 g KH2PO4, 
1 L dH2O 
PBST  PBS, 0.05 % Tween20 
SDS Sample 
buffer 
0.2 M Tris-HCl, 3 % SDS, 10 % glycerol, 3 % 2-
Mercaptoethanol, 0.25 ‰ Bromophenol blue, pH 6.8 
TAE  10 mM Tris-HCl, pH 7.4, 0.02 M Glacial Acetic Acid, 
1 mM EDTA, pH 8.0 
Lower buffer  1.5 M Tris-HCl, 0.4 % SDS, pH 8.8 
Upper buffer  0.5 M Tris-HCl, 0.4 % SDS, pH 6.8   138 
10× SDS-PAGE 
running buffer 
3.03 M Tris-HCl, 1 % SDS, 14.42 % Glycine, pH 8.3 
7% SDS-PAGE 
mini gel 
Resolving gel: 1.75 mL Protogel 30 % Acrylamide 
0.8 % Bis-Acrylamide (National Diagnostics), 1.88 mL 
Lower Buffer, 3.87 mL dH2O, 5 µL Tetramethyl-
ethylenediamine (TEMED) and 25 µL Ammonium 
Persulfate (APS) 10 %; let polymerise under water-
saturated Butanol then add 
Stacking Gel: 0.4 mL Protogel (as above), 0.8 mL 
Upper Buffer, 1.9 mL dH2O, 3.125 µL TEMED and 
15.625 µL APS 10 % 
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3  Results 
In order to determine the function of Themis2 in B cells I first sought to 
establish a Themis2-deficient mouse strain which would allow analysis of 
B cell development and activation in vivo  as well as in vitro. At the 
beginning of this study, neither the Themis2-deficient mouse strain 
described here, nor any other had been described in literature. 
 
3.1  Generation of a Themis2-deficient mouse strain 
Matthew Pierce from Imperial College London generated a mouse strain 
with the targeted allele Themis2
tm1a(KOMP)Wtsi, here further termed 
Themis2
NeoFlox, from embryonic stem cells of the Wellcome Trust Sanger 
Institute’s KOMP repository. I received Themis2
WT/NeoFlox  mice on a 
C57BL/6  background, which  contain a construct in the Themis2  gene 
targeting exon 4 as depicted in Figure 5. Exon 4 is flanked by loxP sites for 
recombination with a Cre recombinase. 5’ of exon 4 a promoterless 
reporter cassette has been inserted allowing for selection using a 
neomycin resistance gene and detection of endogenous Themis2 
promoter activity using a β-galactosidase reporter gene. Splicing into the 
reporter cassette is induced by an EN2 splice acceptor site thus 
transcribing both genes from the endogenous Themis2  promoter. Both 
genes are expressed as non-fusion proteins due to self-cleaving T2A 
oligopeptide sequences. The whole cassette is flanked by FRT sites and   140 
can be deleted using FLP recombinase. Although this allele is termed a 
“knockout-first” allele by KOMP, I decided to breed a complete null allele 
as data suggested that there was still residual THEMIS2 produced. 
Although strongly reduced on both protein and mRNA levels, I could still 
detect residual THEMIS2 protein by immunoblot and I could detect splicing 
from Themis2 exon 3 to exon 4 and from exon 4 to exon 5 by qRT-PCR in 
Themis2
NeoFlox/NeoFlox mice (data not shown). In two sequential steps I first 
crossed Themis2
+/NeoFlox mice to C57BL/6J-Tg(Prm-cre)70Og mice which 
have Cre under control of the protamine 1 promoter. This leads to deletion 
of  Themis2  exon 4 in the male germline as the protamine 1 promoter 
drives Cre recombinase expression in male gametes (O'Gorman et al., 
1997). The newly produced allele, in which Themis2 exon 4 is deleted but 
the reporter cassette is still functional, is called Themis2
tm1b(KOMP)Wtsi and is 
here  further referred to as Themis2
NeoKO. Subsequently, Themis2
+/NeoKO 
mice were bred with C57BL/6J-Tg(ACTFLPe)9205Dym mice which have a 
heat-stable form of the recombinase FLP, termed FLPe, under the control 
of the human ACTB promoter. This cross efficiently removed the reporter 
cassette, leaving behind only an FRT- and a loxP-site in between Themis2 
exon 3 and exon 5, creating the Themis2
tm1d(KOMP)Wtsi  allele, henceforth 
called Themis2
KO. Themis2
KO/KO mice were used for all experimental work 
presented here with the exception of the data on Themis2  promoter 
activity for which Themis2
+/NeoFlox mice were used. FLPe and Cre genes 
were removed by backcrossing and experimental mice (Themis2
KO/KO) 
were bred from the intercross of Themis2
+/KO  parents to produce both   141 
mutant and littermate control (WT, Themis2
WT/WT) animals. Initial data on B 
cell numbers during development suggested greater data dispersion if 
Themis2
KO/KO mice were compared to in house C57BL/6J-Nimr controls (a 
genetically drifted colony of C57BL/6J that was established at NIMR about 
40 years ago). The variability could have arisen from the fact that the 
embryonic stem cell line from which the Themis2 alleles originated was on 
a C57BL/6N background and mice were not fully backcrossed to 
C57BL/6J-Nimr. To minimise biological variability, I decided to only use 
age- and sex-matched littermate controls for the determination of Themis2 
phenotypes. 
The targeted exon in Themis2
KO  mice, exon 4, is the biggest exon of 
Themis2  as  illustrated in Supplementary Figure 5. Deletion  of  Themis2 
exon 4 in Themis2
KO/KO  mice leads to loss of a substantial part of the 
protein. Exon 4 encodes the C-terminal part of the first CABIT domain, all 
of the second CABIT domain, the NLS and the proline-rich SH3-binding 
site. Furthermore, as exon 4 starts and ends in different phases, deletion 
of exon 4 leads to a frameshift from exon 3 into exon 5. Consequently, 
both exon 5 and exon 6 are then out of frame leading to loss of the 
complete C-terminus, including the SH2-binding site, in  addition to all 
functional domains encoded by exon 4. Thus all that is left of the protein if 
exon 4 is deleted, is an N-terminal fragment of the first CABIT domain 
followed by a frameshifted C-terminal tail.   142 
 
 
Figure 5: Themis2 KOMP gene targeting strategy and derivation of 
Themis2 alleles. 
Naturally occurring Themis2  wild type (WT) allele and the KOMP 
repository-derived, promoterless Themis2
NeoFlox allele are shown on top. 
The Themis2
NeoFlox allele contains a reporter cassette flanked by FRT-sites 
for recombination with a FLPe-deleter strain. The reporter cassette 
consists of an EN2 splice acceptor site (EN2 SA), followed by a T2A self-
cleaving oligopeptide and the coding sequence (CDS) for the β-
galactosidase reporter gene (β-Gal). Subsequently encoded are another 
T2A self-cleaving oligopeptide followed by a CDS for a neomycin-
phosphotransferase (Neo
R) enabling selection with G418. Transcription is 
terminated using an SV40 polyadenylation site (pA).  This setup allows 
discrete expression of THEMIS2 fragments, β-galactosidase and 
neomycin-phosphotransferase as non-fusion proteins though the self-
cleaving oligopeptides. It also permits the assessment of the Themis2 
promoter-activity via measurement of β-galactosidase activity as the whole 
construct is promoterless and the β-galactosidase is under control of the 
endogenous Themis2 promoter. Downstream of the reporter cassette exon   143 
4 is flanked by two loxP sites for recombination using a Cre-deleter strain. 
Crossing of mice bearing a Themis2
NeoFlox allele to either a Cre- or FLPe-
deleter strain results in creation of the Themis2
NeoKO or Themis2
Flox alleles 
respectively. Crossing of these strains with the opposite deleter strain 
leads to production of the Themis2
KO allele.   144 
 
3.2  Expression of the Themis family in B cells 
First, I measured the expression of Themis family members in B cells. On 
the one hand this served to expand and confirm publicly available 
expression data and determine possible B cell developmental or activation 
stages in which Themis2 might be of particular importance. On the other 
hand this was necessary in order to determine if there was expression of 
other Themis family members that might functionally substitute for 
Themis2 in its absence, as has been shown for other signalling molecules 
downstream of the BCR such as in the case of Rac1/Rac2  or 
Vav1/Vav2/Vav3 (Fujikawa et al., 2003; Walmsley et al., 2003).  
 
3.2.1  Expression of the Themis family in B Cell subsets 
I performed high throughput RNA sequencing on sorted mouse follicular B 
cells to directly compare the expression of CABIT-domain containing 
genes in the most abundant mature B cell subset. As depicted in Figure 
6A, only Themis2 is expressed at high levels whereas neither the other 
Themis-family members Themis1 and Themis3 nor the two other CABIT-
domain containing proteins in the mouse genome, Garem and Gareml, are 
expressed to a significant degree. Next,  I sorted developmental B cell 
subsets from the bone marrow (pro-B, pre-B, immature B,) and spleen 
(transitional type 1 (T1), T2, T3,) as well as mature, naïve B cell subsets 
from the bone marrow (recirculating, mature B cells), spleen (follicular and 
marginal zone B cells) and peritoneal cavity (B1 and B2 cells) and   145 
analysed them by qRT-PCR for the expression of the Themis family as 
illustrated in Figure 6B. As positive controls I used RNA from thymus 
tissue, splenic and lymph node T cells for Themis1  and RNA from the 
small intestine for Themis3  respectively. Similarly, I sorted antigen-
experienced B cells from the bone marrow (plasma cells) and from the 
spleen (plasmablasts, plasma cells, germinal centre B cells, IL-10-
producing B regulatory cells) for analysis by qRT-PCR as shown in Figure 
6C. Consistent with publicly available data and published studies 
(Lesourne et al., 2009) the results show that Themis1 is only expressed in 
T cells and in the thymus but not in any B cell population. Themis3 was 
not detectable in any sorted B or T cell population but readily detectable in 
the gut. Themis2 is expressed in all analysed B cell populations. I also 
noted that germinal centre B cells have reduced expression of Themis2 
compared to follicular B cells (p = 0.017 in Mann Whitney), again in 
agreement with publicly available data from the Immgen consortium 
(www.immgen.org) (Heng and Painter, 2008). Moreover, I found reduced 
Themis2 expression in regulatory B cells, which had been cultured and re-
stimulated with LPS, PMA and ionomycin in vitro  to induce IL-10 
production (p = 0.006 in Mann Whitney). Overall, Themis2 is expressed 
non-redundantly in the B cell lineage and its expression is reduced in 
antigen-experienced B cells.   146 
 
 
Figure 6:Themis2 is expressed non-redundantly in the B cell lineage. 
(A) Mean ± SEM of mRNA expression of all mouse CABIT domain-
containing proteins in follicular B cells sorted via flow cytometry and 
analysed by RNA sequencing. Data are displayed as read density. (B) 
Mean ± SEM of mRNA expression by quantitative real-time PCR (qRT-  147 
PCR) analysis of Themis family members in whole organs or various T 
and B cell developmental populations sorted via flow cytometry. (C) 
Mean ± SEM of mRNA expression by qRT-PCR of Themis family 
members in antigen-experienced B cell populations. Germinal centre B 
cells, regulatory B cells, plasmablasts and plasma cells were isolated and 
sorted as described in section 2.6 of materials and methods. All other cell 
types were gated and sorted as depicted in Figure 12. All data are from ≥ 
3 biological replicates per population and sorting purities generally were 
> 95 %. LN, lymph node; PEC, peritoneal exudate cells; MZ, marginal 
zone B cells; PC, plasma cells; PB, plasmablasts; GC, germinal centre B 
cells; Breg, regulatory B cell. n.d. not detected.   148 
 
3.2.2  Themis2 promoter activity in B cell subsets 
To further corroborate Themis2 expression in B cells I measured Themis2 
promoter activity in Themis2
+/NeoFlox  mice using the β-galactosidase 
reporter controlled by the endogenous Themis2 promoter in a FACS-Gal 
assay. In this assay the non-fluorescent substrate FDG is converted into 
fluorescein by the activity of β-galactosidase. As transcription of the β-
galactosidase gene is controlled by the endogenous Themis2 promoter, 
the amount of β-galactosidase is assumed to be proportional to the 
amount of THEMIS2 produced. Kinetic measurements established that 
measurements were taken after an appropriate reaction time and before 
substrate depletion, allowing for discrimination of both higher and lower 
fluorescein production in the assay (Supplementary Figure 6A). Themis2 
promoter activity was detected in B cells and CD11c
+  cells such as 
dendritic cells but not in T cell (Supplementary Figure 6B), consistent with 
publicly available expression data for  Themis2  (www.immgen.org, 
www.biogps.org). I found that developing and mature, naïve B cells with 
the  Themis2
NeoFlox  reporter construct showed strong promoter activity 
compared to wild type controls whereas reporter activity in B220
- cells in 
the spleen or in CD5
+ T cells in the peritoneal cavity was low both in terms 
of mean fluorescence intensity of fluorescein and the percentage of 
fluorescein-positive cells (Figure 7). The FACS-Gal data further support 
previous findings that Themis2 is highly expressed in B cells and dendritic 
cells but not T cells.   149 
 
Figure 7: Themis2 promoter activity corroborates the expression of 
Themis2 in B cells. 
Themis2 promoter activity was assessed by FACS-Gal as a function of the 
activity of the β-galactosidase reporter expressed under control of the 
endogenous  Themis2  promoter from the promoterless Themis2
NeoFlox 
allele. Fluorescein is produced from the reaction of β-galactosidase with 
the non-fluorescent substrate FDG. Depicted are mean fluorescence 
intensity (MFI) or the percentage of fluorescein positive cells among B cell 
developmental subsets in the bone marrow, spleen or peritoneal exudate 
after a 45 min reaction time stopped by addition of the inhibitor PETG. 
Data are representative of 3 independent experiments. MZ, marginal zone; 
Non B, B220
- cells.   150 
 
3.2.3  Themis2 splice variants 
Several splice variants were initially reported for human THEMIS2 (Treeck 
et al., 2002) whereas so far in public databases only a single isoform has 
been annotated in mice. I sought to determine whether there were different 
splice variants in murine B cells. Therefore I designed PCRs with primers 
located in exon 1 and exon 6 of murine Themis2 to test whether any exons 
might be skipped and amplicons shorter than expected for Themis2 mRNA 
containing all six exons (full-length Themis2) would be produced in the 
reactions. Four different primer pairs used in gradient PCRs to allow for 
various degrees of stringency in primer annealing, showed that full-length 
Themis2 was the only mRNA species containing both exon 1 and exon 6 
(Figure 8). Unspecific  bands in between different reactions were 
inconsistent in their expected, relative molecular lengths, generally more 
prone to changes in annealing temperature and consequently did not 
support the idea of low amounts of shorter Themis2 transcripts but rather 
off-target amplifications. This suggests that full-length Themis2 is the only 
isoform, at least in follicular B cells, as no additional transcriptional start or 
termination sites have been reported for murine Themis2 to date.   151 
 
 
Figure 8: A transcript comprised of all six exons is the major splice 
variant of Themis2 in follicular B cells. 
(A) Cartoon of relevant exons indicating primer locations and (B) agarose 
gels from four different PCRs with cDNA from total RNA of follicular B cells   152 
as template and amplified with four different primer pairs. Forward primers 
of each pair anneal in Themis2 exon 1 and reverse primers in exon 6 CDS 
or 3’ UTR. To avoid unspecific amplifications, the stringency of the PCR 
reaction was varied by an annealing temperature gradient from 50 – 65 °C 
as indicated by the black triangles. PCR reactions were resolved in a 2 % 
agarose gel. Expected band sizes for full-length Themis2 mRNA: Primer 
pair 1: 1973 bp; Primer pair 2: 2080 bp; Primer pair 3: 2279 bp; Primer pair 
4: 1943 bp; M, 100-bp DNA ladder (30 bands, 100 – 3000 bp).   153 
 
3.3  Analysis of Themis2  expression in Themis2-deficient 
mice 
In order to analyse the function of Themis2 in B cells, I created Themis2-
deficient mice with the Themis2
KO allele. Themis2
KO/KO mice were viable, 
bred in normal numbers and were produced at expected Mendelian ratios 
from heterozygous parents as shown in Supplementary Figure 7.  
 
3.3.1.1  Analysis of Themis2 splicing in Themis2-deficient B Cells 
To analyse whether Themis2
KO/KO mice are truly deficient for Themis2, I 
performed qRT-PCR analysis of Themis2 mRNA at various exon junctions 
(Figure 9A). I found that in Themis2
KO/KO  mice  Themis2  mRNA is 
expressed at normal levels compared to wild type controls but that exon 4 
is missing as predicted. Instead, a new splice junction is created and the 
message is spliced from exon 3 into exon 5 in Themis2
KO/KO  B cells 
whereas such splicing was not detectable in wild type B cells (Figure 9B). 
These data were confirmed by RNA sequencing analysis. In Themis2
KO/KO 
follicular B cells no reads align to Themis2 exon 4 indicating its deletion, 
instead reads aligning over an exon 3 - 5 splice junction are readily 
detectable (Figure 9C). This leads to the predicted frameshift of exon 5 
and 6 compared  to exon 3 as confirmed by the RNA sequencing 
(Figure 9D). As the first premature stop codon caused by the frameshift is 
only found in exon 6, the last exon, it is not surprising that the mRNA is not    154 
 
Figure 9: Themis2 exon 4 is deleted in Themis2
KO/KO mice leading to 
a truncated and frameshifted transcript and a novel splice junction. 
(A) Cartoon indicating Themis2 mRNA exon junctions and (B) qRT-PCR 
analysis of the expression of Themis2 across the indicated exon junctions 
in splenic B cells from Themis2
KO/KO  mice or wild type (WT) littermate   155 
controls. WT was set to 100. n.d. not detected. Data are displayed as 
mean ± SEM of a least 2 biological replicates. (C) Alignment of RNAseq 
data from wild-type (WT) and Themis2
KO/KO  follicular B cells to the 
Themis2 gene, showing loss of Themis2 exon 4 and splicing from exon 3 
to exon 5 in Themis2
KO/KO cells. Light brown: UTR; blue: coding sequence; 
grey profile plot: maximum read density; stacked red boxes: individual 
reads; black lines: connection between two parts of a split read showing 
splicing. (D) RNAseq-derived sequence of relevant Themis2 mRNA exons 
and predicted translation showing that exon 3 is spliced directly to exon 5 
giving rise to a frameshift in translation (light gray font) and ending in a 
stop codon (*) in exon 6.   156 
degraded by nonsense mediated RNA decay as this process requires a 
premature stop codon in an exon that is not the final 3’ exon 
(Schweingruber et al., 2013). Furthermore, the RNA sequencing data 
confirm the previous PCR results suggesting that full-length  Themis2 
transcript containing all six exons is the only splice variant in murine 
follicular B cells. 
 
3.3.2  THEMIS2 protein expression 
To confirm the absence of full-length THEMIS2 protein I performed 
immunoblots. I found four different antibodies against murine THEMIS2 
giving bands at the expected molecular weight of about 74 kDa. The 
epitopes of the antibodies are located in exon 4 and exon 6 (Figure 10A). 
Immunoblots probed with four antibodies show that no full-length 
THEMIS2 protein is detectable in cell extracts from Themis2
KO/KO splenic B 
cells (Figure 10B and 10C). Immunoblots probed with an antibody specific 
for an epitope in exon 6, did not show any new, smaller additional bands, 
consistent with the prediction that if any truncated THEMIS2 was produced 
in  Themis2
KO/KO  B cells, its sequence is frameshifted, resulting in a 
different amino acid sequence and termination before the epitope in 
exon 6. Epitopes in  exon 4 also vanish due to its genomic deletion. 
Unfortunately, in the absence of a working N-terminal anti-THEMIS2 
antibody I was unable to determine whether a truncated THEMIS2 protein, 
potentially consisting of the N-terminal part of CABIT1 and a frameshifted 
tail, was produced and stable in Themis2
KO/KO mice.   157 
 
Figure  10:  Full-length THEMIS2 protein is not expressed in 
Themis2
KO/KO splenic B cells. 
(A)  Cartoon representing murine THEMIS2 protein domains, their 
encodement by exons and localisation of epitopes of used anti-THEMIS2 
antibodies.  (B)  Immunoblot analysis of THEMIS2 protein expression in 
splenic B cells from wild type (WT) or Themis2
KO/KO (KO) mice using four 
different anti-THEMIS2 antibodies with the indicated epitopes localised in 
either exon 4 or exon 6. (C) Quantification of (B), THEMIS2 bands were 
normalised to α-TUBULIN bands, WT was set to 100. Data are 
representative of 2 to 3 biological replicates in independent experiments.   158 
 
3.4  Analysis of B cell development in Themis2-deficient 
mice 
Having confirmed the absence of full-length  THEMIS2  in  Themis2
KO/KO 
mice I began their phenotypic analysis. As mice deficient for the T cell-
restricted gene Themis1 show a strong impairment in T cell development, I 
first focussed on the analysis of B cell development in Themis2
KO/KO mice. 
 
3.4.1  B cell development in Themis2-deficient mice 
I analysed the numbers of developing, mature and antigen-experienced B 
cells subset under steady-state conditions by flow cytometry in various 
lymphoid organs including the bone marrow, spleen, peritoneal exudate, 
peripheral and mesenteric lymph nodes, Peyer’s patches and blood. The 
analysis included developing pro-B,  pre-B, immature and mature 
recirculating B cells in the bone marrow, developing transitional type 1, 2 
and 3 cells, as well as follicular and marginal zone B cells in the spleen 
and B1a, B1b and B2 B cells in the peritoneal cavity. I also quantified the 
numbers of antigen-experienced cells counting plasma cells in the bone 
marrow and spleen as well as germinal centre B cells, plasmablasts and 
regulatory B cells in the spleen. The number of all analysed subsets was 
unchanged in Themis2
KO/KO  mice compared to wild type controls 
(Figure 11). Cell surface marker expression on Themis2
KO/KO  cells was 
also identical to control animals (Figure 12). I conclude that by evaluation 
of cell surface markers the development of B cells from early progenitor   159 
cells such as pro-B cells to fully differentiated cells such as plasma cells 
proceeds unperturbed in a Themis2-deficient context. As expected, the 
numbers of CD4
+ and CD8
+ T cells is also normal in Themis2
KO/KO mice. 
 
3.4.2  B cell development of Themis2-deficient bone marrow in 
competition with wild type bone marrow in mixed bone 
marrow chimeras 
As B cell development was normal in mice constitutively deficient for 
Themis2, I decided to use a more sensitive approach by making mixed 
bone marrow radiation chimeras. In these chimeras Themis2-deficient 
cells are in competition with wild type cells making defects much more 
apparent. Either Themis2
KO/KO or wild type CD45.2
+ bone marrow together 
with wild type CD45.1
+  bone marrow was injected into sublethally 
irradiated Rag1-deficient mice to test whether Themis2-deficient cells had 
a developmental defect. 
I created chimeras at four different ratios of CD45.2
+/CD45.1
+  bone 
marrow cells (100 %, 50 %, 20 % or 10 % CD45.2
+  cells) (Figure 13). 
Under each of these conditions, Themis2-deficient bone marrow 
performed equally well at creating the indicated B cell populations in the 
bone marrow, spleen and lymph nodes. Pro-B cell numbers are slightly 
higher than the injection ratio as some of these cells derive from the 
CD45.2
+ Rag1-deficient bone marrow since development is blocked after 
the  pro-B cell stage in these mutants (Mombaerts et al., 1992).  160 
 
Figure 11: B cells numbers are normal in Themis2
KO/KO mice. 
Numbers of B and T cell populations in the indicated organs of 
Themis2
KO/KO and WT mice analysed by flow cytometry. pLN, peripheral 
lymph nodes; mLN, mesenteric lymph nodes. Cell populations were gated 
as  shown in Figure 12. Bars represent mean ± SEM of 8 biological 
replicates in 3 independent experiments.   161 
 
Figure 12: Themis2
KO/KO mice show normal B cell development and B 
cell lineage surface marker expression. 
Flow cytometric surface marker expression and gating strategy used for 
cell population analysis in Figures 11 and 13 and  for cell sorting in   162 
Figure 6. Names next to gates indicate the population; numbers indicate 
the percentage of cells within the marked gate on the total plot. Gating 
strategies were as follows: in bone marrow, pro-B cells (B220
+  CD19
+ 
CD2
- IgM
-), pre-B cells (B220
+ CD19
+ CD2
+ IgM
-), immature B cells (B220
+ 
CD19
+ CD2
+ IgM
+ IgD
-), mature B cells (B220
+ CD19
+ CD2
+ IgM
+ IgD
+); in 
spleen, transitional type 1 (T1, B220
+  CD93
+  CD23
-  IgM
+), type 2 (T2, 
B220
+ CD93
+ CD23
+ IgM
+) and type 3 (T3, B220
+ CD93
+ CD23
+ IgM
low) B 
cells, marginal zone B cells (MZ, B220
+ CD93
- CD23
- IgM
+) follicular B 
cells (B220
+  CD93
-  CD23
+  IgM
+), plasmablasts (PB, B220
+  CD138
+) 
plasma cells (PC, B220
-  CD138
+), germinal centre B cells (GC, B220
+ 
PNA
+  GL7
+) and regulatory B cells (Breg, B220
+  CD19
+  CD1d
+  CD5
+), 
CD4 T cells (CD4
+), CD8 T cells (CD8
+); in peritoneal exudate cells (PEC), 
B1a cells (IgM
+ CD5
+ CD23
-), B1b cells (IgM
+ CD5
- CD23
-) and B2 cells 
(IgM
+ CD5
- CD23
+), T cells (CD5
+ IgM
-); blood, mesenteric lymph nodes 
(mLN), peripheral lymph nodes (pLN) and Peyer’s patches, B cells (B220
+ 
TCRβ
- IgM
+ IgD
+), CD4 T cells (B220
- TCRβ
+ CD4
+ CD8
-), CD8 T cells 
(B220
- TCRβ
+ CD4
- CD8
+).   163 
 
Figure 13: Themis2-deficient bone marrow gives rise to expected B 
cell lineage proportions under competition from wild type bone 
marrow. 
Bone marrow from CD45.2
+ Themis2
KO/KO mice or wild type (WT) littermate 
controls was mixed with bone marrow from CD45.1
+ wild type mice (10, 
20, 50 or 100 % CD45.2
+ cells) and injected intravenously into sublethally 
irradiated Rag1-deficient mice. After 6 weeks mice were analysed for 
reconstitution of the B cell lineage by flow cytometry. Cell numbers in 
populations were evaluated using gating strategies as in Figure 12 with 
additional staining for CD45.1 and CD45.2. Depicted are the mean ± SEM 
of 6 mice/group. Dotted lines indicate CD45.2
+ / CD45.1
+ ratio at injection.   164 
 
3.4.3  Themis2-deficient  follicular B cells  are  transcriptionally 
similar to wild type controls 
Since  Themis2-deficient B cells develop normally according to the 
immunophenotypic analysis, I investigated whether their transcriptome 
might be changed due to subtle alterations caused by the absence of 
Themis2. Therefore I analysed transcription in splenic, follicular B cells 
from  Themis2
KO/KO  animals and wild type littermate controls by high 
throughput RNA sequencing of poly-A
+ enriched total RNA. The results in 
Figure 14  show that the transcriptome of Themis2-deficient follicular B 
cells is highly similar to their wild type counterparts. Statistical analysis of 
differentially expressed genes resulted in only three genes being 
statistically significantly differentially regulated with a > 2-fold change in 
expression between genotypes. The statistically significantly differentially 
regulated genes did not suggest any obvious pathways being deregulated 
in Themis2-deficient follicular B cells, neither by manually perusing the list 
nor by computational pathway analysis. A comprehensive gene list from 
this analysis is given in the appendix in section 6.3.2.    165 
 
Figure 14: Themis2
KO/KO follicular B cells are transcriptionally similar 
to wild type controls. 
Scatterplot of gene expression of follicular B cells from Themis2
KO/KO mice 
or wild type littermate controls sorted by flow cytometry and analysed by 
RNA sequencing. Expression is plotted as read densities. Each red dot 
represents a gene, dotted lines indicate read density = 1 and dashed lines 
indicate 2-fold deregulation thresholds. A value of 10
-4 was added to the 
read density values to display genes with nRPKM = 0. Dots represent 
mean of 3 biological replicates per genotype.   166 
 
3.4.4  Themis2-deficient follicular B cells show similar usage of 
immunoglobulin genes 
To extend the analysis of the RNA sequencing data and check whether 
there are indications of differences in B cell repertoire between 
Themis2
KO/KO and wild type control follicular B cells I analysed the usage 
of the immunoglobulin V, D, J and C regions at the IgH and both IgL loci. 
This could indicate changes in positive or negative selection. Presence of 
annotation for each of these genes was checked manually to verify a 
complete analysis of VDJ gene usage. I show that usage of V, D, J and C 
regions in all three immunoglobulin loci (heavy chain, κ chain and λ chain 
loci) are indistinguishable (Figure 15). The results suggest that the B cell 
repertoire is largely identical in Themis2-deficient mice as positive and 
negative selection seem to proceed normally and a bias in VDJ  gene 
usage was not detected. 
In summary, the data from the immunophenotypic analysis of constitutively 
Themis2-deficient mice and mixed bone marrow radiation chimeras as 
well as the genome-wide RNA sequencing analysis indicate that B cell 
development proceeds normally in Themis2
KO/KO mice.   167 
 
 
Figure 15: Normal usage of immunoglobulin genes in Themis2
KO/KO 
follicular B cells. 
(A) Expression of VH or Vκ genes in sorted, splenic, follicular B cells from 
mice of the indicated genotypes as determined by RNAseq and displayed 
as read densities. VH and Vκ genes are ordered by level expression in wild 
type (WT) mice. Data is mean ± SEM of 3 biological replicates. (B) 
Expression of Jκ, Cκ, Vλ, Jλ, Cλ, DH, JH and CH genes in sorted, splenic, 
follicular B cells from mice of the indicated genotypes as determined by 
RNAseq and displayed as read densities. Data is mean ± SEM of 3 
biological replicates.   168 
 
3.5  Analysis of B cell activation in Themis2-deficient mice 
Since B cell development seemed unaffected by loss of Themis2  I 
proceeded to analyse B cell activation. Although according to the 
developmental analysis steady state numbers of antigen-experienced B 
cells are normal, there could be defects with respect to timing, strength or 
robustness of the immune response. Firstly though, in order enable correct 
data interpretation, I needed to test whether in activated B cells expression 
of other CABIT domain containing proteins is induced to exclude functional 
redundancy. 
 
3.5.1  Regulation of Themis2  expression and CABIT domain-
containing proteins upon activation 
To this end, I stimulated splenic B cells in vitro  with anti-IgM, LPS or 
CD40L and IL-4 over a 24 h time course and analysed the expression of 
Themis family members via qRT-PCR at the indicated time points. Figure 
16A shows that Themis2 transcription is reduced upon in vitro culture but 
that stimulation with any of the agonists leads to an up to 40-fold greater 
reduction in Themis2  mRNA. I found lowest expression at 6 h after 
stimulation, after which time, Themis2  mRNA levels increased again. 
Other Themis family members were just above the reliable, lower limit of 
detection or below detection at all time points and either did not increase 
or further decreased during the time course. Themis3 was not detectable 
at any given time point of any stimulation. The data demonstrate that   169 
Themis2 is the only expressed Themis family member in activated splenic 
B cells. 
To rule out any abnormal deregulation of CABIT domain containing 
proteins in Themis2
KO/KO B cells as well as in wild type B cells I used RNA 
sequencing data of either follicular B cells left unstimulated or stimulated 
for 6 h with anti-IgM, LPS or CD40L and IL-4. Shown in Figure 16B, RNA 
sequencing data for wild type controls gave the same results as the qRT-
PCR. Analysis of Themis2-deficient follicular B cells revealed that there 
was no abnormal upregulation of other CABIT containing proteins either. 
To summarise, I found no evidence of possible functional compensation of 
Themis2 in activated B cells by other CABIT domain containing proteins, 
either in wild type or in Themis2-deficient cells.   170 
 
 
Figure 16: Themis2 is downregulated after in vitro B cell activation 
and is expressed non-redundantly in Themis2-deficient and wild type 
B cells. 
(A)  qRT-PCR for relative mRNA levels of CABIT domain-containing 
proteins of splenic B cells in vitro activated with either anti-IgM, LPS or 
CD40L and IL-4 or left unstimulated for the indicated times. Missing data 
points for Themis1, Garem or Gareml indicate that the transcript could not 
be detected; Themis3 was not detected at any time point. Graphs show 
mean ± SEM of 3 biological replicates and are representative of 2 
independent experiments. (B) mRNA expression determined by RNAseq 
of CABIT domain-containing proteins in splenic follicular B cells from WT   171 
or Themis2
KO/KO mice either unstimulated or activated by the anti-IgM, LPS 
or CD40L and IL-4 for 6 h. Data are displayed as mean ± SEM reads per 
kilobase per million reads (RPKM) of 1 – 3 biological replicates. 
Expression of Themis1, Themis3, Garem and Gareml was not detectable. 
Unstimulated WT data is from the same experiment as in Figure 6A.   172 
 
3.5.2  In vitro B cell activation 
As functional redundancy was excluded I tested several, early B cell 
activation events in vitro. 
 
3.5.2.1  Cell surface activation markers 
Firstly, I checked whether the markers of activation CD69, CD86, CD23 
and MHC class II were regulated in a similar manner in Themis2
KO/KO and 
wild type control B cells. Cells were put into culture and stimulated with 
titrations of either anti-IgM, LPS, BAFF, CD40L, IL-4 or CD40L with IL-4 . 
PMA and ionomycin were used as a control to activate B cells. I performed 
several titrations of the stimuli as it had been reported for Themis1-
deficient mice that weak agonists induced stronger TCR signalling 
whereas stronger agonists induced identical TCR signalling compared to 
wild types (Fu et al., 2013). I also included stimulation with BAFF, although 
not a B cell activating cytokine per se, it is a well-known factor for B cell 
survival and activates similar signalling pathways as BCR engagement 
(Schweighoffer et al., 2013). I did not detect any reproducible differences 
in  cell surface activation marker  expression to any stimulus between 
Themis2-deficient B cells and wild type controls (Figure 17). This suggests 
that immediate events after B cell activation are normal in Themis2
KO/KO B 
cells.   173 
 
Figure  17:  Themis2-deficient B cells show normal regulation of 
activation markers in response to various stimuli in vitro. 
Geometric mean fluorescence intensity (gMFI) measured by flow 
cytometry of CD69, CD86, CD23 and MHC class II on splenic B cells in 
response to various stimuli after in vitro  culture for 24 h. Bars indicate 
mean ± SEM of 3 biological replicates and is representative of 5 similar 
experiments.  174 
 
3.5.2.2  Survival and proliferation 
Using a similar approach I tested whether B cell survival or proliferation 
were altered in Themis2-deficient B cells in vitro. I cultured splenic B cells 
with the same stimuli as above and measured proliferation by CFSE 
dilution and live cells by amino-reactive dye stain using flow cytometry. 
The results shown in Figure 18 demonstrate that both proliferation and 
survival are identical between genotypes when stimulated with any of the 
six different agonists. In conclusion, B cells survival is not compromised by 
Themis2-deficiency  and cells have normal proliferative capacity in 
response to a range of different stimuli. 
 
3.5.2.3  Cytokine production 
Since I had not observed any defects in proliferation, survival or the 
expression of cell surface markers, I went on to measure the expression of 
16 different cytokines (CCL2/JE/MCP-1, CXCL1/KC, CXCL2/MIP-2, GM-
CSF, IFNγ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12 p70, IL-13, IL-17A, 
TNFα, VEGF-A) after in vitro  stimulation with the above-mentioned 
stimulants. I found the most highly expressed cytokines to be IL-6, IL-10, 
TNFα, and VEGF-A (Figure 19) depending on the condition whereas other 
factors were hardly detectable in the B cell cultures (Supplementary Figure 
8). I found neither reduced expression nor unexpected  elevated 
expression of any of the 16 cytokines between Themis2
KO/KO and wild type   175 
                          
Figure 18: In vitro survival and proliferation are normal in Themis2-
deficient B cells. 
Splenic B cells from WT or Themis2
KO/KO mice were cultured for 72 h with 
the indicated stimuli. Cell proliferation and survival were measured by 
CFSE dilution and amine reactive dye staining respectively and analysed 
by flow cytometry. Graphs indicate mean ± SEM of (A) the percentage of 
cells that had divided or (B) the division index representing the average 
number of divisions per cells in the assay or (C) the numbers of live B 
cells. Data shown are from 3 biological replicates and are representative of 
3 similar experiments.   176 
 
 
Figure  19:  Themis2-deficient B cells produce normal amounts of 
cytokines upon in vitro activation. 
Cytokines determined by Luminex 16-plex assay in the supernatant of 
B cells cultured for 72 h in the presence of the indicated stimuli. Graphs 
show mean ± SEM of 3 biological replicates and is representative of 3 
independent experiments.   177 
B cells. The results indicate that stimulation-induced cytokine and 
chemokine secretion are not perturbed in Themis2-deficient B cells. 
 
3.5.2.4  Analysis of gene expression in activated Themis2-deficient B 
cells by RNA sequencing 
I then performed massively parallel RNA sequencing on follicular B cells 
stimulated with anti-IgM or LPS or CD40L and IL-4 and found slightly more 
significantly differentially expressed genes (found in the appendix sections 
6.3.3 to 6.3.5) compared to unstimulated samples but failed to detect any 
prominent outliers between wild type and Themis2-deficient B cells (Figure 
20). Only 3, 8, and 17 genes, respectively, were differentially expressed 
> 2-fold between Themis2-deficient and wild type control B cells. Pathway 
analysis of all statistically significantly differentially expressed genes 
indicated mostly pathways that had already been analysed such as cell 
development and haematopoiesis. Other pathways where both the 
expression of the involved genes and the statistical probability of this 
pathway being dysregulated were low, were not pursued any further with 
the exception of cholesterol biosynthesis pathways, as discussed in 
section 3.5.2.5. I therefore concluded that follicular Themis2
KO/KO B cells 
whether stimulated or not, were transcriptionally very similar to their wild 
type counterparts.   178 
 
Figure 20: In vitro activated Themis2-deficient follicular B cells show 
similar gene expression compared to wild type controls. 
Scatterplots showing comparison of gene expression measured by 
RNAseq in splenic B cells from Themis2
KO/KO and wild type (WT) mice 
cultured for 6 h in the presence of anti-IgM, LPS or CD40L and IL-4. Data 
are displayed as in Figure 14.  Dots represent mean of 1 – 3 biological 
replicates per genotype and condition.   179 
 
3.5.2.5  BCR internalisation 
Three facts prompted the testing of the capacity of Themis2
KO/KO B cells to 
internalise the BCR after cross-linking Firstly, I found genes of cholesterol 
metabolism to be among the differentially regulated genes of the RNA 
sequencing experiment. Pathway analysis suggested that cholesterol 
pathways were deregulated under LPS-stimulated as well as unstimulated 
conditions due  to  reduced  (1.12 - 1.52-fold)  expression  of  Acat2,  Fdft1, 
Nsdhl, Cyp51a1, Dhcr24, Fdps, Msmo1, Sc5d and Sqle in Themis2
KO/KO B 
cells compared to controls. Although the differences were small, the 
cholesterol pathways ranked among the most statistically significantly 
regulated pathways compared to other pathways in the analysis and had 
low p-values in a right-tailed Fisher’s exact test (Supplementary Figure 
3B). BCR internalisation is linked to cholesterol levels and thus can serve 
as a read out (Bléry et al., 2006). Moreover, dysregulation of cholesterol 
genes has also been described for Themis1-deficient T cells. Still, any 
functional consequences of these changes in gene expression have 
remained obscure (Johnson et al., 2009). 
Secondly, as THEMIS2 has so far been surmised to be a scaffolding 
protein in proximal BCR signalling, its role might be in very short-term BCR 
proximal signalling processes occurring rapidly after BCR cross-linking. A 
short-term, BCR proximal process that happens within minutes, such as 
BCR internalisation, had not been tested so far on Themis2-deficient B 
cells. As strong signalling defects were unlikely in view of my previous 
data on B cell activation, smaller kinetic changes in the time frame of   180 
minutes could still occur. One such process that can be readily measured 
is BCR internalisation. 
Thirdly, I noted that Lat2-deficient B cells have been reported to have a 
defect in BCR internalisation (Mutch et al., 2007). LAT2 is another 
scaffolding protein in BCR signalling, which shows little phenotype but is 
also phosphorylated after BCR stimulation and associates with GRB2 
(Brdicka et al., 2002)  and,  in this regard,  bears strong similarities to 
Themis2. Therefore, I tested the internalisation of IgM after cross-linking. 
As illustrated in Figure 21A, I found that the kinetics of BCR internalisation 
are identical between Themis2
KO/KO and wild type B cells suggesting that 
very early events after BCR stimulation are also intact if Themis2 
expression is lost. 
 
3.5.2.6  Antigen presentation 
After BCR internalisation, B cells can present captured antigen to T cells. 
Thus I asked whether Themis2
KO/KO B cells were also equally capable of 
presenting antigen and activating cognate T cells. Ovalbumin (OVA) was 
used as antigen and targeted to the BCR at varying concentrations whilst 
cross-linking the BCR. Then, these antigen-loaded Themis2
KO/KO or wild 
type B cells were cultured with OVA-specific OT-II T cells and T cell 
proliferation and IL-2 secretion were measured. Assay conditions were 
optimised. T cell proliferation and IL-2 secretion were shown to be B cell-
dependent and differential antigen loading was verified (Supplementary   181 
 
 
Figure  21:  Themis2-deficient B cells show normal BCR 
internalisation and antigen-presentation to CD4
+ T cells. 
(A) Kinetics of BCR surface levels on WT or Themis2
KO/KO splenic B cells 
stimulated with anti-IgM F(ab)2. Remaining surface IgM was determined by 
flow cytometry. Graph shows mean ± SEM geometric mean fluorescence 
intensity (gMFI) of 3 biological replicates and is representative of 3 
independent experiments. (B) OT-II T cell IL-2 secretion or percentage of 
divided CTV-labelled OT-II T cells co-cultured for 72 h with WT or 
Themis2
KO/KO splenic B cells that had been pre-loaded with low, medium   182 
or high doses of ovalbumin antigen, or with no antigen. As a control OT-II 
T cells were also either co-cultured alone or with B cells that had been 
loaded with a high dose of ovalbumin antigen and were subsequently fixed 
with paraformaldehyde. No significant cell division or IL-2 secretion was 
detected under these control conditions, verifying that cytokine secretion 
and proliferation of T cells depends on B cell antigen internalisation and 
presentation. IL-2 was also not detected in the absence of T cells 
(Supplementary Figure 8). Bars  depict mean ± SEM of 2 – 3 biological 
replicates and are representative of 2 independent experiments.   183 
Figure 9). However, lack of Themis2 does not change the ability of B cells 
to present antigen and activate CD4
+ T cells as measured by these two 
parameters (Figure 21B). Overall, I therefore conclude that Themis2-
deficiency does not alter B cell activation in vitro or the ability of B cells to 
internalise and present antigen. 
 
3.6  Analysis of antibody  responses in Themis2-deficient 
mice 
Next, I went on to test in vivo antibody responses in Themis2
KO/KO mice 
since in vitro activation of B cells was normal. First, I checked whether 
serum antibody levels were normal in unimmunised Themis2
KO/KO mice 
housed under SPF conditions (Figure 22). All serum immunoglobulins in 
C57BL6/J mice (IgM, IgG1, IgG2b, IgG2c, IgG3, IgA and IgE) were tested 
and showed that levels in Themis2
KO/KO mice were indistinguishable from 
wild type littermate controls. Thus, I started the analysis of antibody 
responses by immunisation with various antigens.   184 
 
 
 
Figure  22:  Themis2-deficient mice have normal serum immuno-
globulin levels. 
Levels of (A) IgM, IgG1, IgG2b, IgG2c, IgG3, IgA and (B) IgE in the serum 
of naïve Themis2
KO/KO or wild type (WT) control mice measured by ELISA. 
Bars  indicate mean ± SEM of 6 – 19 biological replicates and are 
representative of 3 independent experiments.   185 
 
3.6.1  T-independent type 1 immunisation 
Next, I analysed antigen-specific antibody responses to T-independent 
type 1 immunisation with the antigen NP-LPS. The response to NP-LPS 
was of particular interest  as differences in response to LPS had been 
reported for Themis2  overexpression and knock-down in macrophages 
(Peirce et al., 2010). Analysis of NP-specific IgM and IgG antibody 
responses up to four weeks after immunisation were identical between 
Themis2
KO/KO mice and littermate wild type controls (Figure 23A). To get a 
better understanding at the cellular level, I also checked the numbers of 
germinal centre B cells, plasmablasts and plasma cells in the spleen five 
days after immunisation with NP-LPS. In agreement with the antibody 
data, generation of these cell types was unaltered in Themis2
KO/KO mice 
compared to wild type controls (Figure 23B). Thus, the response to NP-
LPS is normal in Themis2
KO/KO mice. 
 
3.6.2  T-independent type 2 immunisation 
Next, I tested the responses of Themis2
KO/KO mice to T-independent type 2 
immunisation with NP-Ficoll. Anti-NP antibody titres were measured for up 
to four weeks but again neither NP-specific IgM nor IgG3 were altered in 
Themis2-deficient  animals (Figure 24) suggesting  that responses to 
repetitive non-protein antigens are also normal in Themis2-deficient mice.   186 
 
 
Figure 23: Themis2-deficient mice respond normally to immunisation 
with the type 1 T-independent antigen NP-LPS. 
(A) Kinetics of NP-specific serum IgM, IgG1, IgG2b, IgG2c and IgG3 levels 
in WT and Themis2
KO/KO  mice following immunisation with NP-LPS on 
day 0 measured by ELISA. Graphs show mean ± SEM of 6 biological 
replicates/group and are representative of 1 – 2 independent experiments. 
(B) Absolute number of germinal centre B cells (GCB), plasmablasts (PB) 
or plasma cells (PC) in the spleens of Themis2-deficient mice on day 5 
after NP-LPS immunisation. Cells were gated as in Figure 12. Bars 
indicate mean ± SEM and are representative of 2 (PBS) or 4 (NP-LPS) 
biological replicates. a.u., arbitrary units.   187 
 
Figure 24: Themis2-deficient mice respond normally to immunisation 
with the type 2 T-independent antigen NP-Ficoll. 
(A) Kinetics of NP-specific serum IgM and IgG3 in WT and Themis2
KO/KO 
mice following immunisation with NP-Ficoll on day 0 measured by ELISA. 
Graphs show mean ± SEM of 6 biological replicates/group. a.u., arbitrary 
units.   188 
 
3.6.3  T-dependent immunisations with NP-CGG and cholera 
toxin 
Finally, I tested the ability of Themis2-deficient mice to mount antibody 
responses to T-dependent antigens. Immunisation of Themis2
KO/KO 
animals or wild type controls with the T-dependent antigen NP-CGG in 
alum resulted in robust induction of NP-specific IgM and IgG1 in the serum 
of both groups, depicted in Figure 25. Rechallenge with soluble antigen 
but without adjuvant lead to rapid induction of memory responses, as 
expected,  particularly for IgG1. However, again both groups responded 
similarly suggesting that memory formation in Themis2
KO/KO mice is intact. 
As alum is also used to prime animals for allergic reactions (see section 
3.7.2) I also measured the production of total IgE in this system. Again I 
found no differences between both groups, either after primary or 
secondary immunisation. 
I wondered whether the immunisation route might play a role so I 
immunised  Themis2
KO/KO mice and controls orally using cholera toxin. I 
measured cholera toxin-specific IgM, IgG1 and IgA antibody responses 
both in the serum and in the faeces but could not find any statistically 
significant differences (Figure 26A and B). In addition, I checked for 
germinal centre B cell and T follicular helper cell numbers in the Peyer’s 
Patches, which  were also equivalent between genotypes (Figure 26C). 
Furthermore, the number of Peyer’s patches along the small intestine was   189 
                        
Figure 25: Themis2-deficient mice have normal primary and memory, 
humoral immune responses upon T-dependent immunisation with 
NP-CGG. 
(A) Kinetics of NP-specific serum IgM and IgG1 or total IgE in WT and 
Themis2
KO/KO mice following immunisation with NP-CGG in alum on day 0 
to measure primary responses and rechallenge with NP-CGG in PBS on 
day 63 to test memory responses. Immunoglobulin levels were determined 
by ELISA. Graphs show mean ± SEM of 6 biological replicates/group. a.u., 
arbitrary units.   190 
 
Figure  26:  Themis2-deficient mice respond normally to oral 
immunisation with cholera toxin. 
WT and Themis2
KO/KO  mice were orally immunised with cholera toxin 
(CTX) on day 0. (A) Kinetics of NP-specific serum IgM, IgG1 or IgA after 
CTX immunisation and (B) NP-specific faecal IgM, IgG1 or IgA on day 14 
after CTX immunisation.  (C)  Cell numbers of germinal centre B cells 
(GCB, B220
+, CD38
low-int, GL7
hi, Fas
hi, PNA
hi) or T follicular helper cells 
(Tfh, TCRβ
+, CD4
+, CXCR5
hi, PD-1
hi) in the Peyer’s patches (PP) and (D) 
number of Peyer’s patches counted along the small intestine of CTX 
immunised mice on day 14. Immunoglobulin levels were determined by 
ELISA, cell numbers were determined by flow cytometry. Graphs show 
mean ± SEM of 5 – 6 biological replicates/group. a.u., arbitrary units; n.s., 
not significant.   191 
also comparable between groups (Figure 26D). In summary, I found no 
indication that Themis2
KO/KO  mice have an impaired humoral immune 
response to T-dependent or T-independent antigens irrespective of the 
route of immunisation. 
 
3.7  Themis2-deficiency in disease models 
Finally,  I sought to determine if Themis2  has a role in actual disease 
models. I surmised that maybe in an even more complex immunological 
situation a phenotype for Themis2  might be found as the exact 
immunological mechanisms that govern these responses are still a subject 
of intense research. It also gave the opportunity to test if any of the 
functions of other cell types, which express Themis2, are compromised in 
Themis2
KO/KO mice. 
 
3.7.1  Influenza infection 
To test for a role of Themis2 in a Th1 dominated immune response mice 
were infected intranasally with X31 influenza. Furthermore, this gave the 
opportunity to test for a function of Themis2 in the lung as opposed to 
previous systemic (intraperitoneal) or gastrointestinal challenges. As this 
system is more complex and physiological compared to the previous 
immunisations, not only B cells play a role; also other Themis2-expressing 
cell types such as macrophages and dendritic cells could impinge on the 
outcome of an influenza infection through many different mechanisms   192 
(Kreijtz et al., 2011). As Themis2
KO is a constitutive null allele these cell 
types too are deficient for Themis2 and could also harbour defects. 
Use of two different infectious doses ensured the ability to detect 
differences between groups as high doses lead to 83 % mortality rate and 
low dose only lead to 33 % mortality. However, I found no significant 
differences in animal weight loss (Figure 27A) or survival (Figure 27B) 
between  Themis2
KO/KO  and wild type control groups. Production of IgG 
specific for X31 haemaglutinin tested 10 days after infection were also 
identical between genotypes (Figure 27C). All surviving mice also showed 
complete immunity to reinfection with X31 influenza at an 18.75-times 
higher dose than the high group confirming that immunological memory 
was intact (data not shown). 
 
3.7.2  House dust mite allergy model 
To study whether there was a function for Themis2 in a Th2 cell-mediated 
disease I used a model of acute allergic lung inflammation. This also 
allowed me to test whether Themis2 might play a role in eosinophils, as 
recently added publicly available data (www.immgen.org) indicate that 
Themis2 is expressed in these cells as well. Therefore mice were primed 
with house dust mite in alum and then intratracheally challenged to induce 
acute airway inflammation. Slightly reduced infiltration was visible in 
histological sections stained with H&E or AB-PAS (Figure 28). I found the 
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Figure  27:  Themis2
KO/KO  mice respond normally to influenza 
infection. 
WT or Themis2
KO/KO mice were intranasally infected with X31 influenza 
TCID50 = 8 × 10
3  (low dose) or 8 × 10
4  (high dose). (A)  Weight loss of 
mice after infection on day 0. Due to high mortality, data beyond day 7 is 
not shown for the high dose group. Graphs show mean ± SEM of 
6 mice/group.  (B)  Kaplan-Meier survival curve of WT or Themis2
KO/KO 
mice from the experiment shown in (A). (C) Serum anti-HA IgG titre on 
day 10 after X31 influenza infection in the mice from experiment shown in 
(A). Bars indicate mean ± SEM of 4 – 6 mice/group; a.u., arbitrary units.   194 
 
total cell count in bronchoalveolar lavages to be significantly reduced by 
half in Themis2-deficient  mice (Figure 29A). Eosinophils, making up to 
40 % of these infiltrating cells (Supplementary Figure 10A), were also 
reduced in absolute numbers (Figure 29B) although percentages of 
different cell types were not altered indicating that the overall cell 
infiltration was reduced. In contrast to the BAL cell counts, numbers of 
myeloid and lymphoid cells in the lung, as assessed by flow cytometry, 
were similar between genotypes (Figure 29C). Total serum IgE levels were 
also normal in Themis2
KO/KO mice both before and after priming and after 
induction of acute airway inflammation (Figure 29D). I also analysed the 
expression of various goblet cell markers (Gob5  and  Muc5ac), 
alternatively activated macrophage markers (Arg1, Fizz1, Ym1) and the 
eosinophil chemoattractant  Eotaxin-1  in total lung RNA. The qRT-PCR 
results suggest that none of these are dysregulated (Figure 29E). 
Moreover, T cell signature cytokines (IL-4, IL-5, IL-13, IL-17A and IFNγ) in 
the lung were also not altered in the response (Supplementary Figure 
10B). Overall these results suggest at best a very mild phenotype in the 
recruitment of cells into the bronchoalveolar lumen of the lung.    195 
 
 
Figure 28: Mildly reduced infiltration into the bronchoalveolar lumen 
of  Themis2
KO/KO  mice in a model of acute allergic inflammation to 
house dust mite. 
Mice were sensitised to house dust mite (HDM) on day 0 and boosted on 
day 14 via intraperitoneal injection of HDM in alum. Then airways were   196 
rechallenged intratracheally on day 28 and 31 with HDM in PBS before 
analysis on day 32. Controls received PBS without HDM. Histological 
sections of the left lung on day 32 stained with hematoxylin and eosin 
(H&E) or alcian blue periodic-acid schiff (AB-PAS) indicating cell infiltration 
(H&E) and mucopolysaccharide production (AB-PAS). Mildly reduced cell 
infiltration is visible in the HDM-treated Themis2
KO/KO mice compared to 
HDM-treated wild type controls. Data representative of 2 independent 
experiments.   197 
 
Figure  29: Reduced total cell numbers and eosinophils in the 
bronchoalveolar lavage fluid of Themis2-deficient mice in an acute 
house-dust mite allergy model. 
Mice were sensitised to house dust mite as described in Figure 28. (A) 
Haemocytometric total cell count in the bronchoalveolar lavage fluid (BAL) 
of mice on day 32. Bars show mean ± SEM of two pooled, independent 
experiments with a total 3 (PBS) or 9 (HDM) mice/group. (B)  Total 
eosinophil count in the BAL of mice on day 32 determined by cytospins. 
Bars show mean ± SEM of two pooled, independent experiments with a 
total 3 (PBS) or 9 (HDM) mice/group. (C) Total cell numbers of leukocytes 
in the inferior, middle and post-caval lobe of the lung of Themis2-deficient 
or control animals on day 32. Populations were analysed by flow cytometry 
and defined with the following markers: alveolar macrophages (Alveolar   198 
MF, CD45
+ SiglecF
+ CD11c
hi F4/80
+), CD11b
- dendritic cells (CD11b
- DC, 
CD45
+  CD11c
+  F4/80
-  CD11b
-), CD11b
+  dendritic cells (CD11b
+  DC, 
CD45
+  CD11c
+  F4/80
-  CD11b
+),  eosinophils (CD45
+  SiglecF
+  CD11c
-), 
inflammatory monocytes (Infl Mono, CD45
+  SiglecF
-  CD11c
-  CD11b
+ 
Ly6C
hi), neutrophils (CD45
+ CD11b
+ Ly6G
+), natural killer cells (NK cells, 
CD45
+  Ly6G
-, NK1.1
+ CD3
-), B cells (CD45
+  CD19
+  TCRβ
-),  γδ  T cells 
(CD45
+,  CD19
-, TCRβ
-, TCRγδ
+), CD4
+  T cells (CD45
+, CD19
-, TCRβ
+ 
CD4
+ CD8
-) and CD8
+ T cells (CD45
+, CD19
-, TCRβ
+ CD4
- CD8
+). Bars 
show mean ± SEM of 4 – 5 biological replicates/group and are 
representative of 2 independent experiments. (D) Kinetics of total serum 
IgE determined by ELISA during the course of the model. Dots indicate 
mean ± SEM of 4 – 5 mice/group. (E) Relative mRNA expression in the 
superior lung lobe of Gob5  and  Muc5ac  indicating goblet cell mucus 
production,  Arg1,  Fizz1  and  Ym1  indicating alternative macrophage 
activation and Eotaxin-1  (CCL11) for eosinophil recruitment. Bars show 
mean ± SEM of 4 – 5 biological replicates/group and are representative of 
2 independent experiments. Statistical significance was assessed using 
the Mann-Whitney test.   199 
4  Discussion 
Data from previous studies suggested that Themis2 might have a role in B 
cell biology. Themis1, the T cell-restricted, highly similar paralogue of 
Themis2 has been shown to have a major role in the positive selection of 
thymocytes (Fu et al., 2009; Johnson et al., 2009; Kakugawa et al., 2009; 
Lesourne et al., 2009; Patrick et al., 2009). Since these two proteins 
showed mutually exclusive expression within T cells (Themis1) and B cells 
(Themis2) respectively I hypothesised that Themis2 might have an equally 
important function in B cells compared to Themis1 in T cells. Later, more 
evidence accumulated suggesting a role for Themis2  in B cell 
development. The ENCODE project showed that typical B cell transcription 
factors such as PAX5, EBF1, PU.1 and NFκB bind in the promoter region 
of Themis2 (Rosenbloom et al., 2013). Furthermore, data in macrophages 
suggested a role for Themis2 in TLR4 signalling, a pathway which is found 
in murine B cells as well (Bekeredjian-Ding and Jego, 2009; Peirce et al., 
2010). Lastly and most convincingly, it was shown that ectopic 
overexpression of  Themis2  in T cells can substitute for Themis1  and 
rescue T cell development in vivo  in the absence of Themis1. These 
results demonstrate that Themis2 is a functional gene. Furthermore, this 
showed that THEMIS2 is rapidly phosphorylated after BCR cross-linking in 
primary B cells, again hinting at a function of Themis2 in this cell type 
(Lesourne et al., 2012). An important role for Themis2 is also suggested 
by its evolutionary conservation as two Themis family members can be   200 
traced down to the sea lamprey (Petromyzon marinus) and are regularly 
found in ray-finned fish, Xenopus  tropicalis, birds and mammals as 
evidenced by available sequences in ENSEMBL (Flicek et al., 2014; 
Johnson et al., 2009; Paten et al., 2008). 
In this thesis I have addressed the question whether Themis2  has a 
function in B cells. To this end, I first measured the expression of Themis2 
and other related Themis family members in developing, mature and 
antigen-experienced B  cell subsets. Then,  I used a newly created 
Themis2-deficient mouse strain to determine any defects in B cell 
development, activation, antibody responses and two disease models. 
 
4.1  Expression of the Themis family 
Combined results from PCRs and RNA sequencing as well as from FACS-
Gal promoter studies indicated that Themis2 is expressed throughout the 
B cell lineage with reduced expression in germinal centre B cells and 
recently activated or cultured B cells. Both Themis1 and Themis3 were not 
expressed in any of the analysed B cell subsets. In contrast, T cells 
expressed  Themis1  but did not express Themis2.  Themis3  was only 
detectable in the small intestine. Data for the other two CABIT domain-
containing proteins Garem and Gareml also suggested that they are not 
expressed in murine B cells. 
Although both qRT-PCR and FACS-Gal clearly show that Themis2  is 
expressed in all B cell subsets there were slight differences in particular 
for pro-B and pre-B cells and transitional B cells. It should be kept in mind   201 
that promoter activity and spliced transcript levels do not necessarily need 
to exactly correlate since for example rapid degradation of the transcript 
would lead to conflicting results between the promoter activity assay and 
qRT-PCR. Moreover, post-transcriptional processing of the mRNA could 
account for the subtle differences observed between these assays. 
The FACS-Gal assay is also subject to the following caveats: First, 
brightness of the cells during flow cytometry depends on other parameters 
such as cell size which is presumably the reason why pro-B and pre-B cell 
results slightly differ between qRT-PCR and FACS-Gal. In the qRT-PCR 
pro-B cells gave lower levels compared to pre-B cells whereas it was the 
opposite in the FACS-Gal assay. Although the differences between pro-B 
and pre-B cells were not statistically significant they were nevertheless 
reproducible an all experiments. Pre-B cells have a bimodal size 
distribution in the forward scatter parameter, in accordance with large 
blasting pre-B cells becoming smaller pre-B cells during B cell 
development (Kurosaki et al., 2010). As assessed in the FACS-Gal, pre-B 
cells had more large cells compared to pro-B cells; pro-B had a lower 
number of large cells but cells were more spread out in the forward scatter 
parameter (data not shown). This could account for the small differences 
observed between those two subsets in the FACS-Gal assay and the qRT-
PCR. 
A second caveat is that the exclusion of dead cells is vital for a correct 
analysis of FACS-Gal assays since only intact cells can retain fluorescein. 
Cells with a normal forward and side scatter and staining profile (indicating   202 
that the cell wall is mostly intact) would be assayed to have a non-active 
promoter due to tiny leaks in the plasma membrane leading to diffusion of 
the intracellularly produced fluorescein into the medium. Besides, it should 
be noted that the osmotic shock to load substrate into the cell leads to 
relatively high cell death even under optimised conditions, making a dead 
cell marker crucial. Different susceptibilities to osmotic shock among 
different B cell subsets could complicate the analysis further. 
Thirdly, introduction of a reporter cassette could alter the locus leading to 
deregulation of the endogenous promoter, which in turn can lead to 
misleading results. The generally very good  correlation between the 
FACS-Gal and qRT-PCR results suggests that  the presence of the 
NeoFlox allele has only minor effects on the promoter activity, if it has any 
at all. However, any remaining minor differences could be accounted for 
by the alteration of the locus as FACS-Gal was measured in 
Themis2
+/NeoFlox  and qRT-PCR was measured in wild type mice 
respectively. 
When B cells were put into culture, Themis2  levels dropped, but even 
more so when cells were stimulated with anti-IgM, LPS or CD40L with IL-4 
showing that Themis2  expression is regulated upon B cell activation, 
hinting at a role for Themis2 in B cell activation. mRNA levels of other 
CABIT domain containing proteins remained barely detectable and were 
not upregulated to potentially compensate for the downregulation of 
Themis2. In addition, no evidence was found for compensation by other 
CABIT-domain containing proteins due to upregulation of Themis1,   203 
Themis3,  Garem  or  Gareml  in  a Themis2-deficient background. In 
conclusion, the data indicate that Themis2 is the only expressed CABIT-
domain containing protein in murine B cells and there is no compensation 
by any of these related proteins. However, although unlikely, it is still 
possible that during the development of Themis2
KO/KO B cells, upregulation 
of another CABIT-domain containing protein during some developmental 
stage masks a phenotype since expression of other CABIT-domain 
containing proteins during B cell development has only been assessed in 
wild type cells but not in Themis2
KO/KO cells. 
In terms of splice variants,  Themis2  was transcribed as a single 
messenger RNA containing all six exons as shown by PCR amplification of 
follicular B cell cDNA with amplicons stretching from exon 1 to exon 6 and 
by RNA sequencing of poly-A
+ –enriched RNA libraries of follicular B cells. 
Since in B cells I was able to detect only one isoform for Themis2, all data 
so far indicate that the Themis2 gene codes only for one protein product. 
This is in contrast to reports in human cells where multiple splice variants 
have been identified (Treeck et al., 2002)  although their physiological 
relevance so far is unclear. Interestingly, in this report differential splicing 
has not only been shown to occur between different exons but also within 
exon 4, which is also reported as isoform by other sources such as 
ENSEMBL and Uniprot with various degrees of supporting evidence. 
These splice sites follow the canonical GT-AG splicing rule and would 
delete a portion of the second CABIT domain.   204 
Unless the assumption of the CABIT domain being a functional domain is 
wrong, none of the human splice variants seem to leave out particular 
domains but instead remove parts of one or multiple protein domains and 
would be predicted to rather obliterate the function of the whole protein. 
Several annotated human Themis2 transcripts involve an excision of exon 
4 (or excisions within exon 4). Exon 4 contains a phase change, so, as in 
mice, its deletion would push any downstream exons out of frame. Human 
Themis2  exon 4 also contains the C-terminal end  of the first CABIT 
domain, the whole second CABIT domain and the proline-rich SH3 binding 
site and therefore its deletion is very likely to produce a non-functional 
product. If however, the computationally predicted CABIT domain is not a 
domain per se then some of the reported splice variants could potentially 
lead to functionally different isoforms. It remains to be determined whether 
the reported transcript variants in humans actually produce distinct protein 
isoforms with distinct functional properties or whether some of the reported 
transcripts are degradation products or splicing intermediates. Structural 
studies would be needed to confirm or refute existence of the 
computationally-predicted CABIT domain. 
 
4.2  Analysis of Themis2-deficient mice 
To address the function of Themis2, I created Themis2-deficient 
Themis2
KO/KO mice. qRT-PCR and RNA sequencing confirmed the deletion  
of Themis2 exon 4 in Themis2
KO/KO mice and immunoblots corroborated 
the ablation of full-length THEMIS2 protein (molecular weight = 74.4 kDa)   205 
and supported the prediction that any truncated THEMIS2 had a frame 
shifted C-terminus since an antibody to an epitope in exon 6 did not detect 
any smaller proteins. The truncated form of THEMIS2 would be expected 
to have a molecular weight of 24.2 kDa (exons 1, 2, 3) or 32.3 kDa (frame 
shifted product of exon 1, 2, 3, 5, 6) if exon 6 were still translated in frame. 
However, this was additionally ruled out by RNA sequencing. Faint 
remaining bands in some of the immunoblots appear to be cross-reactions 
with proteins of similar molecular weight because they were not consistent 
in between all anti-THEMIS2 antibodies. Additionally, genotyping PCRs of 
gDNA and qRT-PCRs of Themis2 transcripts showed that Themis2 exon 4 
is not detectable in Themis2
KO/KO B cells and full-length THEMIS2 protein 
can therefore not be produced anymore. 
 
4.2.1  Possible limitations to the analysis of Themis2
KO/KO mice 
Since, unfortunately, none of the antibodies to the N-terminal region of 
THEMIS2 that I tested were able to detect THEMIS2, I was unable to 
determine whether a truncated and C-terminally frameshifted mutant of 
THEMIS2 was produced in Themis2
KO/KO B cells. That a truncated mutant 
of THEMIS2 is still produced in these mice is a possibility as qRT-PCRs 
indicate that the mutant Themis2 transcript is produced at normal levels at 
the exon junctions 2 – 3 and 5 – 6 and splicing was found from exon 3 to 
exon 5. RNA sequencing data verified the qRT-PCR data and confirmed 
the expected frameshift. Normal expression of the truncated transcript is 
expected as it would be predicted that nonsense-mediated RNA decay   206 
would fail to recognise the truncated transcript as aberrant. In the 
Themis2
KO allele the first frameshifted, premature termination codon (PTC) 
appears in the last exon of the gene, exon 6, just less than 50 bases from 
the original stop codon. As a consequence, the nonsense-mediated RNA 
decay machinery would not be predicted to recognise the transcript as 
aberrant since there are neither exon junction complexes downstream of 
the first PTC nor does the length of the 3’ UTR change significantly 
(Schweingruber et al., 2013). 
If the N-terminal fragment of THEMIS2 would be translated and stable it 
would be comprised of the first 214 amino acids of CABIT1 lacking the last 
23 C-terminal amino acids of the domain. The frameshifted exons 5 and 6 
would give rise to a 74 amino acid-long tail after the truncated CABIT1 
domain, giving rise to a protein of 288 residues in total compared to 663 
amino acids for full-length THEMIS2 (Supplementary Figure 5). However, 
it is unlikely that such a fragment would sustain the function of Themis2 for 
several reasons: 
Firstly, this fragment lacks both the C-terminal, SH2-binding, 
phosphorylation site Y660 and the conserved PRS. Both for Themis2 and 
Themis1 it has been shown that the PRS is required for GRB2-binding 
(Paster et al., 2013; Peirce et al., 2010). 
Secondly, GRB2-binding has been shown to mediate  THEMIS1 
recruitment to LAT and that this recruitment is essential for thymocyte 
development  (Paster et al., 2013). Likewise, when Themis2  was 
ectopically expressed in T cells, it was shown to be recruited to LAT and it   207 
functionally substituted THEMIS1, restoring thymocyte development 
(Lesourne et al., 2012). These results suggest that both Themis1  and 
Themis2  function by the same mechanism, namely PRS-site mediated 
recruitment via GRB2 to the signallosome. The truncated fragment could 
consequently not perform this function as it lacks the PRS. 
Thirdly, both the Themis2 PRS and Y660 have been shown to be critical 
for modulation of TNFα production in macrophages and Y660 has been 
essential for THEMIS2 phosphorylation and LYN recruitment (Peirce et al., 
2010), all of which would be abrogated in the absence of these residues in 
the remaining fragment. 
Fourthly, a point mutation in the C-terminal end of the second CABIT 
domain of Themis1  leading to a premature stop codon (Y489X) also 
abrogated thymocyte development in vivo. This mutation affects a similar 
but slightly smaller part of the protein compared to the Themis2
KO allele 
and again argues that  the  fragment of THEMIS2 that may potentially 
remain in Themis2
KO/KO mice is not functional. 
Lastly, it has been shown that expression of Themis1 mutants of the core 
of CABIT1 or the core of CABIT2 or the PRS or the NLS fail to restore the 
function of Themis1 in Themis1-deficient mice, suggesting that all of these 
functional domains are essential for the function of Themis proteins. Of 
interest though are results showing that if only the conserved cysteines of 
both CABIT domains were mutated these mutants restored thymocyte 
development almost to wild type levels (Zvezdova et al., 2014). It has 
previously been speculated that these cysteines might serve a catalytic   208 
function  (Johnson et al., 2009). These results indicate that these two 
amino acids are of minor importance whether they serve a catalytic 
function or simply a structural function. If they were serving a catalytic 
function, it is dispensable for T cell development (Okada et al., 2014; 
Zvezdova et al., 2014). Overall, these data strongly suggest that the 
truncated THEMIS2 protein would not be able to sustain its function. 
It is difficult  to assess whether the frameshifted C-terminal tail in the 
truncated THEMIS2 mutant could  influence protein stability. The 
expression of the truncated THEMIS2 protein in  Themis2
KO/KO  animals 
might be possible as it is a transcript with a 3’ UTR and polyadenylation. 
On the one hand the frameshifted C-terminal tail  could destabilise the 
protein and lead to its degradation, on the other hand, although less likely, 
it could help stabilise truncated THEMIS2 and help maintain THEMIS2 
functions by higher protein levels of mutant THEMIS2 or not change the 
properties of the protein turnover at all. 
In the course of generating Themis2
KO/KO  mice, I additionally analysed 
mice homozygous for the intermediate allele Themis2
NeoKO 
(Themis2
tm1b(KOMP)Wtsi) in which Themis2 exon 4 is deleted but the reporter 
cassette is still in place. Preliminary data indicated that the presence of the 
reporter cassette with a splice acceptor site and a polyadenylation site 
lead to almost completely abolished transcription of exon 5 and 6 
indicating that even if the truncated protein was produced it would mostly 
consist of exon 1, 2 and 3. Yet, I did not find any developmental defects in 
these mice either (data not shown). This further supports the validity of the   209 
Themis2
KO/KO results as also in the absence of the frameshifted novel C-
terminus, truncated Themis2 is dispensable for B cell development. 
With the caveat in mind that following deletion of Themis2  exon 4 a 
truncated THEMIS2 could still be expressed in Themis2
KO/KO mice, I argue 
that exon 4 is the best exon to target in Themis2  for creation of both 
constitutive and conditional knockout mice since it introduces a frameshift 
in downstream exons and affects all functionally annotated domains and 
sites. All other exons are smaller than exon 4 and deletion of exon 1 could 
lead to reinitiation of translation, potentially yielding only a short N-terminal 
truncation of THEMIS2. In addition, targeting exon 1 could interfere with 
the promoter and normal transcription and is thus unsuitable for a 
conditional mutant and/or reporter constructs. In contrast, deletion of 
exons 2 or 3 would only excise part of CABIT1 and, since they are phase 
symmetric, leave downstream exons in frame; deletion of exon 5 or 6 
would only delete part of the C-terminus and leave CABIT1, CABIT2 and 
the PRS intact. Targeting the whole gene or multiple exons for deletion 
could result in ineffective conditional deletion due to the size of the gene 
and the distance between the loxP sites. Therefore, targeting exon 4, as in 
the Themis2
KO/KO mice, produces the most comprehensive null mutation of 
Themis2  if a conditional allele is desired too, which is a useful tool to 
analyse any Themis2 phenotypes in more detail. 
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4.2.2  B Cell development 
I found B cell development in Themis2
KO/KO mice to be normal since all B 
cell subsets were detected in equal numbers and cell surface markers did 
not change either. Even under competition with wild type cells, Themis2-
deficient B cells developed normally as demonstrated by the mixed bone 
marrow radiation chimera experiments. This was surprising as Themis1-
deficiency leads to reduced single positive thymocytes and peripheral T 
cells due to a defect in selection during T cell development (Fu et al., 
2009; Johnson et al., 2009; Kakugawa et al., 2009; Lesourne et al., 2009; 
Patrick et al., 2009). However, T cell selection and B cell selection differ in 
some aspects  as discussed below in section 4.2.6, which  might  give 
reasons for the difference observed between the two phenotypes. 
Indistinguishable usage of variable region genes suggests that the B cell 
repertoire is comparable as well, although there may be differences in 
combinations of VDJ genes used. If Themis2-deficiency would lower the 
negative selection threshold for BCR signalling similar to Themis1-
deficiency in for TCR signalling (Fu et al., 2013) then one would expect to 
find either more deletion and anergic cells, which was not the case as 
shown by cell numbers, or at least a changed repertoire due to receptor 
editing. 
Identical usage of in particular light chain variable regions and of κ and λ 
constant regions also argues against changes in B cell selection due to 
increased receptor editing since receptor editing often leads to changes in 
light chain recombination, first rearranging at the κ  locus and if   211 
unsuccessful at the λ  locus  (Arakawa et al., 1996; Klein et al., 2004; 
Nemazee, 2006). 
Whole transcriptome analysis of follicular B cells showed no substantial 
differences in gene expression. The few, identified differentially expressed 
genes did not give a clear picture of any affected pathways. Cellular 
pathways and functions in which the number of differentially regulated 
genes was statistically overrepresented and which thus might have been 
affected such as “cellular development” or “cell activation” have been 
tested but did not reveal any differences.  
 
4.2.3  B Cell activation 
Themis2  is  the sole CABIT domain containing protein expressed in 
follicular B cells at steady state and after stimulation with anti-IgM, LPS, or 
CD40L with IL-4. When put into culture Themis2  expression drops  but 
even more so if cells are stimulated with the above stimuli. The immediate 
downregulation of Themis2 suggests a function in cell activation and is 
recapitulated in splenocytes after influenza infection and in lymphocytes 
and macrophages after activation in a collagen-induced arthritis model 
(Peirce et al., 2010). 
Nevertheless, stimulation through either the BCR, TLR4, CD40, IL-4R or 
BAFFR in Themis2-deficient B cells results in equal expression of surface 
activation markers CD23, CD69, CD86 and MHC class  II. Moreover, 
expression of 16 different cytokines as well as proliferation and survival 
are  indistinguishable from the wild type. Normal production of IL-10 by   212 
Themis2-deficient B cells implied that B regulatory cell development and 
function are most likely also unaffected by the absence of Themis2.  
Gene expression profiles of follicular B cells after activation failed to reveal 
clear defects as well. However, under several conditions I found a few 
significantly differentially regulated genes involved in cholesterol 
metabolism. It is interesting to note that also Themis1-deficient thymocytes 
have been reported to have dysregulated genes involved in cholesterol 
metabolism but the significance of this finding has remained elusive so far 
(Johnson et al., 2009). In B cells, availability of cholesterol has been 
implicated in BCR signalling (Karnell et al., 2005) and BCR internalisation 
(Bléry et al., 2006). However, the significance of these differentially 
regulated cholesterol metabolism genes remains obscure since BCR 
internalisation was completely identical between Themis2-deficient and 
control B cells and no defects in BCR signalling were observed either. It is 
possible that very minor signalling defects might be detectable by 
biochemical methods but in the light of not having any downstream 
consequences I decided not to pursue immediate BCR signalling events 
any further. 
Instead, to test whether further downstream interactions with T cells were 
defective, I performed an antigen presentation assay by targeting OVA 
antigen to the cross-linked BCR and co-culturing the antigen-loaded B 
cells  with OT-II T cells. T cell activation was read out by measuring 
proliferation via CTV dilution and IL-2 secretion in the supernatant. In the 
optimised assay, both parameters allowed detection of concentration-  213 
dependent T cell activation in response to different amounts of BCR cross-
linking and antigen loading. Different antigen loading was also confirmed 
on the B  cell surface by flow cytometry  (Supplementary Figure 9). 
Although B cells were not purified by flow cytometry for this assay, the 
antigen presentation was not performed by contaminating myeloid APCs 
as when B cell isolations were incubated without anti-IgM to target the 
antigen to the BCR but with high amounts of OVA antigen as shown in 
Figure 21B “Antigen-loading: none”, T cells were not activated, indicating 
that pinocytosis of antigen and subsequent antigen presentation by 
contaminating APCs  other than B cells  was insufficient to cause T cell 
activation. Furthermore, antigen presentation was an active process, as 
fixed B cells could not activate T cells either. Cultures also needed both B 
and T cells to produce detectable levels of IL-2 and T cell proliferation. The 
results show that Themis2 is dispensable for antigen presentation to CD4
+ 
T cells as both proliferation and IL-2 production in the assay were identical 
between Themis2-deficient B cells and wild type controls. 
In summary, early events after B cell activation are normal in B cells from 
Themis2
KO/KO mice. B cell activation was normal as assessed by surface 
markers, survival, proliferation, cytokine production, BCR internalisation, 
antigen presentation and transcriptome analysis after activation by four 
different stimuli. 
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4.2.4  B Cell antibody responses 
In order to test for more long-term effects of Themis2 after B cell activation 
I measured antibody responses to various types of antigens in 
Themis2
KO/KO mice. To test whether mice started off at equivalent antibody 
levels before immunisation, I first measured total antibody levels in 
unimmunised mice and found that all seven mouse isotypes were present 
at equal levels in the serum of Themis2
KO/KO and wild type control mice. 
Next, I tested a type I T-independent antigen NP-LPS, which, in addition to 
BCR ligation, conveys a second signal. In the case of LPS, receptors such 
as TLR4 are activated. I was particularly interested in NP-LPS since it has 
been shown for LPS-stimulated  macrophages  that  if  Themis2  is 
overexpressed by transfection or silenced using RNAi, TNFα production is 
increased or reduced respectively. This was attributed to regulation of p38 
and ERK, the phosphorylation of which was increased after LPS 
stimulation if Themis2 was overexpressed (Peirce et al., 2010). 
Thus, I immunised mice intraperitoneally with NP-LPS in alum and 
followed the NP-specific antibody response in the serum of the mice for 
four weeks. However, control and Themis2
KO/KO mice responded equally 
well to the immunisation with all analysed parameters including NP-
specific IgM, IgG1, IgG2b, IgG2c and IgG3. Production of splenic germinal 
centre B cells, plasmablasts and plasma cells was also normal in 
Themis2-deficient mice as assessed on day 5 of the response. 
Since this study was focused on B cells, I did not measure serum TNFα 
production as B cells produce much less TNFα than macrophages and   215 
most of the serum TNFα  would be attributed to production by myeloid 
cells. However, it is interesting to speculate whether TNF production in 
Themis2
KO/KO mice is deregulated. It is unlikely that altered TNFα levels, 
potentially caused by Themis2-deficiency,  could cause a change in the 
antibody response to NP-LPS.  Tnf-deficient mice can form antibody 
responses but seem to have defects generating germinal centres. 
Immunisation with the type 1 T-independent antigen Trinitrophenyl (TNP)-
LPS in Tnf-deficient mice results in normal anti-TNP IgM production and 
an only marginally reduced anti-TNP IgG responses (Pasparakis et al., 
1996). Thus it seems unlikely that a smaller reduction in TNFα production, 
as reported in vitro for human Themis2-silenced, LPS-stimulated primary 
macrophages (Peirce et al., 2010), could substantially influence the NP-
LPS responses in Themis2
KO/KO mice. 
Moreover, preliminary experiments with bone marrow derived 
macrophages (BMDMs) from Themis2
KO/KO  mice or wild type littermate 
controls did not support the siRNA and overexpression studies by Peirce 
et al. which showed  that RAW macrophages overexpressing Themis2 
produce more TNFα and human primary macrophages transfected with 
two different small interfering RNAs (siRNAs) against Themis2 produced 
less TNFα  in response to LPS. I found that Themis2
KO/KO  BMDMs 
produced equal amounts of TNFα after LPS stimulation compared to wild 
type controls (data not shown). Similarly  to BMDMs, also B cells 
responded with identical TNFα production to LPS (Figure 19) and showed 
equal antibody responses to other immunisations and equal resistance to   216 
influenza infection and allergy (Figures 24 to 29). One would expect that if 
TNFα  production were severely reduced in Themis2
KO/KO  mice, these 
responses would be affected. For example TNFα  has complex roles 
during influenza infection depending on the cell type which produces it and 
reduced TNFα  generally improves survival during influenza infections 
(DeBerge et al., 2014; Hussell et al., 2001; Peper and Van Campen, 1995) 
yet Themis2
KO/KO  mice responded equally well to influenza infection 
suggesting that TNFα production is most likely not strongly deregulated in 
Themis2
KO/KO mice. 
A possibility to explain the observed discrepancies in LPS-induced TNFα 
production by macrophages reported by Peirce et al. and the preliminary 
BMDM data generated here could be that there are differences between 
the primary, murine BMDMs used here and the murine RAW macrophage 
cell line and the primary human macrophages used in the study by Peirce 
et al. It is possible that the findings represent an artefact found in the 
murine RAW cell line, which is not found in primary, murine BMDMs but 
fortuitously an actual phenotype in human primary macrophages. 
Alternatively, although unlikely, both siRNAs that were used in the study 
might have had off-target effects both leading to reduced TNFα production 
and thus leading to the conflicting results. Controls in this siRNA 
experiment used a pool of non-targeting siRNAs and not just transfection 
reagent, thus changes due to an interferon response to the siRNA by the 
macrophages were excluded.   217 
In any case, Themis2-deficiency after injection of NP-LPS did not appear 
to impinge on B cell function in terms of cell differentiation or antibody 
production, irrespective of whether this was connected to a change in 
TNFα production or not. 
Next, I tested a type II T-independent antigen, NP-Ficoll, in a similar 
manner to NP-LPS. Measurement of NP-specific IgM and IgG3 in the 
serum of Themis2
KO/KO  mice or controls did not show any differences 
suggesting that the response to repetitive non-protein antigens was also 
intact. 
To model the last type of antigen immunisation I used NP-CGG in alum. 
This T-dependent immunisation induced a rapid NP-specific IgM response 
followed by increases in NP-specific IgG1 and total IgE in both 
experimental groups. Reimmunisation with soluble antigen induced a 
strong IgG1 and IgE memory response and, as expected, a more rapid 
IgM response. However both groups responded equally well suggesting 
that not only primary antibody responses but also memory responses were 
intact in Themis2
KO/KO mice. 
As the route of immunisation might influence the outcome, I also tested an 
oral T-dependent immunisation with cholera toxin. This would target 
immune cells in the gut more than previous intraperitoneal immunisations 
and might reveal differences. However, I found cholera-toxin specific IgM, 
IgG1 and IgA in both serum and faeces to be comparable between 
experimental groups. In addition, numbers of germinal centre B cells and T   218 
follicular helper cells as well as the number of Peyer’s patches was 
unchanged in Themis2
KO/KO mice. 
In summary, switching to each mouse isotype was checked in least one 
immunisation but no differences were detected. Overall the results 
conclusively suggest that Themis2  is dispensable for normal antibody 
responses. Although not directly tested in more detail, it also suggests that 
macrophages and dendritic cells, which have also been reported to 
express Themis2, function largely normal in the absence of Themis2 in 
vivo as functions such as antigen presentation are required for a B cell 
response as well. 
 
4.2.5  Infection and allergy models 
Finally, to evaluate the contribution of Themis2 to resistance to disease 
and reveal any defects in particularly complex immunological reactions in 
which cell types other than B cells also play major roles, I challenged 
Themis2-deficient mice with an influenza infection and a model of acute 
allergic lung inflammation. 
Influenza infection was chosen as it is a mainly Th  1 cell driven viral 
infection (Brown et al., 2004) but also Th17 cells and Tregs have been 
found to affect the course of the disease (Kreijtz et al., 2011). Influenza 
infection caused equal weight loss and mortality at two different doses in 
controls and Themis2
KO/KO  mice and anti-haemagglutinin IgG was also 
produced  normally (Figure 27).  In addition, surviving mice were 
reimmunised and showed complete immunity to influenza infection and   219 
increased antibody titres (data not shown). In conclusion, the data reveal 
that Themis2 is not required for resistance to influenza infection. 
To also test Themis2-deficient mice in a Th2-dominated disease I used a 
model of acute allergic lung inflammation using house dust mite as the 
model allergen. I found that IgE levels, goblet cell markers, alternatively 
activated macrophage markers, cytokines and chemokines, and cell 
recruitment in the lung were comparable between genotypes. However, I 
found a small, statistically significant difference in the total cell count of the 
bronchoalveolar lavage fluid. Themis2
KO/KO  mice had reduced BAL cell 
counts, which was concurrent with a reduction in the number of 
eosinophils in the BAL. Recently added, publicly available data 
(www.immgen.com) indicate that Themis2  is also expressed in 
eosinophils. I investigated whether the reduced eosinophilia was due to a 
reduction in the eosinophil chemoattractants Eotaxin-1 or IL-5 (Conroy and 
Williams, 2001) but both of them were expressed at normal levels in lung 
tissues as assessed by qRT-PCR. Analysis of BAL cells by flow cytometry 
surprisingly revealed that the percentage of eosinophils in the BAL 
compared to other cell types was unchanged suggesting that recruitment 
into the BAL in general was impaired and that the eosinophil count was 
statistically significant due to these cells representing the major infiltrating 
cell type (~ 40 % of live cells, Supplementary Figure 10). Considering the 
number of individual tests performed on Themis2
KO/KO  mice,  multiple 
testing becomes a statistical problem. The reduction of only approximately 
44 % with a p-value of 0.002295 argues that the sample size should be   220 
increased (currently n = 10 for wild type and n = 9 for Themis2
KO/KO) to 
confirm the reduction in total BAL cells and eosinophils (and possibly other 
cell types) as they stand in contrast to a lot of negative data even in the 
same experiments. It was surprising that all analysed cell types and not for 
example eosinophils in particular are recruited in lower numbers into the 
bronchoalveolar lumen. This could suggest that the defect might be rather 
found in the epithelium than in immune cells. However, Themis2 
expression is very low both in unstimulated and influenza-infected murine, 
primary airway epithelium cultures from the trachea (Andreas Wack, 
personal communication) and would suggest an indirect mechanism 
possibly influenced by a Themis2-expressing immune cell. 
In summary, apart from the slight reduction in BAL cells, Themis2
KO/KO 
mice responded indistinguishably to induction of acute allergic airway 
inflammation. It still remains to be determined whether the reduced BAL 
cell count can be consistently observed or whether it was due to 
experimental variation. 
 
4.2.6  Possible  explanations for the failure to detect a 
developmental phenotype due to Themis2 deficiency 
In the study presented here the function of Themis2  in B cells was 
analysed, however no clear defects in Themis2-deficient mice, were 
observed so far. The lack of a phenotype could be explained by the 
Themis2 gene not being functional. This is unlikely for two reasons. First, 
Themis2  is found in all vertebrates. This evolutionary conservation   221 
indicates that Themis2 is likely to have an important function (Johnson et 
al., 2009). The second possibility is that the Themis2 gene in laboratory 
mice has become non-functional. However, this is also improbable 
because mouse Themis2  rescued  Themis1-deficiency if ectopically 
expressed in the T cell lineage thus restoring T cell development to normal 
levels (Lesourne et al., 2012). Overall, these findings support that Themis2 
is functional, yet its specific function remains obscure. 
Interestingly, Themis1-deficiency has a dramatic effect on developing T 
cells while Themis2  seems dispensable for B cell development. The 
developmental results presented here thus support the view that selection 
of B and T lymphocytes during development is different to a certain 
degree. There are several indications that the selection process is much 
more stringent for T cells than for B cells, which could help explain why 
Themis1 has an important role in lymphocyte selection and why Themis2 
does not. 
For example, stringency in T cell selection is much more important 
because failure of self tolerance in the T cell compartment would also 
enhance autoreactive B cell responses (Xing and Hogquist, 2012). 
Conversely, B cells have been shown to have a relatively high number of 
autoreactive cells both in mice and men, being around 75 % of all clones 
in early immature B cell clones and around 40 % of newly emigrated 
mature B cell in human blood (Grandien et al., 1994; Wardemann et al., 
2003).   222 
The importance of T cell selection is also shown by the fact that T cells 
have the thymus as a dedicated organ for this process whereas niches for 
positive and negative selection of B cells in the bone marrow are not 
completely clear (Pelanda and Torres, 2012), but a niche of stromal cells 
expressing CXCL12, IL-7 and Galectin-1, with which developing B cells 
sequentially interact to support B cell development, have been reported 
(Mourcin et al., 2011; Tokoyoda et al., 2004). Although there is clear 
evidence for negative selection in B cells, apoptosis as an outcome is only 
a fail-safe mechanism in B cells to prevent autoreactive clones from 
reaching maturity if other mechanism such as receptor editing, anergy and 
ignorance fail. Compared to T cells in which about 75 % of thymocytes 
subjected to selection are deleted in the process (Sinclair et al., 2013), 
clonal deletion in B cells is less frequent. The extent of deletion in B cells 
is currently unknown but might be insignificant based on repertoire and 
receptor editing studies showing 50 – 70 % of immature B cells are 
autoreactive and 30 – 35 % edit their receptors. The remaining 15 – 40 % 
must therefore undergo either anergy, ignorance or clonal deletion, thus 
showing that B cell selection is more lenient (Grandien et al., 1994; 
Pelanda and Torres, 2012; Wardemann et al., 2003). 
Themis1 appears to be regulating the signalling threshold for positive and 
negative selection in T cells but such a threshold for negative selection in 
B cells seems higher, indicated by for example the higher autoreactive B 
cell pool and alternative mechanisms of avoiding self-reactivity such as 
receptor editing. Lack of Themis1  leads to a lowering of the signalling   223 
threshold for negative selection, so thymocytes that would normally be 
positively selected due to a low to intermediate-strength TCR signal are 
negatively selected in the absence of Themis1. The usually positive-
selecting signal is interpreted as a high affinity self-ligand signal leading to 
activation-induced apoptosis (Fu et al., 2013). Whereas Themis1  is 
crucially involved in the selection process, I did not find any evidence for a 
similar function of Themis2 in B cells. Potentially, Themis2 also regulates 
this selection threshold in B cells but its effects might not be as dramatic 
as the ones of Themis1 in T cells or the threshold can be moved more in B 
cells without strongly affecting the outcome of B cell selection. It is 
possible however that the methods used here including B cell 
development in intact and mixed bone marrow chimeras and analysis of 
VDJ gene and Igκ and Igλ usage, are too crude to detect small differences 
in selection. Perhaps more rigorous analyses on a monoclonal BCR 
transgenic background could have identified such a function. 
In summary, the teleologically different requirements for positive selection 
between B and T cells, the higher negative selection thresholds in B cells 
evidenced by more autoreactive clones in the repertoire combined with the 
mechanism by which Themis1 affects T cell selection i.e. dampening of 
TCR signals to fall into the positive selection range, might offer some 
indications for the lack of phenotype in B cell development of Themis2-
deficient mice compared to the relatively strong defect in T cell 
development in Themis1-deficient mice. If Themis2  performs a  similar 
function in B cells to Themis1 in T cells then perhaps the threshold for B   224 
cell negative selection is not lowered enough in the absence of Themis2 to 
see any functional consequences in a polyclonal repertoire. 
In view of this, one can speculate that the different requirements for 
Themis1 and Themis2 might be connected to the different requirements 
for Lat and Lat2 in T cells and B cells respectively. Similarly to THEMIS2, 
LAT2 is not required for B cell development  (Fuller et al., 2011).  In 
contrast, the presence of LAT is crucial for T cell development and so is 
the recruitment of THEMIS1 to LAT (Paster et al., 2013; Zhang et al., 
1999) whereas Lat2-deficient mice show normal development of B cells 
(Wang et al., 2005; Zhu et al., 2004). Evidence suggests that LAT is 
important in T cells for the recruitment of SLP-76 to the plasma membrane 
whereas LAT2 is dispensable for the recruitment of the SLP-76 paralogue 
BLNK (Boerth et al., 2000; Engels et al., 2001; Ishiai et al., 2000; Zhang et 
al., 1998). It is interesting to speculate that maybe THEMIS1 is involved in 
the recruitment of SLP-76 to LAT. Assuming that the signalling mechanism 
of THEMIS2 is identical to the one of THEMIS1 and since LAT2 has been 
proposed to be a functional equivalent to LAT without a PLCγ-binding site 
(Fuller et al., 2011), it is possible that THEMIS2 may be recruited to LAT2 
but since LAT2 is not required for BLNK plasma membrane localisation in 
B cell development, THEMIS2 is not required either because the signalling 
mechanism for the recruitment of BLNK in B cells is different to the one for 
SLP-76 in T cells. However, the molecular mechanism of THEMIS1 is 
potentially very different because it has been reported that THEMIS1 
recruits SH2-domain-containing protein tyrosine phosphatase 1 (SHP-1),   225 
suggesting a different role signalling. Moreover, SLP-76 phosphorylation is 
unaffected in Themis1-deficient thymocytes after TCR engagement (Fu et 
al., 2013)  and THEMIS1 phosphorylation is dependent on SLP-76 
(Brockmeyer et al., 2011) again suggesting that Themis1 acts downstream 
of SLP-76.  Similarly LAT2 could have completely different functions to 
THEMIS2 and not associate with it at all. Whatever the exact mechanism, 
it is interesting to note  the parallels between Themis2  and  Lat2  with 
respect to the known interactions of THEMIS1 and LAT. 
Furthermore, although not expressed in mature B cells, Lat  has been 
shown to have a role during pre-BCR signalling and Lat-deficient  mice 
show a minor accumulation of B220
+  CD43
+  B cells (Su and Jumaa, 
2003). THEMIS2 has been shown to be able to bind to LAT (Lesourne et 
al., 2012) and could therefore be required for LAT signalling in early B cell 
development but again I did not observe any accumulation at the pro B cell 
stage. This indicates that LAT in early B cells signals via pathways that do 
not depend on THEMIS2. 
 
4.3  Future directions 
In conclusion, the results presented here exclude a role for Themis2 in 
most major B cell functions notwithstanding that less recognised 
processes in which B cells are involved could still critically depend on 
Themis2. For example, I have not explored the requirement for Themis2 in 
autoimmunity, which might be particularly interesting if there is a role for 
Themis2  in B cell selection. Furthermore,  I have not tested the role of   226 
Themis2  in helminth, fungal, bacterial or mycobacterial infections. For 
bacterial infections there is recent, limited evidence from the phenotyping 
effort of the Mouse Genetics Project at the Wellcome  Trust Sanger 
Institute (WTSI). They report that Themis2
NeoFlox/NeoFlox  mice respond 
normally to Salmonella typhimurium and Citrobacter rodentium challenge 
(data publicly available through their mouse resources portal, 
www.sanger.ac.uk/mouseportal). We know from our studies that this allele 
is hypomorphic, where Themis2 expression is strongly reduced but most 
likely not completely absent (data not shown), leaving the possibility that 
low levels of Themis2 could still sustain its function. Moreover, the plethora 
of data from the WTSI so far does not indicate a function for Themis2 in 
non-immune processes with the exception of possible chromosomal 
instability shown through an erythrocyte micronucleus assay. Yet, no 
functional outcomes were observed due to chromosomal instabilities such 
as increased incidence of cancer in the Themis2
KO/KO mouse colony or any 
differences in the proliferation or survival of B cells during development or 
after activation. However, these studies could be extended in completely 
Themis2-deficient mice using cancer models. 
Since Themis2 is also widely expressed in myeloid lineage cells, assays 
probing the function of these cells would be interesting as well. In the light 
of the immunisations performed here and in particular in terms of the 
influenza infection, all  of which also require myeloid lineage cells, it is 
however questionable whether major inflammatory properties of these 
cells will be altered. It might be interesting to test whether Themis2 affects   227 
non-inflammatory functions such as wound healing, in which macrophages 
are involved. 
For inflammatory processes it would be interesting to test the susceptibility 
to septic shock by injection of LPS and measuring TNFα production in vivo 
as this might lead to different results than the in vitro data derived from 
bone-marrow derived macrophages. I also did not test different adjuvants 
although Themis2
KO/KO mice seemed to respond normally to all types of 
immunisation including intraperitoneal with alum, orally without adjuvant or 
intranasal influenza infection. 
Since the only defect so far has been obtained in a Th2-driven disease, 
subjecting the mice to a helminth infection with pathogens such as 
Heligmosomoides polygyrus or Nippostrongylus brasiliensis would be an 
interesting set of studies to perform. Another possibility would be to test a 
different lung infection such as Mycobacterium tuberculosum if the barrier 
function of the epithelium is the culprit and not the fact that the disease is 
Th2-driven. 
Lastly, since autoimmunity had not been investigated, an experimental 
autoimmune encephalitis experiment might give information on the 
function of Themis2 particularly with regards to Breg function. I did not 
prioritise these experiments, as IL-10 production by B cells was normal 
and  most  autoimmunity models  are  strongly T cell-driven. Furthermore, 
this study was  focussed on B cells.  However,  the production of 
autoantibodies would be an interesting area of investigation given that 
Themis2 could still have a role in B cell selection similar to Themis1 in T   228 
cell selection. Furthermore, B cells have important roles in other 
autoimmune diseases that could be tested in animal models for their 
dependence on Themis2  such as systemic lupus erythematosus, 
rheumatoid arthritis and type 1 diabetes (Hampe, 2012).  
 
4.4  Concluding remarks 
In summary, although a multitude of evidence suggested a key role for 
Themis2  in B cell biology, I have shown that B cell development and 
activation proceed normally in its absence. In addition, I have shown that 
antibody responses to model antigens are normal and that resistance to 
influenza infection and allergy are similar in Themis2-deficient mice. 
It remains to be determined whether Themis2  is involved in more 
specialised B cell functions in a specific disease context or whether 
Themis2 is involved in other biological processes in other cell types. 
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6  Appendix 
6.1  Supplementary figures 
 
 
Supplementary Figure 1: Regulatory B cell sorting strategy and 
correlation of extracellularly captured IL-10 and IL-10 GFP reporter 
activity. 
Regulatory B cells were sorted according to gating in the upper panel from 
in vitro cultured splenic B cells stimulated with LPS for 24 h and PMA and 
ionomycin for the last 5 h. The lower panel shows the correlation of 
secreted IL-10 that was captured on the cell surface using an anti-CD45-
anti-IL-10 conjugate (exIL10-PE) and the intracellular signal from the IL-10 
GFP reporter (inIL10-GFP) in control IL-10 GFP reporter tiger mouse B 
cells to confirm autocrine secretion and capture of IL-10 and little (false 
positive) paracrine capture by non-IL-10 producing-B cells.   278 
 
 
 
Supplementary Figure 2: Confirmation of cell identity of sorted 
antigen-experienced B cell subsets. 
Relative expression of mRNA of lineage transcription factors or cytokines 
in relevant B cell populations by qRT-PCR to confirm correct sorting. (A) 
Bcl6  mRNA is upregulated in germinal centre (GC) B cells. (B)  Prdm1 
(Blimp1) is upregulated in plasmablasts (PB) and plasma cells (PC). (C) 
B10 cells express high amounts of IL-10 mRNA. Bars show mean ± SEM 
of 3 biological replicates.   279 
 
 
 
Supplementary Figure 3: RNA sequencing read depth and RNA 
sequencing pathway analysis of cholesterol pathways. 
(A) Minimum to maximum box whisker plot of the read depth of all RNA 
sequencing samples in the study. All samples contained more than 
1.32 × 10
7  reads for analysis of the transcriptome. (B)  Statistical 
significance of the association of dysregulated genes between 
Themis2
KO/KO  and wild type follicular B cells with canonical cholesterol 
pathways in the pathway analyses of unstimulated or LPS-stimulated RNA 
sequencing samples. Low p-values indicate a high likelihood of non-
random accumulation of genes from the respective metabolic pathway in 
the dataset of statistically significantly dysegulated genes.   280 
 
Supplementary Figure 4: Example of manual Themis2, Cre and FLPe 
genotyping. 
Genotyping PCRs of a Themis2
NeoKO  and a Themis2
Flox  litter. PCR 
protocols are detailed in the section 6.2. Bands were visualised with UV 
light and ethidium bromide in 2 % agarose gels. Determined genotypes 
are labelled on top of the gel, possible genotypes due to a positive band in 
a particular PCR are indicated on the right. Indicated alleles describe 
Themis2 alleles with the exceptions of Cre for Cre recombinase and FLPe 
for FLPe recombinase being present. + CTR, positive control (previously 
successfully amplified genomic DNA with relevant sequences present).   281 
 
 
 
Supplementary Figure 5: Relation of Themis2  protein sequence, 
exons and functional domains. 
(A) Full-length murine Themis2 in one letter amino acid code. Functional 
domains are overlaid and colour coded. Amino acid font colour indicates 
whether the encoding codon is located in an odd (black) or even (blue) 
numbered exon or whether the codon spans over adjacent exons (purple). 
(B) Labelled as in (A) but if exon 4 is deleted. Loss of exon 4 pushes 
exon 5 and 6 out of frame and produces a frameshifted C-terminus with a 
premature stop codon in exon 6.   282 
 
Supplementary Figure 6: FACS-Gal  Themis2  promoter activity 
kinetics, assay validation and confirmation of cell type specificity. 
(A) Conversion of the substrate FDG into fluorescein was stopped at the 
indicated time points with PETG. Continual increase of the mean 
fluorescence intensity with longer reaction times confirm that differences in 
β-galactosidase expression and consequently Themis2 promoter activity 
could be ideally measured at the chosen time point for analysis (45 min). 
(B) A correct Themis2 allele (Themis2
NeoFlox) and the substrate FDG are 
prerequisites for a detectable fluorescein signal in splenic B cells and 
CD11c
+ cells. The data further substantiate expression of Themis2 in B 
cells and dendritic cells but not in T cells.   283 
 
 
Supplementary Figure 7: Themis2
KO/KO mice are produced normally 
from Themis2
WT/KO interbreeding. 
(A) Themis2
WT/KO × Themis2
WT/KO breeders produce expected Mendelian 
ratios of offspring. Statistical significance was tested using the chi-square 
test. n.s. not significant (B) 10 to 90 percentile box-whisker plot of the litter 
size of 1 ♂ Themis2
WT/KO × 2 ♀ Themis2
WT/KO mice. (C) Distribution plot of 
litter size as in (B).   284 
 
Supplementary Figure 8: Themis2-deficient B cells show no aberrant 
production of cytokines upon in vitro activation. 
Cytokines determined by Luminex 16-plex assay in the supernatant of 
splenic B cells from Themis2
KO/KO or wild type control animals cultured for 
72 h in the presence of the indicated stimuli. Graphs show mean ± SEM of 
3 biological replicates and is representative of 2 – 3 independent 
experiments. Dotted lines indicate reliable detection limit. n.d. not 
determined due to exogenously added IL-4.   285 
 
 
Supplementary Figure 9: Assay validation of antigen-presentation 
assay. 
(A) IL-2 production and percentage of divided OT-II T cells at different B 
and T cell densities or negative controls without B cells or T cells or 
antigen-loading or IgM cross-linking or IgM-cross-linked and antigen-
loaded but paraformaldehyde fixed. Data indicated the optimal assay 
conditions to be 10
5 T cells co-cultured with 2 × 10
5 B cells as IL-2 was in 
an optimal range for the ELISA and around 40 % of the T cells divided. 
None of the negative controls resulted in any significant T cell proliferation 
or IL-2 production. n.d. not determined. (B)  OVA-antigen loading on 
splenic B cells (CD19
+  B220
+) after titration of anti-IgM-F(ab)2-biotin 
(high = 2.5 µg/mL, medium = 0.25  µg/mL, low = 0.025 µg/mL or nil) and 
secondary staining with a constant concentration of anti-biotin-Ig-OVA-
FITC. Antigen-loading was measured by flow cytometry.    286 
 
 
Supplementary Figure 10: In an acute HDM allergy model Themis2-
deficient mice have normal expression of T helper cell cytokines in 
the lung and normal ratios of cell types recruited into the BAL. 
(A)  Percentage of various cell types among live cells in the BAL of 
Themis2-deficient or control mice on day 32 of an acute HDM allergy 
model. Cells were defined as in Figure 29. Bars show mean ± SEM of 4 –
 5 biological replicates/group.  (B)  Relative mRNA levels of signature T 
helper cell cytokines in the superior lobe of the lung of Themis2-deficient 
or control mice determined by qRT-PCR. Bars show mean ± SEM of 3 
(PBS) or 5 (HDM) biological replicates/group. 
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6.2  PCR protocols 
6.2.1  Genotyping  protocol HH3 for wild  type and targeted 
Themis2 allele 
 
 
Volume/ reaction 
[µ µL] 
Final concentration  Reagent   
2.50  1x  10 x Reaction Buffer IV   
3.50  3.5 mM  MgCl2 25mM   
0.40  0.4 mM  dNTP mix 25 mM   
0.50  250 nM  HH3 - 12.5 pmol/mL   
0.50  250 nM  EAS_90 - 12.5 pmol/mL   
0.50  250 nM  EAS_92 - 12.5 pmol/mL   
0.10  1 U/mL  Thermoprimer Plus DNA Pol 
250 U/mL 
 
16.00    PCR quality H2O   
1.00  ~ 4 ng/mL  Template   
24 
 
VOLUME MASTERMIX   
25    TOTAL VOLUME   
       
Step  Temp [°C]  Time  Cycles 
1st Denature  94  5 min 
  Denature  94  30 s    
Anneal  61  30 s  31 
Extend  72  30 s    
Final extend  72  5 min 
  Hold  4  forever 
         
Allele  Expected band size [bp]     
wt  431   
  NeoFlox  364   
  Flox  364   
  NeoKO  364 
    KO  364 
   
        Primer name  5' to 3' sequence 
  HH3:  GCTATCAGTATTTTATGATTGGGAAA 
  EAS_90  GGTCTGAGCTCGCCATCAGTTC 
  EAS_92  CAATCAGCGTAGGGCAACTG 
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6.2.2  Genotyping  protocol HH4 for wild  type and targeted 
Themis2 allele 
 
Volume/ reaction 
[µ µL] 
Final concentration  Reagent   
2.50  1x  10 x Reaction Buffer IV   
3.50  3.5 mM  MgCl2 25mM   
0.40  0.4 mM  dNTP mix 25 mM   
0.50  250 nM  HH4-1 - 12.5 pmol/mL   
0.50  250 nM  HH4-2 - 12.5 pmol/mL   
0.50  250 nM  HH4-3 - 12.5 pmol/mL   
0.10  1 U/mL  Thermoprimer Plus DNA Pol 
250 U/mL 
 
16.00    PCR quality H2O   
1.00  ~ 4 ng/mL  Template   
24 
 
VOLUME MASTERMIX   
25    TOTAL VOLUME   
       
Step  Temp [°C]  Time  Cycles 
1st denature  94  2 min 
  Denature  94  30 s    
Anneal  61  30 s  35 
Extend  72  45 s    
Final extend  72  5 min 
  Hold  4  forever 
         
Allele  Expected band size [bp]     
wt  469   
  NeoFlox  601 (+ 6034)   
  Flox  620   
  NeoKO  none 
    KO  none 
   
        Primer name  5' to 3' sequence 
  HH4_1  CTGAGGGATCCAACTGCTCT 
  HH4_2  GCCATCACGAGATTTCGATT 
  HH4_3  AGATCCATCGGTGACGAGAT 
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6.2.3  Genotyping protocol P4P5P6 for targeted Themis2 exon 4 
present or deleted 
 
Volume/ reaction 
[µ µL] 
Final concentration  Reagent   
2.50  1x  10 x Reaction Buffer IV   
3.50  3.5 mM  MgCl2 25mM   
0.40  0.4 mM  dNTP mix 25 mM   
0.50  250 nM  P4 - 12.5 pmol/mL   
0.50  250 nM  P5 - 12.5 pmol/mL   
0.50  250 nM  P6 - 12.5 pmol/mL   
0.10  1 U/mL  Thermoprimer Plus DNA Pol 
250 U/mL 
 
16.00    PCR quality H2O   
1.00  ~ 4 ng/mL  Template   
24 
 
VOLUME MASTERMIX   
25    TOTAL VOLUME   
       
Step  Temp [°C]  Time  Cycles 
1st Denature  94  2 min 
  Denature  94  30 s    
Anneal  66  30 s  40 
Extend  72  45 s    
Final extend  72  5 min 
  Hold  4  forever 
         
Allele  Expected band size [bp]     
wt  none   
  NeoFlox  490   
  Flox  490   
  NeoKO  289 
    KO  289 
   
        Primer name  5' to 3' sequence 
  P4  AGGAACTTCGTCGAGATAACTTCGT 
  P5  CCGGCACACGTCACCCAGTC 
  P6  CCAACGTGTCATGGCCAGCTGT 
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6.2.4   Genotyping  protocol P8P13P14a for targeted Themis2 
reporter cassette present or deleted 
 
Volume/ reaction 
[µ µL] 
Final concentration  Reagent   
2.50  1x  10 x Reaction Buffer IV   
3.50  3.5 mM  MgCl2 25mM   
0.40  0.4 mM  dNTP mix 25 mM   
0.50  250 nM  P8 - 12.5 pmol/mL   
0.50  250 nM  P13 - 12.5 pmol/mL   
0.50  250 nM  P14a - 12.5 pmol/mL   
0.10  1 U/mL  Thermoprimer Plus DNA 
Pol 250U/mL 
 
16.00    PCR quality H2O   
1.00  ~ 4 ng/mL  Template   
24 
 
VOLUME MASTERMIX   
25    TOTAL VOLUME   
       
Step  Temp [°C]  Time  Cycles 
1st Denature  94  5 min 
  Denature  94  30 s    
Anneal  64.5  30 s  40 
Extend  72  30 s    
Final extend  72  5 min 
  Hold  4  forever 
         
Allele  Expected band size [bp]     
wt  none   
  NeoFlox  557   
  Flox  490   
  NeoKO  557 
    KO  490 
   
        Primer name  5' to 3' sequence 
  P8  CCACAACGGGTTCTTCTGTT 
  P13  TGTATGCTATACGAAGTTATCTCGAC 
  P14a  TGCTCTGGCCTCTGTAGTCA 
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6.2.5  Genotyping  protocol FLPe for presence of the FLPe 
recombinase 
 
Volume/ reaction 
[µ µL] 
Final concentration  Reagent   
2.00  1x  10 x Reaction Buffer IV   
1.60  2 mM  MgCl2 25mM   
0.16  0.2 mM  dNTP mix 25 mM   
0.80  500 nM  305 FLPe fwd Primer - 12.5 
pmol/mL 
 
0.80  500 nM  306 FLPe rev Primer - 12.5 
pmol/mL 
 
0.30  3.75 U/mL  Thermoprimer Plus DNA 
Pol 250U/mL 
 
4.34    PCR quality H2O   
10.00  ~ 4 ng/mL  Template    
10 
 
VOLUME MASTERMIX   
20    TOTAL VOLUME   
       
Step  Temp [°C]  Time  Cycles 
1st Denature  94  3 min 
  Denature  94  30 s    
Anneal  58  1 min  35 
Extend  72  1 min    
Final extend  72  10 min 
  Hold  4  forever 
         
Allele  Expected band size [bp]     
wt  none   
  FLPe
+  725   
 
        Primer name  5' to 3' sequence 
  305 FLPe fwd  CACTGATATTGTAAGTAGTTTGC 
  306 FLPe rev  CTAGTGCGAAGTAGTGATCAGG 
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6.2.6  Genotyping  protocol Cre for presence of the Cre 
recombinase 
 
Volume/ reaction 
[µ µL] 
Final concentration  Reagent   
2.00  1x  10 x Reaction Buffer IV   
1.60  2 mM  MgCl2 25mM   
0.40  0.5 mM  dNTP mix 25 mM   
0.63  393 nM  Cre Primer fwd - 12.5 
pmol/mL 
 
0.63  393 nM  Cre Primer rev - 12.5 
pmol/mL 
 
0.30  3.75 U/mL  Thermoprimer Plus DNA 
Pol 250U/mL 
 
13.45    PCR quality H2O   
1.00  ~ 4 ng/mL  Template    
19 
 
VOLUME MASTERMIX   
20    TOTAL VOLUME   
       
Step  Temp [°C]  Time  Cycles 
1st Denature  94  3 min 
  Denature  94  40 s    
Anneal  62  40 s  30 
Extend  72  30 s    
Final extend  72  5 min 
  Hold  4  forever 
         
Allele  Expected band size [bp]     
wt  none   
  Cre
+  294   
 
        Primer name  5' to 3' sequence 
  Cre Primer fwd  TTCCCGCAGAACCTGAAGATGTTCG 
  Cre Primer rev  GCCAGATTACGTATATCCTGGCAGC 
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6.2.7  PCR protocol for presence of the Themis2 splice variants 
 
Volume/ 
reaction 
[µ µL] 
Final 
concentration 
Reagent   
2.50  1x  10 x Reaction Buffer IV   
3.50  3.5 mM  MgCl2 25mM   
0.40  0.4 mM  dNTP mix 25 mM   
0.50  250 nM  Forward Primer 12.5 pmol/uL   
0.50  250 nM  Reverse Primer 12.5 pmol/uL   
0.10  1 U/mL  Thermoprimer Plus DNA Pol 250U/mL   
16.50    PCR quality H2O   
1.00  ~ 4 ng/mL  Template   
24 
 
VOLUME MASTERMIX   
25    TOTAL VOLUME   
       
Step  Temp [°C]  Time  Cycles 
1st Denature  94  2 min 
  Denature  94  30 s    
Anneal  Gradient: 
50-65 
30 s 
40 
Extend  72  2 min 30 s    
Final extend  72  10 min 
  Hold  4  forever 
         
Amplicon 
(Primer Pairs) 
Expected band size for all exons used 
[bp] 
 
P1f + P1r  1973 
  P2f + P2r  2080 
  P3f + P3r  2279 
  P3f + P3r2  1943 
 
        Primer name  5' to 3' sequence 
  P1f  GGTCTGCTCCGGAGTCTACTT 
  P1r  CTGGAAATGTGGCTTCCCTA 
  P2f  CTAGTCGGAACGCGACCATGGAG 
  P2r  TCCGAGTCCTGTGTGGTGGCA 
  P3f  GCCTGGACCCCACCTCCCTT 
  P3r  TGAGAGGCAGGGCGATGCTGA 
  P3r2  GTCATGGTCATCCATATCCGGGTCA 
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6.3  Differentially  expressed  genes between Themis2-
deficient and wild type control follicular B cells 
 
Below a list of the significantly differentially expressed genes from 
experiments shown in Figure 14 (unstimulated) and in Figure 20 (anti-IgM 
or LPS or CD40L and IL-4 stimulated). Genes are ordered by fold change 
and only genes with a false discovery rate of < 0.05 are reported. A more 
comprehensive list including normalised read counts and read densities for 
every gene of every sample can be found under the following link: 
 
http://www.jimmunol.org/content/suppl/2014/06/06/jimmunol.1400943.DCS
upplemental/JI_1400943_Supplemental_Material_1.xlsx 
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6.3.1  Legend for differentially expressed genes 
Explanations of the headings for the lists below. 
 
Ensembl gene ID  Ensembl Identifier of the gene 
log2 FC KO/WT  Logarithm to the base of 2 of the fold change of 
the average normalised count data in 
Themis2
KO/KO divided by WT  
FDR  False discovery rate of exact binomial test 
between Themis2
KO/KO and WT  
Gene Name  Associated gene name derived from Ensembl   296 
 
6.3.2  Differentially expressed genes without stimulation 
Differences in gene expression between Themis2
KO/KO and WT follicular B 
cells without stimulation. Genes with an FDR < 0.05 are reported and 
ordered by fold change. 
 
Ensembl gene ID 
log2 FC 
KO/WT  FDR  Gene Name 
ENSMUSG00000029657  0.6255  0.006062526  Hsph1 
ENSMUSG00000021250  0.5827  0.020225123  Fos 
ENSMUSG00000089774  0.4532  0.032833023  Slc5a3 
ENSMUSG00000037432  0.3785  0.046491211  Fer1l5 
ENSMUSG00000030357  0.3605  0.000648205  Fkbp4 
ENSMUSG00000076508  0.3441  0.012940005  Igkv17-127 
ENSMUSG00000022403  0.3357  0.009779242  St13 
ENSMUSG00000035024  0.3341  0.033281545  Ncapd3 
ENSMUSG00000079003  0.3234  0.002394673  Samd1 
ENSMUSG00000032122  0.3195  0.005084398  Slc37a2 
ENSMUSG00000076514  0.3162  0.035814877  Igkv17-121 
ENSMUSG00000020048  0.3158  0.004611779  Hsp90b1 
ENSMUSG00000025316  0.2785  0.000154012  Banp 
ENSMUSG00000001829  0.2590  0.036545401  Clpb 
ENSMUSG00000002396  0.2514  0.045642572  Ocel1 
ENSMUSG00000037933  0.2475  0.001212645  Bicd2 
ENSMUSG00000003039  0.2335  0.006780471  Fam32a 
ENSMUSG00000043384  0.2325  0.017089317  Gprasp1 
ENSMUSG00000010755  0.2276  0.006062526  Cars 
ENSMUSG00000027248  0.2269  0.030647881  Pdia3 
ENSMUSG00000003814  0.2134  0.017089317  Calr 
ENSMUSG00000059939  0.2097  0.032833023  9430015G10Rik 
ENSMUSG00000023994  0.2028  0.046491211  Nfya 
ENSMUSG00000039191  -0.2088  0.038671449  Rbpj 
ENSMUSG00000031167  -0.2189  0.009667861  Rbm3 
ENSMUSG00000037355  -0.2560  0.017089317  Uvssa 
ENSMUSG00000022048  -0.2580  0.046491211  Dpysl2 
ENSMUSG00000032018  -0.2743  0.030647881  Sc5d 
ENSMUSG00000028015  -0.2744  0.000527652  Ctso 
ENSMUSG00000042851  -0.3390  0.01008288  Zc3h6 
ENSMUSG00000090115  -0.3448  0.034883705  Usp49 
ENSMUSG00000079470  -0.3514  0.025135359  Utp14b 
ENSMUSG00000021273  -0.3843  0.01337623  Fdft1 
ENSMUSG00000037731  -0.4316  1.04E-10  Themis2   297 
ENSMUSG00000031604  -0.4327  0.016188475  Sc4mol 
ENSMUSG00000001467  -0.4545  0.014751047  Cyp51 
ENSMUSG00000038264  -0.4584  0.044880386  Sema7a 
ENSMUSG00000059743  -0.4679  0.009667861  Fdps 
ENSMUSG00000032360  -0.4717  0.01337623  Hcrtr2 
ENSMUSG00000045294  -0.4936  0.030647881  Insig1 
ENSMUSG00000022351  -0.5504  0.042373282  Sqle 
ENSMUSG00000034926  -0.6027  0.006062526  Dhcr24 
ENSMUSG00000037443  -1.6311  1.24E-75  Cep85 
ENSMUSG00000096979  -2.5871  5.80E-44  AL627077.2 
ENSMUSG00000075014  -4.5080  6.11E-07  Gm10800 
   298 
 
6.3.3  Differentially expressed genes after anti-IgM stimulation 
Differences in gene expression between Themis2
KO/KO and WT follicular B 
cells after 6 h stimulation with anti-IgM in vitro. Genes with an FDR < 0.05 
are reported and ordered by fold change. 
 
Ensembl gene ID 
log2 FC 
KO/WT  FDR  Gene Name 
ENSMUSG00000058626  4.6780  1.11E-06  Capn11 
ENSMUSG00000090186  1.0806  0.000610599  Gm7592 
ENSMUSG00000062783  0.9909  0.000823014  Csprs 
ENSMUSG00000014932  0.9412  3.70E-05  Yes1 
ENSMUSG00000032715  0.9317  0.000552479  Trib3 
ENSMUSG00000079457  0.8264  0.005467994  Gm7609 
ENSMUSG00000097636  0.7652  0.014200861  AC123702.1 
ENSMUSG00000038807  0.7558  0.015465071  Rap1gap2 
ENSMUSG00000031327  0.7238  0.024853785  Chic1 
ENSMUSG00000062157  0.6164  0.029581645  Ifnlr1 
ENSMUSG00000049321  0.5690  0.04325069  Zfp2 
ENSMUSG00000079190  0.5102  0.010040936  AC133103.1 
ENSMUSG00000033111  0.4960  0.048051235  3830406C13Rik 
ENSMUSG00000024989  0.4942  0.029819884  Cep55 
ENSMUSG00000033883  0.4251  0.012906528  D3Ertd254e 
ENSMUSG00000044501  0.3992  0.03989322  Zfp758 
ENSMUSG00000040321  0.3965  0.006303137  Zfp770 
ENSMUSG00000020305  0.3808  0.0442941  Asb3 
ENSMUSG00000072568  0.3598  0.036144598  Fam84b 
ENSMUSG00000022237  0.3584  0.014200861  Ankrd33b 
ENSMUSG00000019699  0.3508  0.005674529  Akt3 
ENSMUSG00000089788  0.3470  0.014200861  Gm16586 
ENSMUSG00000035367  0.3464  0.041925775  Rmi1 
ENSMUSG00000057842  0.3428  0.016162715  Zfp595 
ENSMUSG00000021597  0.3390  0.018717474  Ankrd32 
ENSMUSG00000090015  0.3368  0.041440983  Gm15446 
ENSMUSG00000066798  0.3272  0.007299815  Zbtb6 
ENSMUSG00000044763  0.3246  0.000552479  Trmt10c 
ENSMUSG00000063894  0.3151  0.015855587  Zkscan8 
ENSMUSG00000049164  0.3115  0.010040936  Zfp518a 
ENSMUSG00000067942  0.2736  0.0442941  Zfp160 
ENSMUSG00000056260  0.2699  0.041677391  Lrif1 
ENSMUSG00000046785  0.2674  0.024853785  Epm2aip1 
ENSMUSG00000030660  0.2599  0.033167039  Pik3c2a   299 
ENSMUSG00000047694  0.2570  0.047746315  Yipf6 
ENSMUSG00000037795  0.2394  0.03302315  N4bp2 
ENSMUSG00000024943  0.2385  0.039193798  Smc5 
ENSMUSG00000018287  -0.2016  0.047746315  Spag7 
ENSMUSG00000036646  -0.2072  0.047746315  Man1b1 
ENSMUSG00000029028  -0.2203  0.047548911  Lrrc47 
ENSMUSG00000061032  -0.2224  0.041440983  Rrp1 
ENSMUSG00000022556  -0.2229  0.048177636  Hsf1 
ENSMUSG00000005299  -0.2230  0.047746315  Letm1 
ENSMUSG00000028677  -0.2233  0.0389756  Rnf220 
ENSMUSG00000024098  -0.2287  0.038814332  Twsg1 
ENSMUSG00000038485  -0.2328  0.01736433  Socs7 
ENSMUSG00000004929  -0.2335  0.031678855  Thop1 
ENSMUSG00000020802  -0.2339  0.027578565  Ube2o 
ENSMUSG00000018040  -0.2439  0.027379742  Rrp7a 
ENSMUSG00000025858  -0.2502  0.034089579  Get4 
ENSMUSG00000009293  -0.2528  0.041440983  Ube2g2 
ENSMUSG00000018042  -0.2572  0.041925775  Cyb5r3 
ENSMUSG00000020821  -0.2599  0.047746315  Kif1c 
ENSMUSG00000004054  -0.2619  0.0442941  Map3k11 
ENSMUSG00000029507  -0.2630  0.014200861  Pus1 
ENSMUSG00000030814  -0.2652  0.019373997  Bcl7c 
ENSMUSG00000020235  -0.2692  0.041925775  Fzr1 
ENSMUSG00000044894  -0.2738  0.024853785  Uqcrq 
ENSMUSG00000090841  -0.2759  0.027945346  Myl6 
ENSMUSG00000041697  -0.2764  0.018705291  Cox6a1 
ENSMUSG00000022193  -0.2793  0.041440983  Psmb5 
ENSMUSG00000027613  -0.2804  0.014200861  Eif6 
ENSMUSG00000020471  -0.2857  0.042370419  Pold2 
ENSMUSG00000045365  -0.2874  0.027542731  Rbm15b 
ENSMUSG00000013275  -0.2907  0.006992889  Slc41a1 
ENSMUSG00000040669  -0.2928  0.0442941  Phc1 
ENSMUSG00000048707  -0.2932  0.034350423  Tprn 
ENSMUSG00000079478  -0.2954  0.010485901  Sssca1 
ENSMUSG00000020307  -0.2970  0.031678855  Cdc34 
ENSMUSG00000020917  -0.2982  0.013177668  Acly 
ENSMUSG00000026930  -0.2991  0.038928909  Gpsm1 
ENSMUSG00000035960  -0.3043  0.00459344  Apex1 
ENSMUSG00000029622  -0.3053  0.03302315  Arpc1b 
ENSMUSG00000024787  -0.3100  0.034089579  Snx15 
ENSMUSG00000008193  -0.3101  0.041440983  Spib 
ENSMUSG00000051403  -0.3102  0.042370419  Ppp1r37 
ENSMUSG00000049686  -0.3119  0.047746315  Orai1 
ENSMUSG00000054520  -0.3125  0.047746315  Sh3bp2 
ENSMUSG00000018931  -0.3128  0.039193798  Gm16515 
ENSMUSG00000031708  -0.3146  0.0442941  Tecr   300 
ENSMUSG00000040435  -0.3164  0.005674529  Ppp1r15a 
ENSMUSG00000010406  -0.3164  0.0442941  Mrpl52 
ENSMUSG00000047945  -0.3193  0.042370419  Marcksl1 
ENSMUSG00000042462  -0.3196  0.005674529  Dctpp1 
ENSMUSG00000032583  -0.3218  0.041440983  Mon1a 
ENSMUSG00000020219  -0.3218  0.008303634  Timm13 
ENSMUSG00000023055  -0.3238  0.045838957  Calcoco1 
ENSMUSG00000003528  -0.3256  0.037881174  Slc25a1 
ENSMUSG00000020101  -0.3266  0.03302315  4632428N05Rik 
ENSMUSG00000031158  -0.3301  0.006589499  Timm17b 
ENSMUSG00000042303  -0.3322  0.011724046  Sgsm3 
ENSMUSG00000030609  -0.3369  0.005674529  Aen 
ENSMUSG00000006215  -0.3371  0.010485901  Zbtb17 
ENSMUSG00000019433  -0.3401  0.033167039  Gipc1 
ENSMUSG00000033307  -0.3406  0.03302315  Mif 
ENSMUSG00000018334  -0.3475  0.000567448  Ksr1 
ENSMUSG00000002820  -0.3518  0.041440983  Atg4d 
ENSMUSG00000043445  -0.3563  0.041440983  Pgp 
ENSMUSG00000039747  -0.3592  0.038767958  Orai2 
ENSMUSG00000027952  -0.3670  0.017115305  Pmvk 
ENSMUSG00000029401  -0.3682  0.031482084  Rilpl2 
ENSMUSG00000024772  -0.3714  0.005363223  Ehd1 
ENSMUSG00000002486  -0.3729  0.019244991  Tchp 
ENSMUSG00000045349  -0.3756  0.047746315  Sh2d5 
ENSMUSG00000073411  -0.3767  0.033167039  H2-D1 
ENSMUSG00000029545  -0.3770  0.034089579  Acads 
ENSMUSG00000061232  -0.3873  0.045067678  H2-K1 
ENSMUSG00000064120  -0.3893  0.041925775  Mocs1 
ENSMUSG00000037995  -0.3992  0.041440983  Igsf9 
ENSMUSG00000019158  -0.4087  0.041440983  Tmem160 
ENSMUSG00000003873  -0.4235  0.000755315  Bax 
ENSMUSG00000040857  -0.4381  0.000610599  Erf 
ENSMUSG00000030956  -0.4414  0.006303137  Fam53b 
ENSMUSG00000001473  -0.4563  0.047746315  Tubb6 
ENSMUSG00000033721  -0.4811  0.027578565  Vav3 
ENSMUSG00000002083  -0.4823  0.027578565  Bbc3 
ENSMUSG00000048895  -0.4829  0.047746315  Cdk5r1 
ENSMUSG00000036278  -0.5117  0.0442941  Macrod1 
ENSMUSG00000027533  -0.5366  0.010485901  Fabp5 
ENSMUSG00000032369  -0.5468  0.010485901  Plscr1 
ENSMUSG00000046598  -0.5881  0.047746315  Bdh1 
ENSMUSG00000049892  -0.6446  0.014200861  Rasd1 
ENSMUSG00000036825  -0.6500  0.045838957  Ssx2ip 
ENSMUSG00000031239  -0.6847  0.006611202  Itm2a 
ENSMUSG00000026482  -0.7002  0.010040936  Rgl1 
ENSMUSG00000045136  -0.7247  0.000121648  Tubb2b   301 
ENSMUSG00000059970  -0.7345  0.03302315  Hspa2 
ENSMUSG00000047604  -0.7423  0.032077483  Frat2 
ENSMUSG00000017639  -0.8020  0.039193798  Rab11fip4 
ENSMUSG00000005125  -0.8233  0.010040936  Ndrg1 
ENSMUSG00000019970  -0.8500  1.46E-09  Sgk1 
ENSMUSG00000066026  -0.8530  0.011724046  Dhrs3 
ENSMUSG00000014599  -0.8580  0.042370419  Csf1 
ENSMUSG00000045763  -0.9028  0.024853785  Basp1 
ENSMUSG00000051339  -1.1212  0.000121648  2900026A02Rik 
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6.3.4  Differentially expressed genes after LPS stimulation 
Differences in gene expression between Themis2
KO/KO and WT follicular B 
cells after 6 h stimulation with LPS in vitro. Genes with an FDR < 0.05 are 
reported and ordered by fold change. 
 
Ensembl gene ID 
log2 FC 
KO/WT  FDR  Gene Name 
ENSMUSG00000058626  2.480263396  0.004777414  Capn11 
ENSMUSG00000044037  1.973208515  0.024430669  Als2cl 
ENSMUSG00000031618  1.349804921  0.017005879  Nr3c2 
ENSMUSG00000055809  1.113234493  0.002928018  Dnaaf3 
ENSMUSG00000030742  1.065973111  0.005655804  Lat 
ENSMUSG00000027978  0.975698515  0.000528639  Prss12 
ENSMUSG00000062783  0.887777413  1.27E-07  Csprs 
ENSMUSG00000043833  0.87712003  0.032052304  2900005J15Rik 
ENSMUSG00000052512  0.820252762  0.047443908  Nav2 
ENSMUSG00000045672  0.696510626  0.032052304  Col27a1 
ENSMUSG00000022231  0.686339684  0.006443475  Sema5a 
ENSMUSG00000014686  0.654869288  0.024430669  Ceacam16 
ENSMUSG00000014932  0.600435236  0.006879221  Yes1 
ENSMUSG00000038807  0.581313481  0.017005879  Rap1gap2 
ENSMUSG00000074794  0.568167207  0.017196824  Arrdc3 
ENSMUSG00000034171  0.565870251  0.007668009  Faah 
ENSMUSG00000026604  0.534318554  0.012834219  Ptpn14 
ENSMUSG00000079457  0.530465921  0.00600257  Gm7609 
ENSMUSG00000019737  0.52457171  0.000769316  Syne4 
ENSMUSG00000021094  0.5146233  0.017005879  Dhrs7 
ENSMUSG00000018800  0.501527723  0.049212401  Abca5 
ENSMUSG00000048581  0.482833365  0.017196824  E130311K13Rik 
ENSMUSG00000040415  0.482640585  0.015501959  Dtx3 
ENSMUSG00000042500  0.469092266  0.011244146  Ago4 
ENSMUSG00000005686  0.449044785  0.004777414  Ampd3 
ENSMUSG00000090086  0.431394289  1.60E-05  AI480526 
ENSMUSG00000033209  0.40200269  0.027728504  Ttc28 
ENSMUSG00000035835  0.400675822  0.001976127  BC005764 
ENSMUSG00000012126  0.389477526  1.32E-05  Ubxn11 
ENSMUSG00000079190  0.375132045  0.028062141  AC133103.1 
ENSMUSG00000056185  0.370008259  0.032052304  Snx32 
ENSMUSG00000073434  0.368052191  0.00328668  Wdr90 
ENSMUSG00000032657  0.363420439  0.032052304  Fam189b 
ENSMUSG00000041995  0.361868573  0.017760974  Zbed3   303 
ENSMUSG00000097033  0.357935632  0.001330755  AC122371.1 
ENSMUSG00000063897  0.347315664  0.000570831  CAAA01118383.1 
ENSMUSG00000053560  0.345686402  0.012782187  Ier2 
ENSMUSG00000024462  0.344710854  0.002747661  Gabbr1 
ENSMUSG00000012123  0.339863288  0.032052304  Aim1l 
ENSMUSG00000015335  0.338145559  0.02120223  Zdhhc12 
ENSMUSG00000034833  0.330323277  0.017005879  Tespa1 
ENSMUSG00000024330  0.324833332  0.031712303  Col11a2 
ENSMUSG00000000682  0.316593375  0.017196824  Cd52 
ENSMUSG00000072653  0.304456376  0.027675265  Zfp783 
ENSMUSG00000034121  0.299329681  0.013063051  Mks1 
ENSMUSG00000067370  0.299017907  0.040973344  B3galt4 
ENSMUSG00000052837  0.295864756  0.039131322  Junb 
ENSMUSG00000022372  0.294199349  0.009327152  Sla 
ENSMUSG00000029860  0.289112225  0.015501959  Zyx 
ENSMUSG00000027368  0.283669666  0.007362126  Dusp2 
ENSMUSG00000035545  0.280001624  0.020594716  Leng8 
ENSMUSG00000095041  0.278031225  0.029143322  AC149090.1 
ENSMUSG00000002763  0.276607821  0.001330755  Pex6 
ENSMUSG00000037266  0.275131038  0.002658048  D4Wsu53e 
ENSMUSG00000021263  0.272521332  0.020509347  Degs2 
ENSMUSG00000045252  0.2722587  0.018779249  Zfp574 
ENSMUSG00000037280  0.270046749  0.02611588  Galnt6 
ENSMUSG00000020893  0.263739762  0.007889941  Per1 
ENSMUSG00000028454  0.263367319  2.77E-05  Pigo 
ENSMUSG00000024869  0.261314133  0.007889941  Nudt8 
ENSMUSG00000019039  0.259935897  0.011244146  Dalrd3 
ENSMUSG00000023908  0.259622088  0.015968759  Pkmyt1 
ENSMUSG00000025409  0.258973899  0.030110692  Mbd6 
ENSMUSG00000057411  0.257131462  0.014517648  Fam173a 
ENSMUSG00000030741  0.256236361  0.004100609  Spns1 
ENSMUSG00000002668  0.254487947  0.009327152  Dennd1c 
ENSMUSG00000057948  0.253762738  0.007362126  Unc13d 
ENSMUSG00000071649  0.252776235  0.017410547  B3gat3 
ENSMUSG00000020894  0.251407776  0.000769214  Vamp2 
ENSMUSG00000040712  0.251178247  0.024430669  Camta2 
ENSMUSG00000029404  0.249972091  0.01089652  Arl6ip4 
ENSMUSG00000066892  0.249778806  0.007889941  Fbxl12 
ENSMUSG00000038644  0.245772056  0.035738551  Pold1 
ENSMUSG00000022559  0.241503528  0.011244146  Fbxl6 
ENSMUSG00000023764  0.239119096  0.00876282  Sfi1 
ENSMUSG00000060862  0.23906385  0.009112702  Zbtb40 
ENSMUSG00000027947  0.238831675  0.030110692  Il6ra 
ENSMUSG00000025572  0.235349296  0.020594716  Tmc6 
ENSMUSG00000026944  0.234084982  0.017196824  Abca2 
ENSMUSG00000045193  0.228077809  0.024430669  Cirbp   304 
ENSMUSG00000037679  0.227172522  0.002658048  Inf2 
ENSMUSG00000060601  0.223560785  0.035738551  Nr1h2 
ENSMUSG00000020153  0.221108927  0.043585871  Ndufs7 
ENSMUSG00000054874  0.220083464  0.01170624  Pcnxl3 
ENSMUSG00000024180  0.2181656  0.034315608  Tmem8 
ENSMUSG00000029602  0.217878252  0.03479342  Rasal1 
ENSMUSG00000039205  0.214389643  0.031712303  Ciz1 
ENSMUSG00000092417  0.213614518  0.039804124  Gpank1 
ENSMUSG00000039263  0.211123709  0.017410547  Npepl1 
ENSMUSG00000041354  0.209376119  0.045055342  Rgl2 
ENSMUSG00000030337  0.200996493  0.017005879  Vamp1 
ENSMUSG00000030871  0.197417886  0.035738551  Ears2 
ENSMUSG00000026213  0.197057581  0.032052304  Stk11ip 
ENSMUSG00000042404  0.19435636  0.014895777  Dennd4b 
ENSMUSG00000047767  0.193377734  0.026043662  Atg16l2 
ENSMUSG00000004661  0.192145023  0.017005879  Arid3b 
ENSMUSG00000022946  0.185536103  0.048223905  Dopey2 
ENSMUSG00000044763  0.18424977  0.017005879  Trmt10c 
ENSMUSG00000015377  0.18207532  0.008785062  Dennd6b 
ENSMUSG00000038342  0.181029867  0.024430669  Mlxip 
ENSMUSG00000001127  0.17831433  0.021297209  Araf 
ENSMUSG00000056260  0.177720204  0.040106564  Lrif1 
ENSMUSG00000020455  0.171269617  0.031712303  Trim11 
ENSMUSG00000026229  -0.142570584  0.039811771  Psmd1 
ENSMUSG00000025130  -0.142784612  0.035151542  P4hb 
ENSMUSG00000021595  -0.14372712  0.039811771  Nsun2 
ENSMUSG00000001440  -0.144135042  0.035738551  Kpnb1 
ENSMUSG00000028826  -0.147503973  0.043585871  Tmem57 
ENSMUSG00000062203  -0.14796003  0.03759517  Gspt1 
ENSMUSG00000020738  -0.150402356  0.048638497  Sumo2 
ENSMUSG00000030168  -0.151977983  0.032052304  Adipor2 
ENSMUSG00000025266  -0.153223673  0.039804124  Gnl3l 
ENSMUSG00000027597  -0.156640704  0.035738551  Ahcy 
ENSMUSG00000037197  -0.157463653  0.03759517  Rbm17 
ENSMUSG00000078622  -0.157536186  0.021323753  Ccdc47 
ENSMUSG00000030978  -0.157571216  0.042071831  Rrm1 
ENSMUSG00000040331  -0.158108672  0.021297209  Nsmce4a 
ENSMUSG00000027282  -0.158284708  0.025091055  Mtch2 
ENSMUSG00000025591  -0.16005203  0.048638497  Tma16 
ENSMUSG00000024359  -0.160699609  0.041030709  Hspa9 
ENSMUSG00000031403  -0.161419191  0.048638497  Dkc1 
ENSMUSG00000072872  -0.161892455  0.024430669  Rybp 
ENSMUSG00000063229  -0.162515814  0.03545215  Ldha 
ENSMUSG00000021024  -0.163316614  0.017760974  Psma6 
ENSMUSG00000047388  -0.164665232  0.020110894  Atmin 
ENSMUSG00000056851  -0.164728963  0.017196824  Pcbp2   305 
ENSMUSG00000042487  -0.167059842  0.042071831  Leo1 
ENSMUSG00000035297  -0.167199715  0.02961388  Cops4 
ENSMUSG00000021650  -0.168552792  0.041030709  Ptcd2 
ENSMUSG00000028416  -0.168564777  0.015968759  Bag1 
ENSMUSG00000022024  -0.171716901  0.034220356  Sugt1 
ENSMUSG00000027823  -0.172333636  0.043210105  Gmps 
ENSMUSG00000017548  -0.174263702  0.048638497  Suz12 
ENSMUSG00000037815  -0.17468012  0.02106471  Ctnna1 
ENSMUSG00000053289  -0.174787238  0.005655804  Ddx10 
ENSMUSG00000003814  -0.176491252  0.042071831  Calr 
ENSMUSG00000049969  -0.177196441  0.040106564  Plekhf2 
ENSMUSG00000030753  -0.17723496  0.011244146  Prkrir 
ENSMUSG00000028452  -0.177465254  0.00514756  Vcp 
ENSMUSG00000019777  -0.178517584  0.03545215  Hdac2 
ENSMUSG00000023932  -0.178538106  0.030643332  Cdc5l 
ENSMUSG00000030662  -0.181019508  0.022142011  Ipo5 
ENSMUSG00000021408  -0.181618677  0.017760974  Ripk1 
ENSMUSG00000001305  -0.182720018  0.021297209  Rrp15 
ENSMUSG00000062070  -0.184846993  0.020594716  Pgk1 
ENSMUSG00000020321  -0.185020588  0.01089652  Mdh1 
ENSMUSG00000031954  -0.185306841  0.049778751  Cfdp1 
ENSMUSG00000028633  -0.185806923  0.032052304  Ctps 
ENSMUSG00000026377  -0.1870462  0.021297209  Mki67ip 
ENSMUSG00000026037  -0.187155246  0.044136637  Orc2 
ENSMUSG00000004043  -0.189568132  0.02106471  Stat5a 
ENSMUSG00000022035  -0.189868949  0.032052304  Ccdc25 
ENSMUSG00000032350  -0.191135722  0.025091055  Gclc 
ENSMUSG00000031353  -0.191222944  0.014982131  Rbbp7 
ENSMUSG00000045624  -0.191650389  0.044602314  Esf1 
ENSMUSG00000052144  -0.193427816  0.032052304  Ppp4r2 
ENSMUSG00000004707  -0.193847366  0.023672714  Ly9 
ENSMUSG00000021012  -0.194738271  0.00328668  Zc3h14 
ENSMUSG00000029447  -0.195032702  0.028398973  Cct6a 
ENSMUSG00000024528  -0.196674288  0.037888048  Srfbp1 
ENSMUSG00000020571  -0.199003155  0.011244146  Pdia6 
ENSMUSG00000020917  -0.200466466  0.012920767  Acly 
ENSMUSG00000020089  -0.203059718  0.007889941  Ppa1 
ENSMUSG00000066441  -0.208497253  0.002928018  Rdh11 
ENSMUSG00000027108  -0.208950718  0.017196824  Ola1 
ENSMUSG00000026484  -0.208954982  0.014895777  Rnf2 
ENSMUSG00000024165  -0.210480555  0.006254369  Hn1l 
ENSMUSG00000032575  -0.215658873  0.000769316  Manf 
ENSMUSG00000000628  -0.215871011  0.030110692  Hk2 
ENSMUSG00000020525  -0.228378106  0.012834219  Ppm1d 
ENSMUSG00000026617  -0.236002225  0.022766491  Bpnt1 
ENSMUSG00000050471  -0.24283227  0.011244146  Fam118b   306 
ENSMUSG00000024378  -0.246328957  0.029980226  Stard4 
ENSMUSG00000020250  -0.24729677  0.002658048  Txnrd1 
ENSMUSG00000019837  -0.250073782  0.011244146  Gtf3c6 
ENSMUSG00000032324  -0.258931978  0.013147423  Tspan3 
ENSMUSG00000023832  -0.259194641  0.01089652  Acat2 
ENSMUSG00000032883  -0.276341238  0.022766491  Acsl3 
ENSMUSG00000096336  -0.280995395  0.000528639  Igkv1-135 
ENSMUSG00000021273  -0.299442846  0.01252682  Fdft1 
ENSMUSG00000031349  -0.313835331  4.65E-05  Nsdhl 
ENSMUSG00000021569  -0.33660424  0.040106564  Trip13 
ENSMUSG00000041220  -0.350339405  0.002928018  Elovl6 
ENSMUSG00000004500  -0.363611578  0.008106983  Zfp324 
ENSMUSG00000094694  -0.387674461  0.020594716  Ighv1-9 
ENSMUSG00000026383  -0.389855226  0.015850191  Epb4.1l5 
ENSMUSG00000037731  -0.433942135  2.46E-09  Themis2 
ENSMUSG00000027533  -0.507260373  0.017196824  Fabp5 
ENSMUSG00000042331  -0.549446664  0.003970537  Specc1 
ENSMUSG00000045136  -0.574668666  1.42E-05  Tubb2b 
ENSMUSG00000004267  -0.602928681  0.003189527  Eno2 
ENSMUSG00000095285  -0.70316218  0.032052304  Ighv5-9 
ENSMUSG00000024665  -0.763488881  0.019916117  Fads2 
ENSMUSG00000029223  -0.971341165  0.009112702  Uchl1 
ENSMUSG00000037443  -1.421488041  5.71E-58  Cep85 
ENSMUSG00000096979  -2.20614054  2.35E-32  AL627077.2 
ENSMUSG00000065037  -2.327252008  0.007846716  Rn7sk   307 
 
6.3.5  Differentially  expressed  genes after CD40L and IL-4 
stimulation 
Differences in gene expression between Themis2
KO/KO and WT follicular B 
cells after 6 h stimulation with CD40L and IL-4  in vitro.  Genes with an 
FDR < 0.05 are reported and ordered by fold change. 
 
Ensembl gene ID 
log2 FC 
KO/WT  FDR  Gene Name 
ENSMUSG00000065037  3.0710  0.000717349  Rn7sk 
ENSMUSG00000093077  2.4765  0.001973834  Mir5105 
ENSMUSG00000076258  2.3766  0.002779109  Gm23935 
ENSMUSG00000098178  2.1814  0.007123548  RP23-81C12.3 
ENSMUSG00000093098  2.1315  0.027714817  Gm22641 
ENSMUSG00000075014  2.0613  0.048840878  Gm10800 
ENSMUSG00000024066  2.0445  0.048825333  Xdh 
ENSMUSG00000078763  1.9174  0.041420905  Slfn1 
ENSMUSG00000034171  1.2651  0.033046943  Faah 
ENSMUSG00000045092  1.1275  0.032615203  S1pr1 
ENSMUSG00000020689  1.0400  0.001939409  Itgb3 
ENSMUSG00000054892  0.8472  0.047696446  Txk 
ENSMUSG00000062593  0.8284  0.010195312  Lilrb4 
ENSMUSG00000089672  0.7783  0.007597344  Gp49a 
ENSMUSG00000034833  0.7556  0.010110903  Tespa1 
ENSMUSG00000094924  0.7403  4.02E-10  Cr2 
ENSMUSG00000085175  0.7272  0.041099041  Gm11423 
ENSMUSG00000074056  0.7260  5.50E-05  Gm10615 
ENSMUSG00000052291  0.6947  0.008584951  5330438D12Rik 
ENSMUSG00000097636  0.6915  0.011916895  AC123702.1 
ENSMUSG00000039239  0.6886  0.029823776  Tgfb2 
ENSMUSG00000025357  0.6617  0.043436593  Dgka 
ENSMUSG00000073008  0.6332  3.34E-06  Gpr174 
ENSMUSG00000062939  0.6295  0.000262569  Stat4 
ENSMUSG00000030670  0.6239  0.023607846  Cyp2r1 
ENSMUSG00000064696  0.6124  0.033724667  Gm24148 
ENSMUSG00000059495  0.5857  0.032876075  Arhgef12 
ENSMUSG00000032715  0.5694  0.021498388  Trib3 
ENSMUSG00000050921  0.5522  0.023607846  P2ry10 
ENSMUSG00000025573  0.5491  0.008584951  6030468B19Rik 
ENSMUSG00000026616  0.5399  9.94E-09  Cr2 
ENSMUSG00000031586  0.5280  0.043436593  Rbpms   308 
ENSMUSG00000097571  0.5073  0.001037383  Jpx 
ENSMUSG00000036339  0.5003  1.18E-05  Tmem260 
ENSMUSG00000022901  0.4804  0.000380445  Cd86 
ENSMUSG00000027347  0.4789  0.011916895  Rasgrp1 
ENSMUSG00000053835  0.4761  0.022568087  H2-T24 
ENSMUSG00000026080  0.4727  4.43E-05  Chst10 
ENSMUSG00000079057  0.4644  0.045203526  Cyp4v3 
ENSMUSG00000090086  0.4626  0.000717349  AI480526 
ENSMUSG00000026723  0.4565  0.021645122  Trdmt1 
ENSMUSG00000039853  0.4539  0.0392945  Trim14 
ENSMUSG00000064337  0.4536  0.008584951  mt-Rnr1 
ENSMUSG00000027010  0.4492  0.033046943  Slc25a12 
ENSMUSG00000038520  0.4486  3.99E-05  Tbc1d17 
ENSMUSG00000024677  0.4471  0.023607846  Ms4a6b 
ENSMUSG00000024592  0.4442  0.003366903  C330018D20Rik 
ENSMUSG00000060301  0.4439  0.021498388  2610008E11Rik 
ENSMUSG00000030671  0.4417  0.030145051  Pde3b 
ENSMUSG00000090958  0.4341  0.021645122  Lrrc32 
ENSMUSG00000097347  0.4340  0.043382354  AC121292.1 
ENSMUSG00000097180  0.4304  0.000717349  AC117663.1 
ENSMUSG00000028391  0.4304  0.048840878  Wdr31 
ENSMUSG00000039942  0.4293  0.022568087  Ptger4 
ENSMUSG00000049775  0.4275  0.000548101  Tmsb4x 
ENSMUSG00000055044  0.4240  0.029151962  Pdlim1 
ENSMUSG00000023927  0.4173  0.00271052  Satb1 
ENSMUSG00000052676  0.4153  0.027767886  Zmat1 
ENSMUSG00000072568  0.4075  0.048825333  Fam84b 
ENSMUSG00000072653  0.4044  0.001795787  Zfp783 
ENSMUSG00000027950  0.4042  0.023748824  Chrnb2 
ENSMUSG00000086859  0.3940  0.021498388  2810008D09Rik 
ENSMUSG00000097061  0.3856  0.017582085  AC099934.1 
ENSMUSG00000032344  0.3820  0.023960573  Mb21d1 
ENSMUSG00000074785  0.3793  0.001157564  Plxnc1 
ENSMUSG00000031627  0.3792  0.008173191  Irf2 
ENSMUSG00000043991  0.3761  0.000295643  Pura 
ENSMUSG00000026222  0.3750  0.011916895  Sp100 
ENSMUSG00000054237  0.3731  0.001157564  Fra10ac1 
ENSMUSG00000049950  0.3725  0.000717349  Rpp38 
ENSMUSG00000039783  0.3715  0.020805166  Kmo 
ENSMUSG00000085334  0.3598  0.025591231  Gm12940 
ENSMUSG00000014932  0.3584  0.033046943  Yes1 
ENSMUSG00000089788  0.3545  0.000140384  Gm16586 
ENSMUSG00000050555  0.3522  0.007823148  Hyls1 
ENSMUSG00000074733  0.3518  0.001795787  5830428H23Rik 
ENSMUSG00000015790  0.3444  0.024699511  Surf1 
ENSMUSG00000047242  0.3383  0.048825333  Taf9b   309 
ENSMUSG00000024675  0.3381  0.005117236  Ms4a4c 
ENSMUSG00000030031  0.3370  0.00016545  Kbtbd8 
ENSMUSG00000000682  0.3334  0.032615203  Cd52 
ENSMUSG00000020142  0.3333  0.002664257  Slc1a4 
ENSMUSG00000074024  0.3271  0.018316719  4632427E13Rik 
ENSMUSG00000095123  0.3266  0.043382354  Gm21781 
ENSMUSG00000000617  0.3250  0.033770716  Grm6 
ENSMUSG00000027341  0.3210  0.000295643  Tmem230 
ENSMUSG00000031134  0.3164  0.000741568  Rbmx 
ENSMUSG00000052137  0.3159  0.015250681  Rbm12b2 
ENSMUSG00000037172  0.3152  0.032615203  E330009J07Rik 
ENSMUSG00000042408  0.3089  0.019455285  Zmym6 
ENSMUSG00000031246  0.3086  0.045027051  Sh3bgrl 
ENSMUSG00000003038  0.3039  3.86E-05  Hmgn2 
ENSMUSG00000037266  0.3007  0.002290634  D4Wsu53e 
ENSMUSG00000056145  0.2962  0.036901267  AI504432 
ENSMUSG00000054520  0.2925  0.022568087  Sh3bp2 
ENSMUSG00000063894  0.2904  0.002734759  Zkscan8 
ENSMUSG00000040747  0.2860  0.00336583  Cd53 
ENSMUSG00000020894  0.2848  0.000717349  Vamp2 
ENSMUSG00000026754  0.2840  0.009082003  Golga1 
ENSMUSG00000047880  0.2836  0.001037383  Cxcr5 
ENSMUSG00000025903  0.2827  0.023811964  Lypla1 
ENSMUSG00000043090  0.2790  5.08E-05  Zfp866 
ENSMUSG00000097729  0.2789  0.040452282  AC108401.2 
ENSMUSG00000041235  0.2756  0.015508466  Chd7 
ENSMUSG00000097195  0.2736  0.000741568  Snhg5 
ENSMUSG00000040321  0.2731  0.021803315  Zfp770 
ENSMUSG00000021423  0.2709  0.020275509  Ly86 
ENSMUSG00000057842  0.2699  0.029823776  Zfp595 
ENSMUSG00000029106  0.2688  0.040452282  Add1 
ENSMUSG00000018654  0.2686  0.005446901  Ikzf1 
ENSMUSG00000020069  0.2681  0.020420277  Hnrnph3 
ENSMUSG00000051285  0.2677  0.00812726  Pcmtd1 
ENSMUSG00000067942  0.2593  0.010124387  Zfp160 
ENSMUSG00000041920  0.2583  0.023811964  Slc16a6 
ENSMUSG00000034163  0.2533  0.016916868  Zfc3h1 
ENSMUSG00000026767  0.2526  0.044257644  Fam188a 
ENSMUSG00000040818  0.2504  0.019052569  Dennd6a 
ENSMUSG00000022587  0.2472  0.041369813  Ly6e 
ENSMUSG00000079659  0.2464  0.010575976  Tmem243 
ENSMUSG00000030279  0.2458  0.044000261  C2cd5 
ENSMUSG00000064289  0.2437  0.00314612  Tank 
ENSMUSG00000026771  0.2431  0.036901267  Spopl 
ENSMUSG00000046351  0.2355  0.043247235  Zfp322a 
ENSMUSG00000026034  0.2355  0.017382626  Clk1   310 
ENSMUSG00000026600  0.2342  0.00359028  Soat1 
ENSMUSG00000026004  0.2310  0.020793399  Kansl1l 
ENSMUSG00000016481  0.2300  0.015508466  Cr1l 
ENSMUSG00000026107  0.2299  0.032007878  Nabp1 
ENSMUSG00000020137  0.2251  0.032876075  Thap2 
ENSMUSG00000021327  0.2242  0.01467379  Zkscan3 
ENSMUSG00000045140  0.2217  0.049898085  Pigw 
ENSMUSG00000074578  0.2211  0.024699511  1500012F01Rik 
ENSMUSG00000021510  0.2203  0.047750135  A530054K11Rik 
ENSMUSG00000051316  0.2194  0.018718517  Taf7 
ENSMUSG00000028292  0.2191  0.021522954  Rars2 
ENSMUSG00000052760  0.2166  0.043382354  A630001G21Rik 
ENSMUSG00000031770  0.2151  0.048825333  Herpud1 
ENSMUSG00000056260  0.2119  0.043382354  Lrif1 
ENSMUSG00000092558  0.2111  0.021803315  Med20 
ENSMUSG00000027763  0.2094  0.002187523  Mbnl1 
ENSMUSG00000097772  0.2092  0.01551619  AC107744.1 
ENSMUSG00000049164  0.2090  0.033724667  Zfp518a 
ENSMUSG00000026201  0.2089  0.033466262  Stk16 
ENSMUSG00000050088  0.2085  0.022568087  1600012H06Rik 
ENSMUSG00000044763  0.2052  0.006305874  Trmt10c 
ENSMUSG00000026987  0.2030  0.036123468  Baz2b 
ENSMUSG00000022884  0.2029  0.018123179  Eif4a2 
ENSMUSG00000053641  0.1992  0.017104603  Dennd4a 
ENSMUSG00000020522  0.1977  0.018316719  Mfap3 
ENSMUSG00000027829  0.1961  0.032991082  Ccnl1 
ENSMUSG00000046785  0.1954  0.033515508  Epm2aip1 
ENSMUSG00000053332  0.1889  0.049898085  Gas5 
ENSMUSG00000049606  0.1871  0.047750135  Zfp644 
ENSMUSG00000032244  0.1849  0.014186946  Fem1b 
ENSMUSG00000044149  0.1773  0.036901267  Nkrf 
ENSMUSG00000015597  0.1698  0.043382354  Zfp318 
ENSMUSG00000061665  0.1680  0.047696446  Cd2ap 
ENSMUSG00000068732  0.1633  0.039783046  Tmem167b 
ENSMUSG00000028060  0.1543  0.040562976  2810403A07Rik 
ENSMUSG00000027597  -0.1701  0.028975025  Ahcy 
ENSMUSG00000026933  -0.1709  0.015508466  Camsap1 
ENSMUSG00000018765  -0.1755  0.020805166  Fxr2 
ENSMUSG00000038485  -0.1767  0.01964152  Socs7 
ENSMUSG00000023004  -0.2040  0.047750135  Tuba1b 
ENSMUSG00000028334  -0.2065  0.027767886  Nans 
ENSMUSG00000020781  -0.2117  0.003687863  Tsen54 
ENSMUSG00000003873  -0.2194  0.044013107  Bax 
ENSMUSG00000037536  -0.2244  0.029151962  Fbxo34 
ENSMUSG00000035828  -0.2257  0.015250681  Pim3 
ENSMUSG00000026980  -0.2267  0.021096742  Ly75   311 
ENSMUSG00000025178  -0.2310  0.018260064  Pi4k2a 
ENSMUSG00000028962  -0.2340  0.003343483  Slc4a2 
ENSMUSG00000053730  -0.2357  0.033724667  Tmem39b 
ENSMUSG00000034341  -0.2375  0.014221093  Wbp2 
ENSMUSG00000034412  -0.2376  0.022568087  Tbc1d10a 
ENSMUSG00000040435  -0.2379  0.001496256  Ppp1r15a 
ENSMUSG00000024277  -0.2391  0.049276448  Mapre2 
ENSMUSG00000004043  -0.2429  0.001717443  Stat5a 
ENSMUSG00000020027  -0.2473  0.037179275  Socs2 
ENSMUSG00000002111  -0.2558  0.03414607  Sfpi1 
ENSMUSG00000055067  -0.2591  0.019398411  Smyd3 
ENSMUSG00000040669  -0.2637  0.018123179  Phc1 
ENSMUSG00000020593  -0.2640  0.015250681  Lpin1 
ENSMUSG00000023832  -0.2641  0.016916868  Acat2 
ENSMUSG00000037936  -0.2689  0.015825764  Scarb1 
ENSMUSG00000011877  -0.2767  0.01467379  Git1 
ENSMUSG00000014453  -0.2828  0.003366903  Blk 
ENSMUSG00000048218  -0.2829  0.020805166  Amigo2 
ENSMUSG00000023030  -0.2834  0.020820911  Slc11a2 
ENSMUSG00000025145  -0.2855  0.041420905  Lrrc45 
ENSMUSG00000063268  -0.2916  0.023748824  Parp10 
ENSMUSG00000004947  -0.3021  0.021803315  Dtx2 
ENSMUSG00000050628  -0.3027  0.036222761  Ubald2 
ENSMUSG00000028849  -0.3034  0.023607846  Map7d1 
ENSMUSG00000039382  -0.3049  0.036123468  Wdr45 
ENSMUSG00000072825  -0.3131  0.022522148  Cep170b 
ENSMUSG00000026930  -0.3177  0.001248782  Gpsm1 
ENSMUSG00000024235  -0.3233  0.002968168  Map3k8 
ENSMUSG00000028459  -0.3274  0.015825764  Cd72 
ENSMUSG00000048832  -0.3276  0.003362374  Vps37c 
ENSMUSG00000037731  -0.3342  0.039254098  Themis2 
ENSMUSG00000045639  -0.3368  0.039434202  Zfp629 
ENSMUSG00000028766  -0.3470  0.025552018  Alpl 
ENSMUSG00000001228  -0.3495  0.007823148  Uhrf1 
ENSMUSG00000026819  -0.3587  0.003324185  Slc25a25 
ENSMUSG00000019947  -0.3591  0.010908469  Arid5b 
ENSMUSG00000048285  -0.3604  0.003783012  Frmd6 
ENSMUSG00000025533  -0.3706  0.019513011  Asl 
ENSMUSG00000001473  -0.3740  0.014186946  Tubb6 
ENSMUSG00000028977  -0.3759  0.027057716  Casz1 
ENSMUSG00000026603  -0.3771  0.043382354  Smyd2 
ENSMUSG00000018334  -0.3850  0.00271052  Ksr1 
ENSMUSG00000030956  -0.3889  0.014186946  Fam53b 
ENSMUSG00000052151  -0.3891  0.033515508  Ppap2c 
ENSMUSG00000024353  -0.3992  0.043382354  Mzb1 
ENSMUSG00000030123  -0.4134  0.00271052  Plxnd1   312 
ENSMUSG00000034906  -0.4190  0.007823148  Ncaph 
ENSMUSG00000022475  -0.4258  0.016606746  Hdac7 
ENSMUSG00000031779  -0.4260  0.002059319  Ccl22 
ENSMUSG00000074480  -0.4280  0.00839649  Mex3a 
ENSMUSG00000039747  -0.4293  4.43E-05  Orai2 
ENSMUSG00000072082  -0.4468  0.000717349  Ccnf 
ENSMUSG00000032501  -0.4563  0.049898085  Trib1 
ENSMUSG00000094546  -0.4747  0.010575976  Ighv1-26 
ENSMUSG00000037692  -0.4864  0.014418243  Ahdc1 
ENSMUSG00000047875  -0.5241  0.001238565  Gpr157 
ENSMUSG00000023055  -0.5779  0.000717349  Calcoco1 
ENSMUSG00000035547  -0.5855  0.044013107  Capn5 
ENSMUSG00000018428  -0.5879  0.000380445  Akap1 
ENSMUSG00000058173  -0.6022  0.039692064  Smco4 
ENSMUSG00000038545  -0.6117  0.015250681  Cul7 
ENSMUSG00000037443  -0.6231  3.00E-07  Cep85 
ENSMUSG00000024665  -0.6340  0.004694979  Fads2 
ENSMUSG00000006445  -0.6604  0.00812726  Epha2 
ENSMUSG00000004267  -0.6830  0.010575976  Eno2 
ENSMUSG00000005107  -0.6834  0.036222761  Slc2a9 
ENSMUSG00000045136  -0.6954  2.21E-06  Tubb2b 
ENSMUSG00000002602  -0.7300  0.000717349  Axl 
ENSMUSG00000028164  -0.7625  0.000446559  Manba 
ENSMUSG00000051790  -0.8183  0.026135515  Nlgn2 
ENSMUSG00000032014  -0.8428  0.023895363  Oaf 
ENSMUSG00000090628  -0.8586  0.032751337  Gm17083 
ENSMUSG00000026223  -0.8897  0.021333128  Itm2c 
ENSMUSG00000094694  -1.0240  0.003747648  Ighv1-9 
ENSMUSG00000000982  -1.2176  0.048840878  Ccl3 
ENSMUSG00000004347  -1.3722  7.09E-05  Pde1c 
ENSMUSG00000096979  -1.4101  6.03E-09  AL627077.2 
ENSMUSG00000051339  -1.7172  0.048260718  2900026A02Rik 
ENSMUSG00000022469  -2.1600  0.04464277  Rapgef3 
 
 